Development of an oral vaccine against the ostrich-specific mycoplasma, Mycoplasma struthionis by Van Tonder, Amanda
 
 
Development of an oral vaccine against 




Thesis presented in partial fulfilment of the requirements for the 
degree Master of Science in Biochemistry at the University of 
Stellenbosch  
Supervisor: Prof. Dirk U. Bellstedt 
Co-supervisor: Dr. Annelise Botes 
Faculty of Science 
Department of Biochemistry 
by  









By submitting this thesis/dissertation electronically, I declare that the entirety of the work 
contained therein is my own, original work, that I am the sole author thereof (save to the extent 
explicitly otherwise stated), that reproduction and publication thereof by Stellenbosch University 
will not infringe any third party rights and that I have not previously in its entirety or in part 
submitted it for obtaining any qualification. 
 
Amanda van Tonder 
March 2013 
 


















Copyright © 2013 University of Stellenbosch 
 
All rights reserved 
 
  




The ostrich-specific mycoplasmas Mycoplasma struthionis, Ms02 and Mycoplasma nasistruthionis, 
are associated with respiratory disease in ostriches, which is threatening the South African ostrich 
industry. Antibiotics are available to manage Mycoplasma infections, but a need to prevent 
infections led to an investigation into the development of vaccines against the ostrich-specific 
mycoplasma. After commercially available poultry mycoplasma vaccines proved to be 
unsuccessful in protecting ostriches against ostrich mycoplasma infections, the genome of M. 
struthionis was analysed and the OppA gene identified as a good vaccine candidate. The gene 
was isolated and used to develop the pCI-neo, VR1012 and VR1020 naked DNA vaccines. M. 
struthionis infects the respiratory tract of ostriches, therefore a vaccine that results in mucosal 
immunity is required. The use of a bacterial vector for DNA vaccines has been shown to elicit both 
a humoral and mucosal immune response. Salmonella enterica serovar typhimurium SL3261 was 
used to develop mucosal pCI-neo, VR1012 and VR1020 DNA vaccines. The pCI-neo mucosal 
DNA vaccine was found to be unstable in vivo and the stable mucosal VR1020 and VR1012 DNA 
vaccines were considered for subsequent vaccine trials. The tissue plasminogen activator (TSA) 
signal peptide found in the VR1020 plasmid to direct the secretion of the membrane protein, OppA, 
makes it a good candidate vaccine to compare against the naked DNA vaccine. A preliminary 
vaccine trial conducted with this vaccine was influenced by various factors including avian 
influenza and the statistical results proved to be invalid, but enzyme-linked immunosorbent assays 
(ELISAs) were developed for the successful measurement of the immune response of the 
ostriches. The dose of the mucosal vaccine administered in the preliminary trial might not have 
been enough to elicit an effective immune response in the ostriches. Different doses of the 
mucosal VR1012 and VR1020 DNA vaccines were therefore used in a second trial, but the trial 
was also influenced by a variety of factors. Even though the results of the vaccine trials were not 
successful, a few observations were made that could be used to improve future trials and reduce 
the effect of the factors on the vaccine trials, such as the effect of prior infection, as well as the 
stress on the ostriches. 
  




Die volstruis-spesifieke mikoplasmas, Mycoplasma struthionis, Ms02 en Mycoplasma 
nasistruthionis, word geassosieer met lugweg infeksies in voltruise, wat die Suid-Afrikaanse 
volstruisbedryf bedreig. Antibiotika is beskikbaar om mikoplasma infeksies te beveg, maar „n wyse 
om infeksie te voorkom word benodig. Dus is „n ondersoek geloods om effektiewe entstowwe te 
ontwikkel teen die volstruis mikoplasmas. Na die onsuksesvolle poging om pluimvee mikoplasma 
entstowwe, wat kommersiëel beskikbaar is, te gebruik om volstruise te beskerm teen volstruis 
mikoplasma infeksie, is die genoom van M. struthionis ondersoek en is die OppA geen 
geïdentifiseer as „n entstof kandidaat. Die geen is geïsoleer en gebruik om die pCI-neo, VR1012 
en VR1020 deoksiribonukleïensuur (DNS) entstowwe te ontwikkel. M. struthionis veroorsaak 
infeksie in die respiratoriese kanaal van volstruise, daarom moet die entstof lei tot „n mukosale 
immuunrespons. Omrede daar al bewys is dat „n bakteriële vektor, as draer van „n DNS entstof, 
kan lei tot „n humorale sowel as „n mukosale immuunrespons, is Salmonella enterica serovar 
typhimurium SL3261 gebruik om mukosale pCI-neo, VR1012 en VR1020 DNS entstowwe te 
ontwikkel. In vivo was die mukosale pCI-neo DNS entstof onstabiel. Die stabiele mukosale VR1012 
en VR1020 DNS entstowwe is gebruik vir die daaropvolgende entstof proewe. Die VR1020 
plasmied bevat „n weefsel plasminogeen aktiveerder seinpeptied wat die sekresie van die 
membraan protein, OppA, lei, wat dit „n goeie kandidaat maak om te vergelyk met die skoon DNS 
entstof. „n Verskeindenheid faktore, insluitend voëlgriep, het die voorlopige entstof proef, wat 
uitgevoer is met hierdie entstof, beïnvloed en daar was te veel variasie in die statistiese resultate 
om tot „n gevolgtrekking oor elkeen van die entstowwe te kom. Die ensiem-gekoppelde 
immunosorberende toets wat ontwikkel is, was suskesvol daarin om die imuunrespons van die 
volstruis te meet. Die dosis van die mukosale entstof wat gebruik is in die voorlopige entstof proef, 
was dalk nie genoeg om „n doeltreffend imuunrespons in die volstruise te ontlok nie. Verskillende 
dosisse van die mukosale VR1012 en VR1020 DNS entstowwe is dus gebruik in „n tweede entstof 
proef, maar die entstof proef is ook beïnvloed deur verskeie faktore.  Alhoewel die resultate van die 
entstof proewe nie na verwagting was nie, is observasies gemaak om toekomstige proewe te 
verbeter, soos om die effek van vorige infeksies, sowel as spanning op die volstruise te verminder. 
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Chapter 1: Introduction 
The South African ostriches industry is of significant importance to South Africa‟s economy, 
contributing over 1 billion rand to the country‟s economy annually as well as providing jobs to 
approximately 20 000 people (Anonymous May 2004, Van Helden et al. 2012). South Africa 
produces 70% of the world‟s ostrich products, making them good niche market products for the 
South African export market. The low cholesterol and fat levels in ostrich meat have made it a very 
popular alternative to red meat, arising from the recent trend to follow a healthier lifestyle, as well 
as Europe‟s declining confidence in the safety of red meat after various health scares. The 
increase in the demand for ostrich products has lead to a system of intensive rearing, resulting in a 
rise in diseases, in particular respiratory diseases. 
Respiratory disease in ostriches can lead to production losses, carcass downgrading and 
increased susceptibility to secondary infection. Production losses of up to 30% have raised 
concerns of the economical impact of these diseases and for potential job losses. Mycoplasmas 
are among the pathogens that have been associated with respiratory infections in ostriches. Botes 
et al. (2005b) identified three ostrich mycoplasmas and provisionally described them as Ms01, 
Ms02 and Ms03. Ms01 and Ms03 were subsequently officially described as Mycoplasma 
struthionis and Mycoplasma nasistruthionis (Langer 2009). Antibiotics, such as tylosin, are used to 
treat mycoplasma infections, and infection can be controlled through good biosecurity and farming 
practices. However, these methods only aim to treat or prevent the spread of infection; they are not 
effective at preventing infection. Vaccination against mycoplasma infections in chickens has been 
shown to be very effective in preventing infection thereby overcoming production losses. For this 
reason, an investigation has been launched in this laboratory since 2007 into the development of 
effective vaccination strategies against ostrich mycoplasma infections.  
The first attempts by our laboratory included the use of commercially available poultry mycoplasma 
vaccines, which were ineffective at protecting the ostriches against the three ostrich specific 
mycoplasmas (Pretorius 2009). The second attempt included the design of a DNA vaccine 
effective against the ostrich-specific Mycoplasma struthionis, Ms02 and Mycoplasma 
nasistruthionis. Pretorius (2009) identified a vaccine candidate gene for Mycoplasma struthionis 
using bioinformatic analyses which was then inserted into each of three plasmids, pCI-neo, 
VR1012 and VR1020. Brandt (2012) tested the efficacy of these naked DNA vaccines injected 
intramuscularly with inconclusive results, as these results were compromised by an outbreak of 
avian influenza (AI).  
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The purpose of this study was therefore to prepare mucosal vaccines as an alternative means to 
deliver the DNA vaccines with the following objectives: 
 To identify a suitable bacterial carrier for the DNA vaccines  
 To insert the previously prepared Mycoplasma struthionis DNA vaccines into the chosen 
bacterial carrier using electroporation to generate a mucosal DNA vaccine. 
 To develop enzyme-linked immunosorbent assays (ELISAs) using recombinant 
Mycoplasma struthionis oligopeptide permease (OppA) protein as coating antigen for the 
analysis of the mucosal and serum immune responses of the ostriches against the 
vaccines. 
 To develop ELISAs using Salmonella enterica serovar typhimurium SL3261 
lipopolysaccharides (LPS) as coating antigens for the analysis of the mucosal and serum 
immune responses of the ostriches against the mucosal vaccines.   
 To conduct a vaccination trial to test the ability of the mucosal DNA vaccine to elicit an 
immune response against the Mycoplasma struthionis OppA protein compared to the naked 
DNA vaccine as well as to test the immune response of the ostriches to the carrier bacteria.  
 To conduct a vaccination trial to determine an effective dose for the mucosal DNA vaccine 
needed to elicit an immune response against the Mycoplasma struthionis OppA protein.  
In Chapter 2 of this thesis the general characteristics of mycoplasmas, their pathogenesis and host 
distribution will be discussed, followed by a short description of the ostrich-specific mycoplasmas. 
A discussion on DNA vaccines with specific emphasis on bacterial carriers such as Salmonella 
mutants with which to deliver the DNA vaccines and the immune response elicited when these 
carriers are used follows. The insertion of the naked DNA vaccines against Mycoplasma struthionis 
into a chosen bacterial carrier is described in Chapter 3. A preliminary vaccine trial to compare the 
naked DNA vaccine to the mucosal DNA vaccine is described in Chapter 4, including the ELISAs 
used to test the humoral and mucosal immune response of the ostriches against the chosen 
Mycoplasma struthionis antigen and the carrier bacteria. The results of a further vaccine trial 
conducted to determine an effective dose for the mucosal vaccine that was needed to elicit an 
immune response in ostriches is described in Chapter 5. A conclusion and the future perspectives 
are given in Chapter 6, followed by the reference list. The thesis is concluded with addenda 
containing the results of the stability experiment of the plasmid vaccines in the bacterial carrier, as 
well as the raw data and graphs of both the preliminary vaccine trial, to compare the naked and 
mucosal DNA vaccines, and the vaccine trial to determine the effective dose of the mucosal 
vaccine.  
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Chapter 2: Literature review 
2.1. Mycoplasmas 
2.1.1. General characteristics and morphology 
Mycoplasma is a genus in the family Mycoplasmataceae, which forms part of the order 
Mycoplasmatales, belonging to the class Mollicutes (Le Roux & Hoosen 2010). The name of the 
class Mollicutes comes from the Latin words „mollis‟ meaning „soft‟ and „cutis‟ meaning „skin‟ 
referring to the fact that prokaryotes in this class do not have a bacterial cell wall (Bradbury 2005). 
Other characteristics of free-living prokaryotes in this class are small genomes, with a low G + C 
content as well as some unusual nutritional requirements, such as the need for exogenous sterols 
(Kleven 2008, Weisburg et al. 1989). 
Mycoplasmas are the smallest, self-replicating prokaryotes known to date, with sizes in the range 
of 0.2 to 0.7 µm (Le Roux & Hoosen 2010). Instead of the characteristic bacterial cell wall, 
mycoplasmas have a thin trilaminar cell membrane. Despite the lack of the bacterial cell wall, 
various mycoplasma species are found to have a wide range of shapes, ranging from spherical to 
flask-like and filamentous. Apart from the cell membrane, ribosomes and a circular double-
stranded DNA molecule are the two other major cellular components found in mycoplasmas 
(Bradbury 2005). Due to these characteristics, mycoplasmas are resistant to most antibiotics, 
specifically the antibiotics that inhibit bacterial cell wall synthesis (Kleven 1998). 
Mycoplasma genomes are very small and range in sizes from 0.58 - 1.38 Mbp with a low G + C 
content, ranging from 23% to 40% (Razin, Yogev & Naot 1998). It is thus not surprising that some 
of the first bacterial genomes that were sequenced fully came from this genus, such as the human 
pathogen Mycoplasma genitalium (Fraser et al. 1995). The genomes of a number of other 
mycoplasma species have also been sequenced and published, including the avian mycoplasmas 
M. gallisepticum (Papazisi et al. 2003) and M. synoviae (Vasconcelos et al. 2005). The small 
genome size of mycoplasmas is a result of reductive evolution from Gram-positive bacteria (Le 
Roux & Hoosen 2010, Razin, Yogev & Naot 1998), which resulted in a genome containing the 
minimum set of genes necessary for self-replication. An interesting change that also occurred in 
the mycoplasma genome during its evolution is the reassignment of the UGA stop codon to a 
tryptophan codon, while the other two stop codons remained stop codons. The simplicity of the 
genome does have its downsides in that the organism has a slower growth cycle and it is 
dependent on its host for most of its essential nutrients (Bradbury 2005). 
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2.1.2. Pathogenesis  
Mycoplasmas enter the host mostly by inhalation, targeting the epithelial surfaces of the respiratory 
tract or the urogenital tract. Some mycoplasmas, such as M. synoviae, target the host joints. Apart 
from the ability to reach its targets sites, the gliding motility of some mycoplasmas, also aids in 
breaching the physical barriers of the host, such as the cilia and mucous layer lining the respiratory 
tract (Bradbury 2005, Kleven 2008).  
One of the clinical signs observed during many mycoplasma infections are what are referred to as 
lesions, which is an injury in the epithelial tissue resulting in conditions such as sinusitis and 
catarrhal rhinitis (Botes et al. 2005a). The lesions might be an indirect result of the immune and 
inflammatory responses of the host to the pathogen (Bradbury 2005). Some studies suggest that 
mycoplasma infections occur mainly as a secondary infection in immune-compromised individuals, 
while other studies propose that some mycoplasmas, specifically avian mycoplasmas, appear to 
be part of a disease syndrome that includes various other bacterial species (Bradbury 2005, 
Kleven 2008).  
Mycoplasmas appear to evade the host immune system by antigenic variation, which is a major 
factor in mycoplasma infection (Kleven 1998). Various mechanisms are utilised to cause variation 
of expression, as well as structure, of various important proteins, especially the proteins found on 
the cell surface (Bradbury 2005). Some studies on mycoplasma infection have also shown that 
other pathogens, such as Escherichia coli (E. coli), aid mycoplasmas in a synergistic manner to 
invade the host tissue and cause infection (Bradbury 2005, Kleven 2008). 
An important step in mycoplasma infection is attachment to the target tissue. Most mycoplasmas 
accomplish adhesion with cell membrane-bound components, such as tip structures by M. 
pneumonia, M. genitalium and M. gallisepticum (Hu et al. 1987). Adhesin proteins mediate the 
attachment of mycoplasmas to host cells. The adhesin proteins include the most studied P1 protein 
of M. pneumonia (Razin & Jacobs 1992), the GapA protein of M. gallisepticum (Papazisi et al. 
2003) and MgPa protein of M. genitalium (Le Roux & Hoosen 2010, Hu et al. 1987). The latter two 
both resemble the P1 protein of M. pneumonia (Razin, Yogev & Naot 1998). The P97 protein of M. 
hyopneumoniae (Zhang, Young & Ross 1995) showed no similarity to the P1 protein and might be 
a distinct mycoplasma adhesin. Henrich et al. (1993) studied adherence of M. hominis to its host 
tissue and identified the two surface-localized polypeptides, P50 and P100, as adhesins. The P100 
polypeptide forms the substrate-binding domain of the oligopeptide permease (Opp) system 
named OppA (Henrich et al. 1999). The oligopeptide permease system is an ATP-binding cassette 
(ABC transporter) that uses energy from ATP hydrolysis to pump specific compounds across the 
biological membrane. The different components of this system are shown in figure 2.1 (Davidson & 
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Maloney 2007). Hopfe, Dahlmanns & Henrich (2011) discovered that the cytoadherence property 
of the OppA protein is dependent on its ATPase activity in the Opp system. 
 
2.1.3. Host distribution  
Mycoplasmas colonise a wide range of plant, mammal, insect, reptilian and avian species as 
commensals, but a few mycoplasma species are pathogenic and can lead to disease in their hosts 
(Razin, Yogev & Naot 1998, Volokhov et al. 2011). Apart from being mostly host-specific, 
mycoplasmas appear to be organ and tissue specific as well, mostly colonising the mucosal 
surface found in the respiratory and urogenital tract. Apart from these colonisation sites, some 
mycoplasmas can colonise the alimentary canal, eyes, joints and mammary glands (Vasconcelos 
et al. 2005). The host- and tissue-specificity of mycoplasmas may be attributed to their unusual 
nutritional requirements, such as cholesterol (Kleven 1998).   
Domestic poultry infections have been the focus of most of the studies on avian mycoplasma 
infections, with M. gallisepticum, M. synoviae, M. iowae and M. meleagridis the four major 
pathogens associated with poultry mycoplasma infection. M. gallisepticum and M. synoviae infect 
chickens and turkeys, while M. iowae and M. meleagridis mostly only infect turkeys (Bradbury 
2005). Botes et al. (2005b) studied mycoplasma infections in ostriches and identified three different 
mycoplasmas species that infect ostriches in South Africa using 16S rRNA gene sequencing, and 
Figure 2.1: Oligopeptide permease (Opp) system: A. An oligopeptide binds to the substrate-binding 
domain (OppA). OppA transports the oligopeptide to the hydrophobic transmembrane domain (OppBC). B. 
The interaction of OppA with OppBC along with ATP binding at the hydrophilic ATP-binding domains 
(OppDF) causes i) ATPase activity activation upon closure of OppDF ii) a conformational change in OppBC 
exposing an oligopeptide binding site and iii) OppA to open and release the oligopeptide for binding to 
OppBC. C. After ATP hydrolysis on both OppA and OppDF, OppBC undergoes another conformational 
change, releasing the oligopeptide into the cytoplasm. Adapted from Davidson & Maloney (2007). 
ADP + Pi 
C. A. B. 
OppA ATP 
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provisionally named them Mycoplasma struthionis 01 (Ms01), Mycoplasma struthionis 02 (Ms02), 
and Mycoplasma struthioniss 03 (Ms03) after their host Struthio camelus; the ostrich. 
2.1.4. Ostrich-specific mycoplasmas 
General characteristics and phylogeny  
Botes et al. (2005b) tested samples from the main ostrich producing areas in South Africa. Apart 
from the identification of three novel mycoplasma species, Botes et al. (2005b) also determined 
that these three mycoplasmas did not infect poultry in close proximity to the infected ostriches, and 
are thus host-specific to ostriches. Langer (2009) isolated Ms01 and Ms03 from samples collected 
from ostriches in Namibia in an attempt to classify these species and described them as 
Mycoplasma struthionis sp. nov. and Mycoplasma nasistruthionis sp. nov. Langer (2009) found 
some similarities but also differences between these two species. On agar both species have a 
fried-egg appearance and are non-motile, they are chemo-organotrophs and require serum or 
cholesterol for growth (Langer 2009).  
Mycoplasma struthionis, isolated from the lower respiratory tract, therefore replaces the provisional 
naming of ostrich-specific mycoplasma Ms01. These mycoplasmas form trunk-like structures and 
as can be seen in figure 2.2A, the cells do not aggregate. Mycoplasma nasistruthionis, isolated 
from the upper respiratory tract, replaces the provisional naming of the ostrich-specific 
mycoplasma Ms03. As seen in figure 2.2B the cells of this mycoplasma do aggregate (Langer 
2009). To date ostrich-specific mycoplasma Ms02 has not been described. 
 
A phylogenetic study of the three mycoplasmas (figure 2.3) shows that M. struthionis (Ms01) falls 
in the same clade as Mycoplasma falconis, distinct from Ms02 and Mycoplasma nasistruthionis 
(Ms03) that falls in the same clade as Mycoplasma synoviae (Botes et al. 2005b). Due to the close 
relationship, Botes et al. (2005b) proposed that the previous identification of Mycoplasma synoviae 
in ostriches (Verwoerd 2000) might have rather been Ms02 or Mycoplasma nasistruthionis (Ms03). 
Figure 2.2: Scanning electron micrographs, taken from Langer (2009), of A. Mycoplasma struthionis sp. nov. 
and B. Mycoplasma nasistruthionis sp. nov. (Langer, Stefan 2009) 
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Prevention, treatment and control 
Mycoplasma infections in ostriches are associated with respiratory disease. As in mycoplasma 
infections in many other hosts, mycoplasma infections in ostriches are associated with co-
infections with other bacterial pathogens (Botes et al. 2005a). Among the clinical signs observed 
are swelling of the sinuses, foaming of the eyes, a rattling sound in the throat as well as a watery 
discharge from the nostrils. These symptoms result in a reduction in growth rate, which delays 
slaughter age, as well as carcass downgrading and susceptibility to secondary infections resulting 
in stock and production losses (Olivier 2006). 
Methods of control of mycoplasma infection in avian species include good biosecurity practices 
and good farming practices, but these methods are only partially effective. Regular monitoring of 
feed and water quality, weight increase, stress conditions and symptoms can aid in the 
management of mycoplasma infection (Olivier 2006). Some ostriches are mycoplasma carriers, 
showing no symptoms, and are only partially responsive to the treatments available, making it 
difficult to control mycoplasma infections on ostrich farms. 
Mycoplasmas can be treated with antibiotics, but are resistant to conventional antibiotics that 
prevent cell wall formation, such as penicillin and cephalosporin (Kleven 1998). Among the 
antibiotics that mycoplasmas are sensitive to are tetracycline and macrolides that target protein 
synthesis and fluoroquinolones that inhibit DNA replication and transcription. In the South African 
ostrich industry the tetracyclines, oxytetracycline, doxycycline, chlortetracycline; the macrolide, 
tylosin; and the fluoroquinolone, advocin are used against mycoplasma infections (Olivier 2006). 
Even though these antibiotics are effective against the symptoms of mycoplasma infection, they 
only aid in the management and do not lead to the total eradication of mycoplasma infections. The 
use of antibiotics can lead to antibiotic resistance and antibiotics are not totally effective and 
expensive, and there is therefore an urgent need for an effective means to prevent mycoplasma 
infections in ostriches. 
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.  Figure 2.3: Phylogenetic relationships of the three ostrich-specific mycoplasma species to other 
mycoplasmas using 16S rRNA sequences. One of the shortest trees from the parsimony analysis is shown 
with the branch lengths indicated above branches and the bootstrap values below the branches. Branches 
with less than 50% bootstrap support are not shown (Botes et al. 2005b)  
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2.2. Vaccines  
2.2.1. A short history of vaccines 
Vaccines are biological agents used to improve immunity against a specific disease. The word 
vaccine originated from the latin word for cowpox disease, Varioloe Vaccinae, which was the first 
vaccine used in the Western World. Prior to this variolation, the smallpox virus itself was used to 
inoculate people, which was common practise in China. In the 18th century, Edward Jenner 
showed that cowpox could be used to prevent smallpox. Variolations were able to reduce the 
mortality rate as well as the development of scarring upon natural infection, but the use of the 
cowpox vaccine was a safer method. In the 19th century, Louis Pasteur found a way to attenuate 
organisms in the laboratory and developed vaccines against anthrax and rabies (Plotkin 2011). 
The chemical inactivation of a Salmonella sp. by Salmon and Smit in 1886 opened other 
possibilities that led to the development of the killed vaccines that were effective against cholera, 
typhoid and the plague towards the end of the 19th century (Plotkin 2011). Albert Calmette and 
Camille Guérin used Mycobacterium bovis to develop the live attenuated Bacille Calemette Guérin 
vaccine that was effective against tuberculosis in the early 20th century. Another important vaccine 
developed during this period was the live attenuated vaccine effective against yellow fever by Max 
Theiler in 1937 (Plotkin 2011). 
2.2.2. Types of vaccines 
At the start of the 21st century, the three main types of vaccines in use were live attenuated, killed 
and subunit vaccines (Alpar, Papanicolaou & Bramwell 2005). Live attenuated vaccines are 
mutants of the causative pathogens compromised in their ability to cause disease in the host, and 
include examples such as the vaccines for measles, yellow fever and mumps (Mäkelä 2006). The 
selected mutants are still immunogenic and can protect the host against infection from the wild 
type pathogen, but this is also a safety concern, as there remains the possibility of reversion to the 
pathogenic form (Alpar, Papanicolaou & Bramwell 2005). Killed vaccines are inactivated whole 
organisms and an example is the pertussis vaccine (Mäkelä 2006). Major safety concerns 
associated with killed vaccines include the possibility of incomplete activation, variable potency and 
contamination as was observed with the inactivated polio vaccine created by Salk in 1955, and 
adverse reactions, such as local inflammation and seizures caused by the pertussis vaccine. 
Subunit vaccines are vaccines where only a part of the pathogen is used and include the tetanus 
and diphtheria vaccines (Alpar, Papanicolaou & Bramwell 2005). Subunit vaccines are produced 
rapidly in cultured microorganisms, such as E. coli, at lower cost (Alpar, Papanicolaou & Bramwell 
2005). This type of vaccine does have its flaws in that some have shown low immunogenicity and it 
is sometimes difficult if not impossible to identifiy the specific antigens that are capable of eliciting 
an immune response. The identification of candidate antigens as well as their presentation to the 
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immune system has become the main focus of current vaccine research (Alpar, Papanicolaou & 
Bramwell 2005). 
Wolff et al. 1990 (Wolff et al. 1990) observed expression of a reporter transgene in transfected 
mouse cells after an injection of plasmid DNA. After Tang et al. (1992) introduced a plasmid 
containing a gene encoding a protein to the mouse skin and observed an immune response, he 
suggested that this method could be used as a genetic immunization against pathogens. Together 
this led to the discovery of DNA vaccines that can be produced at lower cost, with increased 
stability, higher purity and a lower risk of reversion (Alpar, Papanicolaou & Bramwell 2005). This 
vaccine type also has the advantage that only the antigen of interest is expressed and both 
antibody- and cell-mediated immune responses can be induced. There are, however, concerns 
associated with DNA vaccines, such as germ-line alterations and the induction of immune 
tolerance and autoimmunity (Alpar, Papanicolaou & Bramwell 2005). Despite these concerns 
numerous advantages of DNA vaccines make them a more attractive approach for vaccine design 
(Alpar, Papanicolaou & Bramwell 2005). 
2.2.3. Mycoplasma vaccines 
There have been a number of attempts to generate effective mycoplasma vaccines. Vaccines 
against the poultry mycoplasmas Mycoplasma gallisepticum and Mycoplasma synoviae, include 
inactivated, oil emulsion bacterins and live attenuated vaccines (Kleven 1998). An immune 
response was elicited in ostriches againts two commercially available oil-emulsion poultry 
mycoplasma vaccines, Ms-Bac and Mg-Bac against Mycoplasma synoviae and Mycoplasma 
gallisepticum, respectively (van der Merwe 2006). Further studies showed that these vaccines 
were unable to protect the ostriches against ostrich-specific mycoplasma infection (Pretorius 
2009). It was also found that cultivation of the ostrich-specific mycoplasmas is difficult, which 
makes it difficult to follow the traditional routes of vaccine development (Botes et al. 2008). The 
advantages of DNA vaccines over killed and live vaccines, has directed recent research on 
mycoplasma vaccines mainly to DNA vaccines. DNA vaccines generated against Mycoplasma 
hyopneumoniae, which causes enzootic pneumonia in pigs, have shown promising results with an 
immune response elicited in mice (Chen et al. 2003) and reduced infection in pigs (Fagan et al. 
1996). 
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2.2.4. DNA vaccines 
DNA vaccine design 
The typical generation of a DNA vaccine is shown in figure 2.4. Firstly the genome of the pathogen 
is studied to identify a suitable vaccine candidate gene. This candidate gene should ideally encode 
an antigenic protein that can elicit a protective immune response (Doria-Rose, Haigwood 2003). 
Membrane proteins associated with cytadherance and transport are immunogenic and considered 
as good candidates for use in the development of DNA vaccines. Pretorius (2009) used next 
generation sequencing to sequence a major part of the genome of Mycoplasma struthionis. 
Through bioinformatic analysis of the contiguous sequences that were generated, the oppA gene 
of Mycoplasma struthionis was identified by sequence homology to the oppA gene of Mycoplasma 
hominis (Pretorius 2009). The oppA gene is the substrate binding domain of oligopeptide 
permease system (figure 2.1) involved in host attachment and nutrient uptake, making it a good 
candidate gene for vaccine development (Garmory & Titball 2004, Tanabe et al. 2006).  
The next step in developing a DNA vaccine is to insert the candidate gene into a suitable vaccine 
plasmid. A number of elements are required to construct a suitable plasmid that can be used as a 
vector for DNA vaccination. An origin of replication (ori), the sequence where replication is initiated, 
and a selection marker are both required to allow plasmid reproduction and the stable maintenance 
of the plasmid when grown in bacteria. An example of a suitable ori is the Co1EI gene of E. coli of 
the pUC plasmid, which is a high copy number ori, and increases the plasmid yield (Ertl & 
Thomsen 2003). An antibiotic resistance gene is used as the selection marker to ensure 
multiplication of plasmids containing the candidate gene. To direct expression of the candidate 
gene in a eukaryotic host a strong eukaryotic promoter and a eukaryotic polyadenylation (polyA) 
signal must be included. Eukaryotic promoters that mediate high expression levels include the 
Rous sarcoma virus promoter (RSV) and the Simian vacuolating virus promoter (SV40) (Donnelly 
et al. 1997). The cytomegalovirus promoter immediate early gene promoter (CMV-IE), along with 
the first intron from the IE1 gene (intronA), results in strong expression and is most often used (Ertl 
& Thomsen 2003). The polyA signals used most often are the polyA signal of SV40 and bovine 
growth hormone (BGH) to stabilize the mRNA transcript (Gurunathan, Klinman & Seder 2000). The 
promoter and polyA signal are separated by a multiple cloning site, which is used to insert the 
candidate gene using restriction sites (Ertl & Thomsen 2003). The candidate gene is then cloned 
into such a plasmid vector to generate the required DNA vaccine. 
The vaccine plasmid into which the candidate gene is inserted is multiplied in bacteria, such as E. 
coli, to increase the number of plasmid copies. The DNA vaccine can then be isolated from the 
bacteria and purified for host immunization. The routes of administration mostly used to deliver 
DNA vaccines are intramuscular injections (i.m.) or intradermal injections (i.d.) with either a 
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hypodermic needle or a gene gun (Dufour 2001). After DNA immunization, either the somatic cells 
at the site of injection, myocytes in the case of i.m. injection, or professional antigen presenting 
cells (APCs) such as dendritic cells (DCs) and macrophages can be transfected. The transfected 
somatic cells express and secrete the antigen for presentation by professional APCs. The 
transfected APCs can either process and present the antigen itself or secrete the antigen for 
presentation by another APC. APCs then present the antigen on Major Histocompatibility Complex 
(MHC) class I and class II molecules as shown in figure 2.4B. MHC class I molecules present the 
antigen to the cytotoxic T-lymphocytes (CTLs) receptors and CD8+ receptors resulting in a cellular 
immune response. The antigen presented on MHC class II molecules is presented to helper T-
lymphocytes receptors and CD4+ receptors. Helper T-lymphocytes promote a cellular immune 
response by aiding in the proliferation of activated CTLs. Helper T-lymphocytes also stimulate the 
proliferation of B cells to produce a humoral immune response (Gurunathan, Klinman & Seder 
2000). DNA vaccines thus have the potential to elicit both a B- and a T-cell immune response. 
Efforts to generate DNA vaccines against pathogens were effective in many mouse studies, but 
appeared to be less effective  in humans and larger animals. The low potency was attributed to the 
low level of APC transfection achieved, which redirected research to improving methods of 
administration. Methods that have been used include electroporation after needle injection, jet 
ejection and topical application at mucosal sites. To elicit an effective immune response with these 
methods, large doses of plasmid DNA are required, also resulting in low potency in large animals. 
Research efforts then focused on effective modes of delivering the plasmid DNA to the immune 
system (Donnelly, Berry & Ulmer 2003). These efforts included adjuvants, such as liposomes and 
biodegradable polyester particles (Alpar, Papanicolaou & Bramwell 2005). Liposomes are 
bilayered phospholipid particles used to encapsulate both water-soluble and hydrophobic particles, 
but can be toxic and in biological environments tend to be unstable (Alpar, Papanicolaou & 
Bramwell 2005). Biodegradable polyester particles are polymers, such as polyglycolide (PGA) and 
polylactide (PLA), used to encapsulate particles (Alpar, Papanicolaou & Bramwell 2005). Although 
these particles have been used successfully to deliver protein antigens, they carry a slight negative 
charge that may lead to inefficient encapsulation of DNA plasmid vaccines (Alpar, Papanicolaou & 
Bramwell 2005). A method of delivery that shows promise is the use of bacterial vectors to deliver 
DNA vaccines, especially to elicit a mucosal immune response that would be required to create an 
effective vaccine against Mycoplasma spp. as described in the next section (Alpar, Papanicolaou & 
Bramwell 2005). 




Figure 2.4: Graphic representation of DNA vaccine design and immune activation taken from (Dufour, V. 
2001). A. DNA vaccine preparation: 1. The identification and isolation of a candidate gene. 2. Cloning of 
candidate gene into a suitable expression vector. 3. The amount of plasmids is increased by propagation in 
bacteria. 4. Isolation and purification of plasmids from the bacteria to immunize the host. B.  Immune 
response elicited by DNA vaccine: After injection of the vaccine, the candidate gene is transcribed and 
translated in the nucleus and presented on MHC class I and II molecules. i. MHC class II molecules are 
found on APCs such as DCs and B cells and present the antigen to CD4+ receptors present on helper T-
lymphocytes. I.m. injections primarily promotes the activation of a T-helper cell 1 (Th1) response, which aids 
in the proliferation of activated CTLs. A T-helper cell 2 (Th2) response can also occur and activates a 
humoral immune response by stimulation of B cell maturation. B cell maturation results in both the 
production of antibodies and development of memory B cells ii. MHC class I molecules are found on 
nucleated cells, thus excluding erythrocytes, and present the antigen to CD8
+
 receptors on cytotoxic T-
lymphocytes. Once activated the CTL can either induce apoptosis of cells displaying the antigen or activate 
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2.2.5. DNA vaccines against the ostrich-specific mycoplasma, Mycoplasma struthionis 
Pretorius (2009) isolated the oppA gene from Mycoplasma struthionis and inserted the gene into 
each of three plasmid vectors, pCI-neo, VR1012 and VR1020. All three of these plasmids have a 
CMV promoter promoting strong expression of the gene upstream of a universal vaccine candidate 
gene insertion site. Apart from the CMV promoter, the pCI-neo plasmid vector (figure 2.5) also has 
a phosphotransferase gene, which is a selectable marker for mammalian cells aiding in the 
selection of the stable transformants, a downstream SV40 polyA signal and the ampicillin 
resistance gene (Promega September 2009, Mortensen et al. 2001). The VR1012 plasmid vector 
(Vical Inc) is made up of intronA, the BGH polyA signal and contains a kanamycin resistance gene. 
The VR1020 plasmid vector (Vical Inc) also has a BGH polyA signal and kanamycin resistance 
gene, but differs from VR1012 with the presence of the upstream tissue plasminogen activator 
(tPA) signal peptide that aids in secretion of the protein after expression (Coban et al. 2005). In this 
way, Pretorius (2009) therefore generated three potential DNA vaccines for use against the ostrich-
specific mycoplasma, Mycoplasma struthionis. The effectivity of these vaccines have not been 
conclusively determined.  
 
2.2.6. Bacterial carriers of DNA vaccines 
Advantages and disadvantages of bacteria as DNA vaccines carriers 
Apart from the use of bacteria to improve the DNA vaccine delivery to the host immune system, 
bacteria also add other advantages for their use as DNA vaccine carriers. The use of naked DNA 
as a vaccine requires prior plasmid amplification and purification, which can be labour intensive 
and plasmid degradation can occur during storage. However, a DNA vaccine plasmid can be 
Figure 2.5: Circle map of the pCI-neo vector map. Neo = neomycin phospotransferase, CMV I.E. = 
cytomegalovirus immediate-early. 
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transformed into a bacterial vector with relative ease using methods such as electroporation or 
chemical methods. After transformation, only proliferation of the bacteria is required to produce the 
bacterial DNA vaccine, lowering the cost and labour necessary for mass production and large-
scale immunization (Schoen et al. 2004). 
Bacterial DNA carrier vaccines are commonly administered as oral vaccines, which reduces the 
time and labour required to immunize large groups of animals. Oral vaccination also reduces the 
amount of stress the host experiences which then reduces the risk of a compromised immune 
system (Qu et al. 2008). The use of naked DNA vaccines mostly stimulate a serum immune 
response, but bacterial DNA vaccines can elicit both a mucosal and serum immune response 
(Barry et al. 1996). Other advantages of bacterial DNA vaccines include their use to target specific 
sites for release of the DNA vaccine and the possibility that more than one DNA vaccine can be 
delivered per bacterial carrier (Barry et al. 1996, Pasetti et al. 1999). 
A concern for the use of bacteria as vaccine carriers is the possibility of reversion to virulence, but 
this risk is lowered when the bacterial strain is attenuated with multiple deletions (Autenrieth & 
Schmidt 2000). Live viruses have also been considered as vaccine carriers, but the use of bacterial 
carriers has some advantages over viruses when infection by the vector occurs. If a host is 
immune compromised, the carrier vector can cause infection, but there are effective antibiotics 
available to clear up a bacterial infection, which is better than the treatments required for viral 
infection (Schoen et al. 2004). 
Use of bacteria as DNA vaccine carriers 
Bacteria can be used to deliver DNA vaccines to the immune system either as recombinant 
vaccines, where the bacteria are used to express the antigen for presentation to the immune 
system, or as carrier, where the bacteria deliver the DNA plasmid vaccine to the immune system. 
Chen and co-workers (2006b) found that using Salmonella typhimurium only as a bacterial carrier 
of the antigen, NrdF, is more effective as an oral vaccine to induce an immune response than if 
Salmonella enterica serovar typhimurium is used to express the antigen (Fagan et al. 1997).  
Intracellular bacteria are exploited as carriers of DNA vaccines for their ability to infect the gut 
mucosa successfully and to stimulate an immune response. The bacteria most often used are the 
extracellular bacteria, Yersinia spp.; the intracytosolic bacteria, Listeria monocytogenes and 
Shigella spp. and the intraphagosomal bacteria, Salmonella spp. (Pasetti et al. 1999, Sizemore, 
Branstrom & Sadoff 1997). Proliferation of the bacterium, Yersinia enterolitica, occurs 
extracellularly once it crosses the mucosal barrier to the abdominal lymphatic tissue. Attenuation 
can diminish the resistance of this bacterium to phagocytosis allowing delivery of DNA vaccines. 
Shigella spp. cross the mucosa microfold cells (M cells)  found in Peyer‟s patches and have the 
ability to invade macrophages and DC‟s. L. monocytogenes, is the only Gram-positive carrier strain 
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that has been used thus far. This organism has the advantage over Gram-negative bacteria in that 
it does not possess lipopolysaccharides, eliminating their potential toxic effects. L. monocytogenes, 
also has the ability to invade the APC‟s and multiply within the cell cytosol, but this organism can 
spread to other tissues by moving from one cell to another. Attenuated strains used can still enter 
the cell cytoplasm, but are hampered in their ability to spread to other cells. Salmonella spp., more 
specifically Salmonella enterica serovar typhimurium and Salmonella enterica serovar typhi also 
enter the lymphatic system through the M cells that line Peyer‟s patches and then induce their 
uptake by phagocytes. Attenuated Salmonella spp. can still induce uptake by the phagosome, but 
do not replicate, and release the DNA vaccine (Gurunathan, Klinman & Seder 2000). 
2.2.7. Salmonella as carriers of DNA vaccines  
Salmonella are Gram-negative bacteria in the order Enterobacteriales. These rod-shaped (figure 
2.6) bacteria are facultative anaerobes and intracellular pathogens of both humans and animals. 
Salmonella are considered good candidates for DNA vaccine carriers due to their ability to invade 
phagocytes and proliferate without being phagocytosed, thereby evading the host immune system 
(Schoen et al. 2004, Turner, Carbone & Strugnell 1993). Numerous attenuated Salmonella spp. 
have been modified for use as carriers of DNA vaccines, some of which are listed in Table 2.1. 
Most of the studies listed were conducted in mice, but a few of the studies have shown that they 
can give protection to infection with virulent pathogens.   
The Salmonella enterica serovar typhimurium strain SL3261 was used to carry a DNA vaccine 
against Feline Immunodeficiency Virus (FIV) that elicited an immune response in cats (Titball et al. 
1997). In dogs, Salmonella enterica serovar typhimurium LVR01 was used as a DNA vaccine 
carrier to elicit an immune response against Echinococcus granulosus (Chabalgoity et al. 2000). It 
has been proposed that using a strain of Salmonella that naturally infects the host might elicit a 
better immune response as these strains are adapted for infection of the host of interest 
(Chabalgoity et al. 2000, Stabel et al. 1993). In pigs various Salmonella spp. have been used as 
carriers against various diseases, such as Brucella abortus (Stabel et al. 1993) and Mycoplasma 
hyopneumoniae (Fagan et al. 1997, Fagan et al. 2001,Fagan et al. 1997). In chickens Salmonella 
spp. have also shown promise as carriers of a DNA vaccine against Eimeria tenella (Pogonka et al. 
2003). In the context of this study Salmonella enterica serovar typhimurium is a common pathogen 
found in ostriches (Verwoerd 2000). 
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Salmonella enterica serovar typhimurium SL3261 is a non-reverting, highly attenuated aroA mutant 
generated by Hoiseth and Stocker (1981). This strain has a deletion in the aroA gene, with the 
result that it has become an auxotrophic organism with limited growth in vivo (Chen et al. 2006b, 
Fagan et al. 1997, Fagan et al. 2001). Auxotrophic mutations inhibit bacterial proliferation due to an 
inability to produce essential compounds (Raupach & Kaufmann 2001). Salmonella enterica 
serovar typhimurium SL3261 require the compounds p-aminobenzoic acid and 2,3-
dihydroxybenzoate, not found in mammalian cells, for aromatic amino acid synthesis as well as for 
growth (Raupach, Kaufmann 2001). In spite of this, a mucosal as well as a humoral immune 
response can be elicited by such aroA mutants (Yang et al. 1990).The aroA mutants can invade, 
colonize and persist in vivo, but remain avirulent. This allows the bacterium to prime both cellular 
and humoral immunity by interaction with macrophages, B cells and T cells, making it a good 
candidate for use as a DNA vaccine carrier. These mutants have been shown to serve as effective 
carriers of DNA vaccines (Bao & Clements 1991, Chatfield et al. 1993). 
Immune response elicited by Salmonella bacteria  
To determine the immune response elicited by Salmonella spp. various studies have been 
performed, but so far only a basic understanding of Salmonella infections has been established. 
The mucosal immune response elicit by bacteria after oral or intranasal application is shown in 
figure 2.7. (Kiyono & Fukuyama 2004). Salmonella spp., in most studies administered orally, attach 
to the epithelial layer of the intestinal tract with the aid of fimbral adhesions and invade the M cells 
that line the Peyer‟s patches in the intestine. M cells are specialized epithelial cells found in the 
Nasopharynx-associated lymphoid tissue (NALT) and Peyer‟s patch follicle; and transport 
microorganisms and other macromolecules across the epithelial layer to the cells of the immune 
system. M cells play an important role in stimulation of mucosal immunity. The bacterium then 
induces phagocytosis by APC‟s. APC‟s include cells such as DC‟s, macrophages (Mϕ) and B cells. 
DC‟s take up the bacterial antigens by endocytosis and macrophages phagocytose bacteria 
(Kiyono, Fukuyama 2004). 
Figure 2.6: Scanning electron micrograph of Salmonella typhimurium taken from Rocky Mountain 
Laboratories (2006) 
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Table 2.1: Strains of attenuated Salmonella spp. used as vaccines carriers.   






Impaired in their ability to produce aromatic amino 
acids required for in vivo replication 
SL3261 




hyopneumoniae (porcine enzootic 
pneumonia), Eimeria tenella 
(coccidiosis) 
(Kiyono & Fukuyama 
2004) 
SL7207 
Listeria monocytogenes (listeriosis), H9 
low-pathogenic avian influenza virus 
(Bauer et al. 2005,  
Pan et al. 2009) 
SL7237 Listeria monocytogenes (listeriosis) (Darji et al. 2000) 
CS332 
Mycoplasma hyopneumoniae (porcine 
enzootic pneumonia) 
(Chen et al. 2006a) 
aroC LVR01 
Echinococcus granulosus (hydatid 
disease) 
(Chabalgoity et al. 2000) 
htrA 
Mutation in a gene for a stress protein (heat shock 
protein) 







Mutation in DNA adeninemethylase gene and 
defective in macrophage intracellular survival 
(mutation in two component regulatory gene) 
SV4089 Eimeria tenella (coccidiosis) (Du & Wang 2005) 
Δcya, 
Δcrp 




 Brucella abortus (brucellosis) (Stabel et al. 1991) 
phoP 
Defective in macrophage intracellular survival 




Helicobacter pylori (gastritis and gastric 
ulcers) 
(Corthesy-Theulaz et al. 
1998) 
gale 
Inactivation that leads to galactose-induced cell 
lysis, interfering with Vi polysaccharide production 
Ty21a E. coli (diarrhea) 







Double aro mutant Ty2 Clostridium tetani (tetanus) (Chatfield et al. 1992) 
ΔguaBA 
Deletion mutation that impairs guanine nucleotide 
biosynthesis 
CVD 915 Clostridium tetani (tetanus) (Chatfield et al. 1992) 
aroA his 
Impaired in their ability to produce aromatic amino 
acids required for in vivo replication, histamine 
requiring mutant 
SL1438 E. coli (diarrhea) (Bost & Clements 1995) 
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Salmonella enterica serovar typhimurium and Salmonella enterica serovar typhi can evade the 
host immune immune system. The mechanism, by which this is accomplished, was thought to 
involve the induction of phagocytosis by DC‟s. Recently Tobar et al. (2006) described this 
mechanism in more detail, explaining that these bacteria prevent degradation by lysosomes, 
allowing proliferation. Mutated Salmonella spp. are attenuated in their ability to evade the host 
system by this mechanism as shown in figure 2.8 (Bost & Clements 1995). Once the bacterium is 
phagocytosed by an APC, the lysosome degrades the bacterial carrier (Tobar et al. 2006) 
releasing the DNA plasmid vaccine into the cytosol. The DNA plasmid then moves to the nucleus 
for antigen gene expression. From here, the adaptive immune response can be elicited, the first 
method is by direct priming, the antigen released in the cytosol is processed by the APC and 
presented to T-cytotoxic cells via MHC class I. The second method involves cross-priming, where 
the processed antigen is released, after apoptosis, from the cell and internalized by another APC. 
The antigen is then processed in an endosome and presented via MHC class II molecules to T-
helper cells. Lastly microbe-associated molecular patterns (MAPS) can be recognised by Toll-like 
receptors (TLR) to elicit an innate and adaptive immune response (Xu & Ulmer 2003). 
Salmonella spp. have a number of MAPS recognized by the host. Among the most important are 
lipopolysaccharides (LPS) and flagellin. LPS, found on the outer membrane of the bacterium, is 
recognized by Toll-like receptor 4 (TLR4) to stimulate the innate immune system. Flagellin, 
recognised by TLR5, forms part of the filaments that make up the flagellum of the bacteria and 
translocate across the epithelial barrier inducing an inflammatory response (Pan et al. 2009). Once 
the bacteria is internalised by DCs the bacterium is processed and the peptides presented on the 
cell surface. Helper T cells then recognise antigen bound MHC class II molecules and are 
activated to provide help for immunoglobulin A (IgA) committed B cell development (figure 2.8). 
This is followed by affinity maturation to increase the affinity of the antibody for the antigen. The 
CD4+ T cells and IgA+ B cells migrate from the inductive sites, via the efferent lymphatic vessels, to 
the mesenteric lymph nodes. From the lymph nodes, the cells migrate, via the thoracic duct and 
blood circulation to the effector sites. The effector sites include the glandular tissues and lamina 
propria of both the respiratory and intestinal tracts. CD4+ T helper cell type 2 (Th2) cells produce 
various cytokines, such as interleukin-5 (IL-5) and IL-6, which stimulate the differentiation of the 
immature IgA+ B cells into mature IgA producing plasma cells. The plasma cells produce IgA, in the 
dimeric or polymeric forms, which bind to Ig receptors. The secretory IgA are released from the 
monolayer of the epithelial cells into the nasal passage and intestinal tract, respectively (Kiyono, 
Fukuyama 2004). 
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If all of the factors discussed before are taken into account, the Salmonella enterica serovar 
typhimurium SL3261 bacterial strain thus holds excellent potential as a DNA vaccine carrier for use 
in ostriches which was the strategy followed in this study. The preparation and stability of mucosal 
vaccines against the ostrich mycoplasma, Mycoplasma struthionis, using Salmonella enterica 
serovar typhimurium SL3261 as a carrier bacteria will be described and the results of the 















Figure 2.7: The mucosal immune response (Kiyono & Fukuyama 2004): 1. Antigens, introduced intranasally 
or orally, invade the M cells that line the epithelial layer. 2. APC internalize the bacteria, process the bacterial 
antigens and present the antigens on their surfaces, bound to MHC class II molecules. 3. Helper T cells 
recognise antigen bound MHC class II molecules and are activated to provide help for IgA committed B cell 
development. 4. The CD4
+
 T cells and IgA
+
 B cells migrate from the inductive sites, via the efferent lymphatic 
vessels, to the cervical lymph nodes and to the mesenteric lymph nodes for NALT and Peyer‟s patches 
respectively. From the respective lymph nodes, the cells migrate, via the thoracic duct and blood circulation 
to the effector sites. 5. CD4
+
 T helper cell type 2 (Th2) cells produce various cytokines, such as interleukin-5 
(IL-5) and IL-6, which stimulates the differentiation of the immature IgA
+
 B cells into mature IgA producing 
plasma cells. The plasma cells produce IgA, in the dimeric or polymeric forms, which bind to Ig receptors. 
Secretory IgA is released from the monolayer of the epithelial cells into the nasal passage and intestinal 
tract, respectively. 
1. 
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Figure 2.8: Delivery of DNA plasmid vaccine by attenuated Salmonella spp. taken from Xu & Ulmer (2003). 
1. The bacteria are internalized by an APC where lysosomes degrade the bacterial carrier releasing the DNA 
plasmid vaccine into the cytosol. The DNA plasmid moves to the nucleus for expression of antigen. The 
immune response can be primed by Salmonella spp. in various ways. 2. The first method is by direct priming. 
The antigen is processed by the APC and presented to T cells via MHC class I molecules on the surface of 
the APC. 3. An adaptive immune response can also be elicited by cross priming. The processed antigen is 
released, after apoptosis, from the cell and internalized by another APC. The antigen is then processed and 
presented via MHC class I molecules to T cells. 4. Lastly MAPS can be recognised by Toll-like receptors 
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Chapter 3: Oral vaccine preparation 
3.1. Introduction 
The effectiveness of a DNA vaccine depends mainly on the immunogenicity of the chosen antigen, 
and the level of gene expression in eukaryotic cells (Raupach & Kaufmann 2001). The elements of 
the bacterial plasmid into which the vaccine candidate gene is inserted also plays a role in the 
ability of the DNA vaccine to elicit an immune response. The most important factors include an ori, 
which directs the production of high plasmid yields, a strong promoter and polyA termination 
sequence that all influence the level of gene expression and directs expression of the candidate 
gene and an antibiotic resistance gene for successful transformation selection (Alpar, 
Papanicolaou & Bramwell 2005, Dufour 2001). Other elements that can be included are an intron 
following the promoter for higher expression levels, a signal sequence, such as tPA, to direct 
secretion of the translated protein, cytidine-phosphate-guanosine (CpG) motifs can also be 
included to increase the antigen-specific immune response (Donnelly et al. 1997). The routes of 
DNA vaccine delivery include mostly intramuscularly, but to produce a mucosal immune response 
the oral or intranasal routes are suggested (Ertl & Thomsen 2003). The vaccine delivery systems 
can also play a role in the ability and effectiveness of a DNA vaccine to elicit an immune response. 
Routes that have been investigated to protect the DNA vaccine from extracellular degradation are 
encapsulated in biodegradable polyester particles, enclosed in liposomes and delivery via bacterial 
carriers (Gurunathan, Klinman & Seder 2000). Other factors that also play a role include the 
frequency of immunization and the localisation of the expressed antigen (Alpar, Papanicolaou & 
Bramwell 2005, Gurunathan, Klinman & Seder 2000). The choice of each of these factors differs 
from one DNA vaccine to the next and various strategies can be investigated to ensure that the 
DNA vaccine is capable of eliciting an immune response and confer protection.  
Pretorius (2009) identified the vaccine candidate gene, oppA in M. struthionis using bioinformatic 
analysis, which forms part of the oligopeptide permease system. The gene was isolated and 
transformed into each of three plasmids; pCI-neo, VR1012 and VR1020. Brandt (2012) injected the 
ostriches intramuscularly with each of the three naked DNA vaccines, but the results were 
inconclusive due to an outbreak of avian influenza (AI) that influenced the outcome of the vaccine 
trial. In the attempt to create an effective ostrich-specific mycoplasma vaccine the use of a 
bacterial carrier to deliver the DNA vaccine was considered as a potential improvement, but more 
importantly because a mucosal immune response was actually required as Mycoplasma struthionis 
infects the respiratory tract of ostriches. Salmonella enterica serovar typhimurium SL3261 was 
chosen as a potential carrier because it contains a deletion in the aroA gene limiting its growth in 
vivo. This strain is also capable of eliciting a humoral and mucosal immune response (Dufour 
2001) and Salmonella species are common pathogens of the ostrich gastro-intestinal tract.  
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To prepare the mucosal DNA vaccine each of the three naked DNA vaccines had to be prepared in 
sufficient amounts. To this end the vaccines were first transformed in E. coli cells for proliferation, 
and then purified. To insert a DNA vaccine into Salmonella enterica serovar typhimurium SL3261 
the method of electroporation is often used. Electroporation (figure 3.1) is a method by which an 
electrical field is applied to transform the bacterial cell with the plasmid (Sanderson, MacLachlan, & 
Hessel 1995). Electroporation is preferentially used because it is a faster transformation method, 
with a higher efficiency than chemical methods (O'Callaghan & Charbit 1990, Taketo 1988). For 
this reason each of the three DNA vaccines were electroporated into the carrier bacteria and the in 
vivo stability of the DNA vaccines in the bacterial carrier was also tested. 
 
3.2. Materials and Methods 
3.2.1. Naked DNA vaccines 
3.2.1.1. Transformation  
The recombinant plasmids pCI-neo, VR1012 and VR1020, containing the oppA gene, were 
previously prepared in the laboratory (Pretorius, 2009). An amount of 50 ng of each vector was 
mixed with 50 µl competent JM109 E. coli cells in a 17 x 100 mm polypropylene round-bottom tube 
(14 ml Falcon® tube) and incubated on ice for 10 min. The mixture was heat shocked in a 42°C 
water bath for 45 sec and then incubated on ice for 2 min. The transformed cells were incubated in 
950 µl of Luria broth (LB) medium (10 g/L Bacto-tryptone (Biolab, Merck), 5 g/L Bacto-yeast extract 
(Biolab, Merck), 5 g/L NaCl and pH set to 7) at 37°C, and rotated on an orbital shaker (IKA® K260 
basic) at 150 rpm for 30 min. One hundred microliter of the transformed cells were plated onto 
plastic Petri dishes containing LB agar (LB medium with 15 g/L agar (Biolab, Merck). For the 
recombinant plasmid pCI-neo, the antibiotic ampicillin (100 µg/ml, Sigma-Aldrich) was added to the 
Figure 3.1: Electroporation i. Competent bacterial cells and DNA plasmids are mixed in a cuvette. ii. An 
electrical field is applied and the ions move according to charge. iii. Pathways form across the bacterial cell 
membrane which allows the entry of plasmid DNA into the cell. iv. When the electrical field is removed, the 
cell membrane repairs itself, closing the pathways. 
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LB agar plates and for the recombinant plasmids VR1012 and VR1020 the antibiotic kanamycin 
(100 µg/ml, Biochemica, Fluka). The plates were incubated at 37°C for 16 hours. 
The successful transformation of the recombinant plasmids into the JM109 E. coli cells was tested 
using a diagnostic colony PCR. The primer pairs used to test for the positive transformants are 
shown in Table 3.1. The PCR reaction mixture contained 1 µl of a 10x reaction buffer, 0.6 μl of a 
25 mM MgCl2, 0.5 μl of each primer (20 pmol/μl), 0.4 μl deoxyribonucleotide triphosphate (dNTP) 
mix (containing 5 mM of each dATP, dCTP, dGTP and dTTP) (Bioline), 0.025 U/µl Taq DNA 
polymerase (Supertherm polymerase, JMR Holdings), and 6.9 μl autoclaved Milli-Q water. A 
colony was picked from the LB agar plates using a sterilized toothpick and mixed in the PCR 
mixture to release some of the bacteria. The PCR was conducted under the following conditions: 
the first denaturation cycle at 95°C for 5 min; then 25 cycles each consisting of a 30 sec 
denaturation step at 94°C, a 30 sec annealing step at 55°C and a 30 sec extension step at 72°C; 
followed by a final extension cycle at 72°C for 7 min. This PCR reaction was carried out in a Veriti 
96-well thermal cycler from Applied Biosystems.   
Table 3.1: Primer sets chosen for each of the recombinant vectors  




















The PCR products were analysed by gel electrophoresis on a 1% (w/v) agarose gel (Seakem® LE 
agarose for gel electrophoresis, Lonza) in 1x TAE buffer (40 mM Tris-acetate; 20 mM glacial acetic 
acid and 1 mM EDTA, pH 8.0) and 0.175 μg/ml ethidium bromide for DNA visualization. The PCR 
products were prepared for loading onto the gel by mixing 10 µl of PCR product with 0.1 volumes 
of gel loading buffer (50% (v/v) glycerol; 0.1% (v/v) bromophenol blue; 50 mM EDTA and 100 mM 
Tris-base, pH 8.0). The samples were then electrophoresed (100 V, ~60 min) and the DNA 
visualized under ultraviolet (UV) light.  
3.2.1.2. Plasmid purification 
For each of the three DNA vaccines four fresh starter cultures were prepared in 14 ml Falcon® 
tubes by inoculating 5 ml LB medium containing antibiotic with a single positively transformed 
colony from the LB agar plates produced in section 3.2.1.1. The tubes were incubated for 8 hours 
at 37°C, shaking at 200 rpm on an orbital shaker (IKA® K260 basic). Two large overnight cultures 
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were prepared by inoculating 100 ml LB medium, containing antibiotic, with 2 ml of the 5 ml starter 
culture, prepared above, and incubating at 37°C, shaking on an orbital shaker at 200 rpm for 16 
hours. After 16 hours the OD600 of each overnight culture was measured and the recommended 
culture volume to be used in the Nucleobond® Xtra Midi Endotoxin-free plasmid purification kit 
(Macherey-Nagel) was calculated using the following equation:  
V[mL ] = 400 / OD600. 
The cells from the overnight cultures were harvested by centrifugation at 6,000 x g for 10 min at 
4°C. The pellet was resuspended in 8 ml resuspension buffer (RES-EF) containing RNase A. Eight 
millilitres of Lysis buffer (LYS-EF) was added and the tube inverted five times. While the tube was 
incubated at room temperature for 5 min, 15 ml of equilibration buffer (EQU-EF) was used to 
equilibrate the Nucleobond® Xtra Column filter. After the 5 min incubation period, 8 ml of 
neutralization buffer (NEU-EF) was added and the tube inverted 10-15 times. For each of the 
following steps the Nucleobond® Xtra Column was allowed to empty by gravity flow. After the crude 
cell lysate was incubated on ice for 5 min, the tube was inverted 3 more times to obtain a 
homogenous solution and was then loaded onto the column. Before the column filter was removed, 
5 ml of wash buffer (FIL-EF) was added to wash the residual lysate onto the column. The column 
was then washed two more times to remove any endotoxins. The second wash was with 35 ml 
wash buffer (ENDO-EF) and the third wash was with 15 ml wash buffer (WASH-EF). Once the 
column was properly washed and allowed to empty by gravity flow the DNA was eluted with 5 ml 
elution buffer (ELU-EF) and collected in a 14 ml Falcon® tube. A Nucleobond® finalizer was used 
to concentrate and desalinate the DNA vaccine. The salt in the eluate was precipitated by 0.7 
volumes of room temperature isopropanol incubated at room temperature for 2 min. The mixture 
was then added to a 30 ml syringe, with the Nucleobond® Finalizer attached, and slowly pressed 
through with a constant force. For every following step, the Nucleobond® Finalizer was removed 
from the syringe before the plunger was removed and the Nucleobond® Finalizer was then 
reattached. The flow-through was discarded and 2 ml endotoxin-free 70% ethanol was added and 
slowly pressed through the Nucleobond® Finalizer. The Nucleobond® Finalizer was then cleared of 
the ethanol by pushing air through until it was dry. The Nucleobond® Finalizer was transferred to a 
1 ml syringe and the purified plasmid eluted into an 1.5 ml Eppendorf tube with 500 µl endotoxin-
free H2O. The concentration of the purified DNA vaccines were measured on a nanodrop ND 1000 
spectrophotometer and the purified DNA vaccines were stored at 4°C until use. The purified DNA 
vaccine was also analysed by gel electrophoresis on a 1% (w/v) agarose gel  in 1x TAE buffer (40 
mM Tris-acetate; 20 mM glacial acetic acid and 1 mM EDTA, pH 8.0) and 0.175 μg/ml ethidium 
bromide as the DNA stain. The plasmids were prepared for loading onto the gel by mixing 2 µl of 
plasmid with 0.1 volumes of gel loading buffer (50% (v/v) glycerol; 0.1% (v/v) bromophenol blue; 50 
mM EDTA and 100 mM Tris-base, pH 8.0). The samples were then electrophoresed (100 V, ~60 
min) and the DNA visualized under ultraviolet (UV) light.  
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3.2.2. Mucosal DNA vaccine preparation 
3.2.2.1. Salmonella enterica serovar typhimurium SL3261  
Salmonella enterica serovar typhimurium SL3261 was received from the Salmonella Genetic Stock 
Centre (SGSC) (Dr. K. E. Sanderson from the University of Calgary). On arrival the strain was 
immediately streaked on plastic Petri dishes containing Tryptic soy agar (TSA) (Biolab, Merck) and 
incubated at 37°C for 24 hours. One or two colonies was selected from the TSA plate and streaked 
on Xylose lysine deoxycholate (XLD) agar (Biolab, Merck) and incubated at 37°C for 24 hours. A 
few of the Salmonella colonies were incubated in 5 ml Tryptic soy broth (TSB) (Biolab, Merck) and 
incubated at 37°C for 24 hours, shaking at 200 rpm on an orbital shaker. Salmonella enterica 
serovar typhimurium SL3261 freezer stocks were prepared from the TSB cultures by mixing with 
an equal volume of 30% (v/v) glycerol and stored at -80°C for up to one year. 
3.2.2.2. Electroporation of DNA vaccines into Salmonella enterica serovar typhimurium SL3261  
Each of the DNA vaccines; were transformed into Salmonella enterica serovar typhimurium 
SL3261 by electroporation adapting the method published by Sanderson, MacLachlan & Hessel 
(1995). Electroporation competent Salmonella enterica serovar typhimurium SL3261 cells were 
prepared as follows. A fresh overnight culture was prepared in a 14 ml Falcon® by inoculating 5 ml 
TSB with Salmonella enterica serovar typhimurium SL3261 freezer stocks prepared in section 
3.2.2.1, using a loop. The fresh overnight culture was incubated at 37°C shaking at 200 rpm on an 
orbital shaker for 16-18 hours. Two 100 ml TSB cultures were each inoculated with 1 ml of the 
fresh overnight culture and grown at 37°C with shaking at 200 rpm on an orbital shaker to an OD600 
of 0.75, as measured with a DU 650 spectrophotometer (Beckman). The cells were chilled on ice 
for 15 min and then centrifuged at 4,000 x g, 4°C for 10 min in an Avanti J-E centrifuge (Beckman). 
The supernatant was discarded and the pellet resuspended in cold distilled water equal to the 
original culture volume and centrifuged as before. The supernatant was discarded again and the 
pellet resuspended in a half of the original culture volume of cold distilled water and centrifuged 
again as before. The pellet was resuspended in 1/50 the original culture volume of 10% (v/v) 
glycerol and centrifuged at 4,000 x g, 4°C for 10 min. The pellet was resuspended in 1/100 the 
original culture volume of 10% (v/v) glycerol. The electrocompetent cells were kept on ice until use. 
If the cells were not used immediately for electroporation, they were stored at -80°C until use. 
Electrotransformation was done as follows. In an 1.5 ml Eppendorf tube, 40 µl of the competent 
Salmonella enterica serovar typhimurium SL3261 cells were mixed with 50 ng DNA vaccine in 2 µl 
TE buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA). Using a Pasteur pipette the entire contents of the 
Eppendorf tube was transferred to a chilled electroporation cuvette (Gene pulser cuvette with a 0.2 
cm electrode gap, Bio-rad) and all the moisture removed from the outside. The mixture was pulsed 
once in a Gene pulser II (Bio-Rad) set at 12.5 kV/cm, 25 µF capacitance and 200 Ω resistance to 
Stellenbosch University  http://scholar.sun.ac.za
27 
 
yield a pulse length of 5 m/s. The mixture was added to 1 ml Super optimal broth (SOC) medium 
(20 g/L Bacto-tryptone (Biolab, Merck), 5 g/L Bacto-yeast extract (Biolab, Merck), 10 mM NaCl, 2.5 
mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM Glucose) in a 14 ml Falcon® tube and incubated at 
37°C for 1 hour without shaking. One hundred microliter of the transformed cell suspension was 
plated onto plastic Petri dishes containing TSA with antibiotic; for the DNA vaccine pCI-neo 100 
µg/ml ampicllin was used and for the DNA vaccines VR1012 and VR1020 100 µg/ml kanamycin 
was used. The plates were incubated at 37°C for 16-18 hours. 
The successful electrotransformation of the recombinant vectors into Salmonella enterica serovar 
typhimurium SL3261 cells were tested using the diagnostic colony PCR described in section 
3.2.1.1. The primers used for each recombinant vector are listed in Table 3.2. Following 
amplification the PCR products were analysed on a 2% (w/v) agarose gel (Seakem® LE agarose 
for gel electrophoresis, Lonza) in 1x TAE buffer (40 mM Tris-acetate; 20 mM glacial acetic acid and 
1 mM EDTA, pH 8.0) and 0.175 μg/ml ethidium bromide as the DNA stain. The agarose gel was 
visualized under UV light. To prepare freezer stocks of the successful transformants, 2 positive 
colonies selected, from the TSA plates, were added to a 14 ml Falcon® tube containing 5 ml of 
TSB containing antibiotic, ampicillin (100 µg/ml, Sigma-Aldrich) for the pCI-neo transformants and 
kanamycin (100 µg/ml, Biochemica, Fluka) for the VR1012 and VR1020 transformants. The 
Falcon® tubes were incubated at 37°C shaking at 200 rpm on an orbital shaker for 16-18 hours. 
The TSB cultures were then mixed with an equal volume of 30% (v/v) glycerol and stored at -80°C 
for up to one year. 
Table 3.2: Primer sets for each of the recombinant vectors 

















3.2.2.3. Stability of DNA vaccines in Salmonella enterica serovar typhimurium SL3261 
To test persistence of the DNA vaccine after transformation into Salmonella enterica serovar 
typhimurium SL3261, the following method was followed. A fresh overnight culture of each of the 
three mucosal DNA vaccines was prepared by inoculating 5 ml TSB containing antibiotic, 100 
µg/ml ampicllin for the pCI-neo DNA vaccine and 100 µg/ml kanamycin for the VR1012 and 
VR1020. The cultures were incubated shaking at 200 rpm on an orbital shaker at 37°C for 18 
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hours. For each of the three mucosal DNA vaccine constructs two Petri dishes containing TSA and 
antibiotic and two Petri dishes containing only TSA was streaked with the fresh overnight culture. 
The plates were incubated at 37°C for 18 hours. The diagnostic colony PCR described in section 
3.2.1.1. and the primer sets in Table 3.2 were used to test 10 randomly selected colonies on the 
TSA plates with antibiotic and 10 randomly selected colonies from the plates without antibiotic. The 
PCR products were analysed on a 1% agarose gel prepared as in section 3.2.1.1. and visualized 
under UV light. One positive colony from each TSA plate was selected and streaked onto a new 
set of TSA plates, the plates were then incubated at 37°C for 18 hours. The diagnostic colony PCR 
described in section 3.2.1.1. and the primer sets in Table 3.1 were once again used to test 10 
colonies on the TSA plates with antibiotic and 10 colonies from the plates without antibiotic. This 
was repeated for 100 generations (5 days). 
3.3. Results 
3.3.1. Naked DNA vaccines 
3.3.1.1. Transformation  
JM109 E. coli cells were successfully transformed with the DNA vaccines containing the oppA 
gene using heat shock. Transformation was confirmed by testing randomly selected colonies from 
the antibiotic containing LB agar plates and using a colony PCR and the primer sets in Table 3.1 
(figure 3.2 and 3.3). The colony PCR used to test for the successful transformation with 
recombinant pCI-neo plasmid produced an amplification product of 3000 bp. The colony PCR 
product to test for the successful transformation with the recombinant VR1012 or VR1020 plasmids 
produced amplification products of 900 bp. 
3.3.1.2. Plasmid purification 
The Nucleobond® Xtra Midi Endotoxin-free plasmid purification kit was used to successfully purify 
the transforments as can be seen in figure 3.4. The bands in lane 2 and 3 (approximately 8000 bp) 
represents the isolated pCI-neo DNA vaccine expected to be 8301 bp. The difference in size is due 
to a supercoiled structure formation of the pCI-neo plasmid. The bands in lanes 4 to 5 and 6 to 7  
(between 6000 and 8000 bp) represents the isolated VR1020 and VR1012 DNA vaccines, 
respectively. These bands are found in the expected size ranges of the VR1020 (7873 bp) and 
VR1012 (7740 bp) DNA vaccines. 
 





Figure 3.3: Transformation products of transformation of JM109 E. coli cells with the recombinant plasmids 
VR1012 and VR1020 shown on a 1% (w/v) agarose gel. Lane 1-10: 10 μl diagnostic colony PCR product 
using randomly selected colonies from LB agar plates with recombinant VR1012 vaccine transformants. 
Lane 13-22: 10 μl diagnostic colony PCR product using randomly selected colonies from LB agar plates 
with recombinant VR1020 vaccine transformants.    























Figure 3.2: Transformation products of transformation of JM109 E. coli cells with the recombinant pCI-neo 
plasmid shown on a 1% (w/v) agarose gel. Lane 1 and 12: 5 μl DNA Ladder mix (Generuler
TM
, Fermentas). 






















  1              2         3          4         5       6        7         8           9    10      11  12 




3.3.2. Mucosal DNA vaccine preparation 
3.3.2.1. Salmonella enterica serovar typhimurium SL3261 
XLD medium is a selective growth medium used to isolate Salmonella and Shigella species. Wild 
type Salmonella produce hydrogen sulphide (H2S) resulting in red colonies with a black center. 
Salmonella enterica serovar typhimurium SL3261 is an aroA mutant and does not produce H2S, 
resulting in translucent colonies on the XLD agar plates (figure 3.5) (O'Callaghan, Charbit 1990, 
Taketo 1988).  
 
  
Figure 3.5: XLD medium: i. Wild type Salmonella growth displayed as red colonies with a black center taken 
from (Zimbro et al. 2009). ii. Mutant strain Salmonella enterica serovar typhimurium SL3261 displayed as 
translucent colonies photo taken by Amanda van Tonder.  
ii. i. 
Figure 3.4: Purified plasmid viewed on a 1% (w/v) agarose gel. Lane 1: 5 μl DNA Ladder mix (Generuler
TM
, 
Fermentas). Lane 2 and 3: Purified recombinant pCI-neo plasmid. Lane 4 and 5: Purified recombinant 
VR1020 plasmid. Lane 6 and 7: Purified recombinant VR1012 plasmid. 
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3.3.2.2. Electroporation of DNA vaccines into Salmonella enterica serovar typhimurium SL3261  
The electrotransformation of Salmonella enterica serovar typhimurium SL3261 with each of the 
DNA vaccines was carried out successfully by adapting the method of Sanderson, MacLachlan & 
Hessel (1995). Figure 3.6 and 3.7 show the products of a diagnostic colony PCR where primer sets 
in Table 3.2 were used to test the successful electroporation. The approximate product size 
expected for successful electroporation of the pCI-neo DNA vaccine was 3000 bp and for the 
VR1012 and VR1020 DNA vaccines was 1500 bp. The electroporation of the recombinant VR1012 
and VR1020 vaccines was more successful than that of the recombinant pCI-neo vaccine.  
3.3.2.3. Stability of DNA vaccines in Salmonella enterica serovar typhimurium SL3261 
The stability of the DNA vaccines in Salmonella enterica serovar typhimurium SL3261 was tested 
for 100 generations in the absence and presence of antibiotic, to assess the effect of an 
environment free of antibiotics and the ability of the carrier bacteria to retain the plasmid, 
respectively. After the first day all the colonies tested were positive. From the second day the 
number of selected colonies testing positive for the pCI-neo recombinant vaccine fluctuated both in 
the presence and absence of antibiotic. The number of chosen colonies that tested positive for the 
VR1012 DNA vaccines remained relatively the same, with some colonies testing negative on the 
plates grown without antibiotic, especially on the fifth day (figure 3.8). For the VR1020 DNA 
vaccine, the results observed were very similar to those obtained with the VR1012 DNA vaccine. 
Figure 3.6: Diagnostic colony PCR of electroporation products. Lane 1: 5 μl DNA Ladder mix 
(Generuler
TM
, Fermentas). Lane 2-11: 10 μl PCR product from selected colonies on LB agar plates with 
transformants from electroporation of Salmonella enterica serovar typhimurium SL3261 with recombinant 
pCI-neo plasmid containing oppA gene. Lane 13-22: 10 μl PCR product from selected colonies on LB agar 
plates with transformants from electroporation of Salmonella enterica serovar typhimurium SL3261 with 
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Each of the recombinant plasmids, pCI-neo, VR1012 and VR1020, containing the oppA gene, was 
successfully transformed into JM109 E. coli cells for plasmid amplification. The plasmid was 
purified using a Nucleobond® Xtra Midi Endotoxin-free plasmid purification kit. The purified 
recombinant plasmid was used previously as a naked DNA vaccine and its efficacy tested in a 
preliminary vaccine trial as an intramuscular vaccine, but the trial was influenced by an outbreak of 
AI giving inconclusive results (Brandt 2012). As Mycoplasma struthionis causes infection in the 
respiratory tract of ostriches, a mucosal immune response is required. 
A literature study revealed that the use of bacteria as carriers of DNA vaccine can stimulate both a 
mucosal and serum immune response. The use of Salmonella as bacterial vaccine carriers have 
shown promise in cats (Titball et al. 1997), dogs (Chabalgoity et al. 2000), pigs (Fagan et al. 1997, 
Stabel et al. 1993, Fagan et al. 2001) and chickens (Pogonka et al. 2003). Salmonella enterica 
serovar typhimurium SL3261 was chosen as a carrier to deliver the recombinant DNA plasmid 
vaccines. This strain is a highly attenuated aroA mutant with limited growth in vivo (Chen et al. 
2006b, Hoiseth, Stocker 1981). XLD agar is a selective medium that contains a number of 
components that aid in the isolation of Salmonella and Shigella spp. Of note is the sodium 
thiosulfate and ferric ammonium citrate that is added to this medium. These two substances allows 
for the detection of H2S production by the formation of black colonies (Zimbro et al. 2009). Wild 
type Salmonella spp. produce H2S, resulting in red colonies with black centers. Salmonella aroA 
mutants do not produce H2S and appear as translucent colonies on the XLD agar (Cooper et al. 
1994). 
Figure 3.7: Diagnostic colony PCR of electroporation products. Lane 1-10: 10 μl PCR product from 
selected colonies on LB agar plates with transformants from electroporation of S. enterica serovar 
Salmonella enterica serovar typhimurium   SL3261 with recombinant VR1012 plasmid containing oppA 
gene. Lane 11: 5 μl DNA Ladder mix (Generuler
TM
, Fermentas). 

































Figure 3.8: Day 5 of stability assessment of DNA vaccines in Salmonella enterica serovar typhimurium   
SL3261 tested with a diagnostic colony PCR. i. Mucosal pCI-neo DNA vaccine. Lane 1-10: 10 µl of colony 
PCR from selected colonies on TSA plates without the antibiotic, ampicillin. Lane 11: 5 μl DNA Ladder mix 
(Generuler
TM
, Fermentas). Lane 12-21: 10 µl of colony PCR from selected colonies on TSA plates with the 
the antibiotic ampicillin. ii. VR1012 mucosal DNA vaccine. Lane 1-10: 10 µl of colony PCR from selected 
colonies on TSA plates without the antibiotic kanamycin. Lane 11: 5 μl DNA Ladder mix (Generuler
TM
, 
Fermentas). Lane 12-21: 10 µl of colony PCR from selected colonies on TSA plates with the antibiotic 
kanamycin. iii. VR1020 mucosal DNA vaccine. Lane 1-10: 10 µl of colony PCR from selected colonies on 
TSA plates without the antibiotic kanamycin. Lane 12: 5 μl DNA Ladder mix (Generuler
TM
, Fermentas). Lane 
11, 13-21: 10 µl of colony PCR from selected colonies on TSA plates with the antibiotic kanamycin. 
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The three recombinant plasmids were successfully transformed into Salmonella enterica serovar 
typhimurium SL3261 using electroporation to produce three mucosal DNA vaccines. The 
transformation efficiency for the recombinant plasmid pCI-neo was low, but for the recombinant 
plasmids VR1012 and VR1020 it was very high. The lower transformation efficiency of the pCI-neo 
DNA vaccine might be due to its size (8309 bp), which is much larger than that of the other DNA 
vaccines VR1012 (7740 bp) and VR1020 (7873 bp).  
The stability of the DNA vaccines in the carrier bacterium Salmonella enterica serovar typhimurium 
SL3261 was tested for 100 generations with and without the selective pressure of antibiotic. Under 
selective pressure all three of the DNA vaccines, the carrier bacteria appear to be able retain the 
plasmids. In an antibiotic-free environment the VR1012 and VR1020 DNA vaccines were more 
stable than the recombinant plasmid pCI-neo, which showed variable stability. The higher tendency 
of Salmonella enterica serovar typhimurium SL3261 to retain the VR1012 and VR1020 DNA 
vaccines might also be due to the larger size of the pCI-neo DNA vaccine. Of the three mucosal 
DNA vaccines prepared, the VR1012 and VR1020 mucosal DNA vaccines appear to be more 
stable and might be a better choice for future vaccine trials. In the next chapter, the use of these 
mucosal DNA vaccines in a preliminary vaccine trial to test their ability to elicit immune responses 
is described.  
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Chapter 4: Preliminary vaccine trial 
4.1. Introduction 
An important step in vaccine development is to assess the vaccine‟s ability to elicit a specific 
acquired or adaptive immune response. Once this has been established, the ability of the vaccine 
to confer protection against the pathogen is evaluated by challenging the vaccinated animal with a 
virulent form of the pathogen indicating that the vaccine is able to prevent the disease caused by 
the pathogen. Together the effectiveness of these two processes is referred to as “vaccine 
efficacy”. The specific acquired immune response elicited by a vaccine can be either a humoral or 
a cell-mediated immune response, and in some cases both types of immune responses can be 
elicited. During a humoral immune response B-cells produce antibodies in the serum and mucosa, 
and during a cell-mediated immune response T-helper or T-cytotoxic cells are activated and 
multiply (Cooper et al. 1994, Coombes & Powrie 2008). One major advantage of DNA vaccines is 
that they can induce both humoral and cell-mediated immune responses. However, the 
measurement of cell-mediated immune responses is complicated because this requires special 
tissue culture equipment, whilst the measurement of antibody levels is much easier (Wagner, 
Hewlett & Bloom 2009). The method most commonly used to test the humoral immune response 
induced by a vaccine is the enzyme-linked immunosorbent assay (ELISA). ELISAs are simple to 
perform, sensitive, fast and reliable systems that can be used to detect and quantify antibodies or 
antigens present in a sample (Wagner, Hewlett & Bloom 2009). Two separate research groups, 
Engvall and Perlmann from Sweden as well as Avrameas and Guilbert from the Netherlands, 
published the ELISA and enzyme immunoassay (EIA) techniques, respectively in 1971, as an 
alternative to the radioimmunoassay (RIA). ELISA is a versatile assay with many different types, 
such as competitive, direct, indirect and sandwich ELISA as well as combinations of these main 
types.  
For the determination of the levels of antibodies elicited by the DNA vaccine, an indirect ELISA 
was used in this study. This method uses a labeled secondary antibody for the detection of the 
primary antibody present in a sample, making this method more sensitive (Hsieh 2010). This 
increase in sensitivity is the result of the binding of considerably more secondary antibodies than 
primary antibodies. The signal is further amplified by the use of the biotin/avidin detection system 
(Crowther 2000). Biotin is a molecule that can be coupled to an antibody, leaving the antigen 
binding capacity unaffected. Avidin is a tetrameric protein with four high affinity binding sites that 
binds with high specificity to biotin. Avidin can also be linked to enzyme. Such an indirect ELISA is 
shown in figure 4.1. The principle of this ELISA is that the amount of product formed, i.e. the final 
absorbance measured, is proportional to the amount of ostrich antibody present in the sample. In 
this chapter, this ELISA was used to assess the amounts of antibodies present in sera and saliva 
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to test the humoral and mucosal immune response against the different DNA vaccines that had 
been prepared.  
 
 
Pretorius (unpublished) generated three naked DNA vaccines in the laboratory against 
Mycoplasma struthionis using the method described in figure 2.5A. First a candidate gene, oppA, 
was identified and isolated, the gene was then cloned into each of three plasmid vectors, pCI-neo, 
VR1012 and VR1020 (Pretorius 2009). The naked DNA vaccines were prepared as described in 
Chapter 3 for electroporation into the carrier bacteria, Salmonella enterica serovar typhimurium 
SL3261, to generate three mucosal vaccines respectively. Of the three mucosal vaccines 
generated, the Salmonella enterica serovar typhimurium SL3261 carrying the VR1012 and VR1020 
DNA vaccines were the most stable. One of the elements distinguishing the VR1020 plasmid from 
the VR1012 plasmid is the presence of a short signal sequence (tPA signal peptide) that signals a 
protein for the secretory pathway, which can possibly aid in the transfer of the membrane protein, 
OppA, to the outside of the cell. It is thought that the expression of higher levels of the vaccine 
protein extracellularly results in higher amounts of the protein being exposed to the antigen-specific 
B cells and thereby may lead to an improved immune response.yh Haddad et al. (1997) used COS 
cells to show that including a tPA signal in the vaccine plasmid results in the secretion of the 
translated protein through the endoplasmic reticulum and the Golgi apparatus. The tPA signal 
peptide has been used in vaccine plasmids and then used in both mucosal and naked DNA 
vaccines to elicit an immune response against the antigen of interest (Haddad et al. 1997, Parida 
et al. 2005).    
Figure 4.1: A diagram of the indirect ELISA used in this study. 1. The antigen is immobilised on a solid 
phase. 2. A sample to be tested for antibody presence is added and if antibodies specific for the antigen are 
present, they will bind. 3. A biotinylated secondary detector antibody is added that binds to the bound sample 
antibodies. 4. Peroxidase-labelled avidin is added which binds with high affinity and specificity to biotin. 5. 
The enzyme, peroxidase, acts as a catalyst when a substrate is added. The absorbance of the product that 
forms can then be measured 
Coating 
antigen 
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In this chapter, the ability of the VR1020 mucosal DNA vaccine to elicit a humoral and mucosal 
immune response compared to the VR1020 naked DNA vaccine was evaluated. To this end, 
ostriches were immunized with the vaccines after being assessed for; possible prior Salmonella 
and ostrich Mycoplasma infections, and the ostriches‟ changes in weight were monitored. Six 
indirect ELISAs as illustrated above, were developed to analyse the humoral and mucosal immune 
responses of the ostriches against the Mycoplasma struthionis OppA protein, as well to the carrier 
bacteria, Salmonella enterica serovar typhimurium SL3261. To develop the ELISAs the OppA 
protein of Mycoplasma struthionis and LPS from Salmonella enterica serovar typhimurium SL3261 
had to be isolated for use as coating agents. To assess the humoral immune response, secondary 
antibodies prepared against ostrich immunoglobulins (Ig) isolated from ostrich serum were 
previously prepared in this laboratory. To assess the mucosal immune response, secondary 
antibodies against ostrich IgA were required. Immunoglobulin A is the main antibody found in 
mucosal secretions. IgA found in the mucosal secretions is linked to a secretory piece, which aids 
in the transport of IgA across the mucosal epithelium into the mucosal slime layer, and protects it 
there against proteolysis. Botes (2004) isolated IgA from ostriches, ostrich IgA only, which is 
referred to as protein 1 here, and IgA to which the secretory piece is linked, which is referred to as 
protein 2 here. An immune response was elicited in rabbits against these isolated proteins to 
produce the secondary rabbit anti-ostrich IgA protein 1 and protein 2 (Botes 2004). Antibodies to 
protein 1 and protein 2 were both used as secondary antibodies in respective ELISAs to assess 
the mucosal immune responses of the ostriches in the preliminary vaccine trial. The results 
obtained were analysed statistically using an ANOVA to determine if the immune responses 
elicited by the naked DNA vaccine, injected intramuscularly, and the mucosal vaccine, 
administered orally, were statistically relevant. 
4.2. Materials and Methods 
4.2.1. Preliminary vaccine trial on a commercial ostrich farm in Oudtshoorn, Western Cape. 
4.2.1.1. Vaccine trial design. 
A vaccine trial to compare the VR1020 naked DNA vaccine and VR1020 mucosal DNA vaccine 
was performed on 120 ostriches on a commercial ostrich farm in Oudtshoorn, Western Cape, with 
ethical clearance from the University of Stellenbosch Animal Ethics Committee. The trial was 
designed so that there were 4 groups each consisting of 30 ostriches. One group received 100 
µg/ml of the VR1020 naked DNA vaccine intramuscularly and one group received 109 c.f.u./ml of 
the VR1020 mucosal DNA vaccine orally. The last two groups were used as a control groups, one 
group received 109 c.f.u./ml of the Salmonella enterica serovar typhimurium SL3261 without the 
recombinant vaccine plasmid inserted and the other group received no vaccinations. The vaccine 
trial was performed over a period of 9 weeks with a vaccination at week 0 and a booster 
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vaccination at week 6. Blood samples from every ostrich were collected in 5 ml Serum sep clot 
activator tubes (Vacuette) using 18G x 1” needles (Vacuette) every 3 weeks. Two saliva samples 
were collected every 3 weeks from each ostrich by swabbing the trachea with sterile swabs (plain, 
Rayon tipped, sterile swabs with a plastic applicator, Copan). The ostriches were also weighed 
every 3 weeks during the trial. 
It should be mentioned that further bleeds were planned at week 9 and possibly at week 12, but 
shortly after the week 6 bleed the flock was diagnosed as being positive for AI and was destroyed 
by the Western Cape Veterinary Services, bringing the trial to a premature end. 
4.2.1.2. Preparation of the VR1020 naked DNA vaccine. 
The VR1020 naked DNA vaccine was prepared as described in section 3.2.1.2. The vaccine was 
diluted in PBS buffer (pH 7.2) to a concentration of 100 µg/ml less than 24 hours before 
vaccination and stored at 4°C until use.  
4.2.1.3. Preparation of the VR1020 mucosal DNA vaccine. 
A freezer stock of the VR1020 mucosal DNA vaccine prepared in section 3.2.2.2. was streaked 
onto Petri dishes containing TSA with 100 µg/ml kanamycin. The TSA plates were incubated 
overnight at 37°C for 16-18 hours. The diagnostic colony PCR described in section 3.2.2.2. and the 
primer sets in table 3.2 were used to test 10 colonies on the TSA plates and the PCR products 
visualized on a 1% agarose gel as prepared in section 3.2.1.1. and then visualized under UV light. 
Two positive colonies were transferred to a 17 x 100 mm polypropylene round-bottom tube 
containing 5 ml TSB with 100 µg/ml kanamycin and incubated at 37°C shaking at 200 rpm on an 
orbital shaker (IKA® K260 basic) for 16-18 hours. One millilitre of the overnight culture was then 
mixed with 49 ml TSB with 100 µg/ml kanamycin and incubated at 37°C, shaking at 200 rpm on an 
orbital shaker (IKA® K260 basic) to the exponential growth phase. The cultures were centrifuged 
at 8000 x g for 10 min in an Avanti-J-E centrifuge (Beckman). The pellets were washed with 2 ml 
PBS buffer each and then centrifuged again at 8000 x g for 10 min. The pellets were then 
resuspended in 1 ml PBS (pH 7.5) and kept at 4°C until use. A serial dilution of the prepared 
recombinant mucosal vaccine was prepared as shown in figure 4.2 and 100 µl of the last three 
dilutions plated onto each of three Petri dishes containing TSA with 100 µg/ml kanamycin. The 
plates were incubated at 37°C for 16-18 hours to determine the colony forming units (c.f.u.). To 
prepare the vaccine for vaccination the recombinant mucosal vaccine was diluted in PBS (pH 7.5) 
to a dilution of 109 c.f.u./ml in a sterilized vaccine serum bottle.  
4.2.1.4. Preparation of the Salmonella enterica serovar typhimurium SL3261 control. 
The freezer stock generated in section 3.2.2.1. was inoculated in a 14 ml Falcon® tube containing 
5 ml TSB and incubated at 37°C shaking at 200 rpm on an orbital shaker® for 16-18 hours. One 
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millilitre of the overnight culture was then mixed with 49 ml TSB and incubated at 37°C, shaking at 
200 rpm on an orbital shaker® to the exponential growth phase, an OD600 of approximately 0.1000. 
The cells were harvested by centrifugation at 8,000 x g for 20 min in an Avanti-J-E centrifuge 
(Beckman). The pellets were washed with 2 ml PBS buffer each and centrifuged again at 8,000 x g 
for 10 min. The pellet was then dissolved in 1 ml PBS and stored at 4°C until use. A serial dilution 
of the cells was prepared, as in figure 4.2 and the last three dilutions plated onto Petri dishes 
containing TSA. The plates were incubated at 37°C for 24 hours, and the c.f.u. determined. The 
cells were then diluted to 109 c.f.u./ml in a sterilized vaccine serum bottle.  
 
4.2.2. Analysis of samples collected during the preliminary vaccine trial on a commercial 
ostrich farm in Oudtshoorn, Western Cape. 
4.2.2.1. Processing of blood and saliva samples collected.  
The blood samples collected were incubated at 37°C for an hour, and then stored overnight at 4°C. 
The samples were centrifuged at 140 x g for 20 min and the serum transferred into an Eppendorf 
tube and stored at -20°C until use. One of the swab samples from each ostrich was stored at 4°C 
until used for analysis of the ostrich immune response using an ELISA. The other swab sample of 
each ostrich was immersed in 200 µl PBS (pH 7.2) and briefly vortexed before the swab was 
removed. The samples were then stored at 4°C until analysed for ostrich Mycoplasma and 
Salmonella infection after which it was stored at -20°C.   
4.2.2.2. Analysis of saliva samples for Mycoplasma infection. 
To test for Mycoplasma infection three PCR reactions were run on each sample testing for each of 
the three ostrich specific mycoplasmas; Mycoplasma struthionis, Ms02, and Mycoplasma 
nasistruthionis. The PCR reaction mixture contained 2 µl of a 10x reaction buffer, 1.6 μl of a 25 mM 
Figure 4.2: Serial dilution of Salmonella enterica serovar typhimurium SL3261 mucosal vaccines. Mix 10 µl 
of the 1 ml prepared vaccines with 990 µl PBS to prepare a 10
2
 dilution. Transfer 10 µl of the 10
2
 dilution to a 
clean tube containing 990 µl and mix. Repeat this to a desired dilution. Prepare the last dilutions by mixing 
20 µl of the 10
?
 dilution with 180 µl for a 10 dilution. Plate 100 µl of the last three dilutions on each of three 
TSA plates containing the appropriate antibiotic 
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MgCl2, 0.4 μl of each primer (20 pmol/μl), 0.8 μl dNTP mix (containing 5 mM of each dATP, dCTP, 
dGTP and dTTP) (Bioline), 0.025 U/µl Taq DNA polymerase (Supertherm polymerase, JMR 
Holdings), 12.7 μl autoclaved Milli-Q water and 1 µl of the swab sample prepared in section 
4.2.2.1. The primers used to test for each of the ostrich mycoplasmas are listed in Table 4.1 
(originally developed by Botes, 2005b). The PCR was performed as follows: 30 cycles each 
consisting of a 30 sec denaturation step at 94°C, a 15 sec annealing step at 57°C and a 1 min 
extension step at 72°C; followed by a final extension cycle at 72°C for 6 min. The PCR product 
was then electrophoresed as described in section 3.2.1.1 and visualized under UV.  








Ms01 Z (F) 5‟-AACATTAGTTAATGCCGGATACG-3‟ 
499 
Ms01 D (R) 5‟-GCCAGTATCCAAAGCGAGCC-3‟ 
Ms02 
Ms02 H (F) 5‟-AATATAAAAGGAGCGTTTGC-3‟ 
287 
Ms02 A (R) 5‟-AAGGCAATAGCATTTCCTCTACT-3‟ 
Mycoplasma 
nasistruthionis 
Ms03 A (F) 5‟-AGTGCTAATGCCGGATACTTATA-3‟ 
521 
Ms03 C (R) 5‟-CGTTAACCTCTATACAATTCTAGCG-3‟ 
4.2.2.3. Analysis of saliva samples for Salmonella infection. 
The multiplex PCR published by Lim et al. (2003) was used to test for various Salmonella spp. 
infection. The PCR reaction mixture contained 2.5 µl of a 10x reaction buffer, 2.5 μl of a 25 mM 
MgCl2, 1.25 μl of each of the 6 primers listed in Table 4.2 (20 pmol/μl), 1 μl dNTP mix (containing 5 
mM of each dATP, dCTP, dGTP and dTTP) (Bioline), 5 μl Taq DNA polymerase (Supertherm 
polymerase, JMR Holdings), and 2.5 μl autoclaved Milli-Q water. One microlitre of the bacterial 
DNA was amplified with the first denaturation cycle at 95°C for 3 min; followed by 30 cycles 
consisting of a 1 min denaturation step at 95°C, a 30 sec annealing step at 65°C and a 30 sec 
extension step at 72°C; then followed by a final 1 min extension cycle at 72°C. The PCR product 
was analysed on a 2% agarose gel prepared as in section 3.2.2.2. and visualized under UV light.  
Table 4.2: Salmonella enterica serovar typhimurium multiplex primer set 
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4.2.3. Evaluation of immune responses elicited in preliminary vaccine trial 
4.2.3.1. Isolation of OppA protein for ELISA plate coating 
The OppA protein of M. struthionis was used to coat microtitre plates for ELISA analysis of immune 
responses produced by each of the vaccines. To obtain the OppA protein it first had to be 
expressed. The OppA gene fused to GST was previously cloned into the pGEX expression vector 
(Brandt 2012). Brandt (2012) showed that OppA could be expressed as a Glutathione S-
transferase (GST)-tagged fusion protein. The pGEX expression vector plasmid containing the 
OppA gene was transformed into BL21(DE3)pLysS cells and freezer stocks stored at -80°C. As 
controls BL21(DE3)pLysS cells that contain only the pGEX plasmid that had been stored as 
freezer stocks were used. Both of these freezer stocks were streaked separately onto Petri dishes 
containing LB agar and ampicillin (100 µg/ml, Sigma-Aldrich) and incubated at 37°C for 16-18 
hours. A diagnostic colony PCR was run on selected colonies as described by section 3.2.1.1. 
using the primers listed in Table 4.3 to confirm the presence of the oppA gene. A 14 ml Falcon® 
tube containing 5 ml TB medium  (12 g/L Bacto-tryptone (Biolab, Merck), 24 g/L Bacto-yeast 
extract (Biolab, Merck), 4 ml/L of 2 M Glycerol and 100ml/L of 1 M Phosphate buffer (pH 7.8), 
glucose (20% m/v), chloramphenicol (34 µg/ml, Sigma-Aldrich) and ampicillin (100 µg/ml, Sigma-
Aldrich) was inoculated with two of the colonies that tested positive for pGEX + oppA. Another 14 
ml Falcon® tube containing 5 ml TB medium, glucose (20% m/v), chloroamphenicol (34 µg/ml, 
Sigma-Aldrich) and ampicillin (100 µg/ml, Sigma-Aldrich) was inoculated with two pGEX only 
colonies. The 14 ml Falcon® tube were shaken at 200 rpm on an orbital shaker ® at 37°C for 16-18 
hours. For protein expression, 2 ml overnight culture was inoculated with 100 ml TB medium 
containing, glucose (20% m/v), chloroamphenicol (34 µg/ml, Sigma-Aldrich) and ampicillin (100 
µg/ml, Sigma-Aldrich). The cultures were incubated at 37°C to an OD600 of 0.6, and then 0.1 M 
(IPTG) (400 µl/100 ml) was added for recombinant gene expression. The cells were harvested 
after 6-8 hours by centrifugation at 10 000 x g for 15 min. The pellet was resuspended in TEN 50 
buffer (10 mM Tris-HCl, pH 8.0; 1 mM EDTA; 50 mM NaCl; 0.1% Triton X-100; 0.2 M DTT and 
10% (v/v) glycerol) and stored at -80°C until use. 
Table 4.3: Primer sets used to test pGEX containing OppA and the pGEX control and the expected 
PCR product sizes after PCR. 
BL21 (DE3)pLys5 cells Primer Sequence 
Amplified product 
size (bp) 








The recombinant protein was isolated from the cells suspended in TEN50 by gravity flow through a 
glutathione agarose gel (Sigma-Aldrich). The glutathione agarose lyophilized powder was swelled 
in MilliQ water at 200 ml/g for 30 min at room temperature then at 4°C overnight. The final bed 
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volume [πr2h = π x (0.18)2 x 10] is 10 ml. The gel was then washed with 10 volumes of water 
before it was de-aerated and the slurry poured into the column. The resin was then equilibrated 
with 10 column volumes of equilibration buffer (PBS buffer (pH 7.4)). The harvested cells were 
prepared for loading onto the column by freeze thawing as described and then the cell suspension 
was sonicated for 2 sec (repeated 5 times) and then incubated on ice for 20 sec. The cell 
suspension was then centrifuged at 4°C, 10 000 x g for 10 min. The clarified supernatant was 
subsequently loaded onto the column and passed through the resin 5 times, before it was 
incubated on the column for 1 hour to allow the GST-tagged OppA protein to bind to the 
glutathione on the resin. The resin was then washed with 4 column volumes PBS-T (PBS (pH 7.2) 
and 1% Triton X-100) and followed by 4 column volumes of PBS buffer (pH 7.2). The GST-tagged 
OppA protein was finally eluted with 3 column volumes elution buffer (10 mM reduced glutathione 
and 50 mM Tris-HCl, pH 9.5), by collecting 1 ml fractions in Eppendorf tubes. The resin was 
washed with 5 column volumes Cleansing buffer 1 (100 mM Borate buffer (pH 8.5) and 500 mM 
NaCl) followed by 5 column volumes MilliQ water. Five column volumes of cleansing buffer 2 (100 
mM acetate buffer (pH 4.5) and 500 mM NaCl) were then used followed by 5 column volumes of 
MilliQ water, before the resin was stored in storage buffer (2 M NaCl, 0.2% thiomersal).   
The protein concentration in each fraction was determined using the Micro Bradford method as 
follows. The Bradford reagent (0.01% (w/v) Coomassie Brilliant Blue G-250, 4.7% (v/v) Ethanol, 
8.5% (v/v) Phosphoric acid) was prepared as described by (Bradford 1976). A protein standard 
series was prepared using BSA and the elution buffer to final concentrations 0, 0.25, 0.50, 0.75, 1, 
1.25 and 1.5 mg/ml. Five microlitre of the BSA standards and fractions were pipetted into a 96-well 
microtitre plate (Microlon®, Greiner bio-one) in duplicate and 250 µl of Bradford reagent was 
added. After the plate was incubated at room temperature for 2 min the absorbance was read at 
620 nm on a Labysystems Multiscan MS microtiter plate reader.  
To confirm that the GST-tagged OppA protein was isolated, the final protein fraction was 
electrophoresed on a sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel. 
A 10% resolving gel was prepared by mixing 8 ml resolving buffer (375 mM Tris-HCl (pH 8.8) 
containing 0.1% (w/v) SDS), 4 ml resolving monomer (30%T, 2.7% C), 30 μL TEMED (N,N,N‟N‟-
tetramethylene diamine) and 36 μL of 20% (w/v) ammonium persulfate and allowed to polymerase 
for 20 min between two glass plates separated by 1.5 mm spacers. A 4.5% stacking gel was then 
prepared by mixing 4.25 ml stacking buffer (125 mM Tris-HCl (pH 6.8) containing 0.1% (w/v) SDS), 
0.75 ml stacking monomer (30%T, 2.7% C), 15 μL TEMED (N,N,N‟N‟-tetramethylene diamine) and 
30 μL 20% (w/v) ammonium persulfate. The gel was allowed to polymerize overnight at 4°C. The 
gel was then setup in a gel apparatus with electrode buffer (25 mM Tris, 192 mM glycine and 0.1% 
(w/v) SDS, pH 8.3). Each of the samples was mixed with an equal volume of reducing treatment 
buffer (125 mM Tris-HCl, 4% (w/v) SDS, 20% (v/v) glycerol and 10% (v/v) 2-mercaptoethanol, pH 
6.8) and 0.1 volumes bromophenol blue (0.1% (w/v) bromophenol blue in 100 mM NaOH). After 
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the mixture was incubated in a boiling water bath for 2 min it was kept on ice until use. Twenty 
microlitres of each sample and 5 µl Pageruler™ Unstained Protein Ladder (Fermentas) were 
loaded on the SDS-PAGE gel and electrophoresed at a constant current of 20 mA. The gel was 
stained with staining solution (0.125% (w/v) Coomassie Brilliant Blue R250, 50% (v/v) methanol 
and 10% (v/v) glacial acetic acid) at 37°C for 1 hour. The gel was then destained in destain 
solution 1 (50% (v/v) methanol and 10% (v/v) glacial acetic acid) for 1 hour at 37°C before 
destaining the gel overnight in destain solution 2 (5% (v/v) methanol and 7% (v/v) glacial acetic 
acid) at room temperature. 
The GST can be cleaved from the protein using site-specific proteases, but in a study performed in 
this laboratory it was shown in a western blot that the antibodies raised against OppA in a rabbit 
did recognize the fusion protein and only recognised OppA and not GST (results not shown). The 
GST was therefore not cleaved from the OppA protein for the ELISAs used to test the immune 
response of the ostriches against the recombinant vaccine. The GST-tagged OppA fusion protein 
will be referred to as OppA when referring to coating of ELISA plates hereafter in this chapter. 
4.2.3.2. Isolation of Salmonella enterica serovar typhimurium SL3261 lipopolysaccharide (LPS) for 
ELISA plate coating 
The hot phenol/water extraction method was used to extract LPS from Salmonella enterica serovar 
typhimurium SL3261 (Westphal 1965, De Castro et al. 2010). A loop was used to transfer cells 
from the freezer stock of the Salmonella enterica serovar typhimurium SL3261, prepared in section 
3.2.2.2., to 4 round-bottom polypropylene tubes each containing 5 ml TSB and incubated at 37°C 
for 16-18 hours, shaking at 200 rpm. Two millilitres of the overnight solutions were used to 
inoculate each of 5 Erlenmeyer flasks containing 100 ml TSB. The flasks were incubated at 37°C 
for 16-18 hours, shaking at 200 rpm. The OD600 was measured and the cells harvested by 
centrifugation at 9000 x g for 20 min at 4°C. The cells were washed twice with 200 ml PBS (pH 
7.2). The cells were then washed 4 times with 50 ml -20°C acetone by adding the acetone and 
incubated at -20°C for 20 min before decanting and adding the acetone for the next round. The 
pellet was then air dried in a fume hood. The dried cells were then placed in a 65-70°C and 
prewarmed 90% phenol was added so that the cells make up 20% of final volume and mixed 
gently with a glass rod. The mixture was stirred at 65-70°C for 30 min. The cells were then 
centrifuged at 10 000 x g for 30 min for 4°C. The water phase was transferred to a glass vial and 
the above steps repeated with the remaining solution. The water phases were combined and 
dialysed against distilled water for 48 hours with 4 water changes and then freeze dried with liquid 
nitrogen and stored at 4°C. 
Confirmation of LPS isolation was performed using silver staining of SDS-PAGE gels (Chevallet, 
Luche & Rabilloud 2006). An SDS-PAGE gel was prepared as in 4.2.3.1., the isolated LPS and a 
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Salmonella enterica serovar typhimurium LPS (Sigma-Aldrich) control sample was loaded onto the 
gel. The gel was electrophoresed at 15 mA to run into the stacking gel and at 25 mA once the 
marker had reached the resolving gel. The remainder of the steps were performed in flat Pyrex 
dishes on an orbital shaker. Firstly, the gel was fixed three times in a fixation solution (30% 
ethanol, 10% acetic acid) for 30 min. The gel was washed twice in 20% ethanol for 10 min and 
then twice in MilliQ water for 10 min. In a new glass bowl, the gel was sensitized in 0.02% (w/v) 
sodium thiosulfate pentahydrate for 1 min before it was washed twice for 1 min in MilliQ water. The 
gel was then impregnated in 12 mM (w/v) silver nitrate (AgNO3) for 20 min whereafter it was 
washed in MilliQ water for 5-10 sec. Using developer solution (3% (w/v) Potassium carbonate, 125 
µl 10% Sodium thiosulfate pentahydrate and 250 µl formaldehyde per 1 L solution) the gel was 
developed for 10 min before it was stopped for 30 min using stopping solution (4% (w/v) Tris and 
2% (v/v) acetic acid). The gel was then stored in MilliQ water. 
4.2.3.3. Biotinylation of rabbit anti-ostrich antibodies 
Three different antibodies were biotinylated and used as secondary antibodies in the ELISAs used 
to test the immune response elicited in the Oudtshoorn vaccine trial. The first antibody; rabbit anti-
ostrich immunoglobulin (Ig); was used to test the immune response in ostrich serum. The 
antibodies were produced in rabbits immunized with ostrich Ig (Van Tonder, A. & Bellstedt, D.U. 
2009). The other two antibodies were rabbit anti-ostrich immunoglobulin A (IgA) and were used to 
test the mucosal immune response in ostrich saliva. These antibodies were produced in rabbits 
immunized with ostrich IgA without the secretory component (protein 1) and ostrich IgA heavy 
chain with its secretory component (protein 2) (Botes 2004). All three antibodies were firstly 
isolated from rabbit serum by ammonium sulphate precipitation as follows. Two millilitres of rabbit 
serum were mixed gently by inversion with 4 ml PBS (pH 7.2) and 6 ml saturated ammonium 
sulphate (pH 7.2). The mixture was incubated at 4°C for 20 min, then centrifuged at 17,640 x g for 
20 min. The pellet dissolved in 4 ml PBS (pH 7.2) and 4 ml of saturated (NH4)2SO4 solution was 
added and incubated at 4°C for 20 min. The mixture was then again centrifuged at 17,640 x g for 
20 min and the pellet finally dissolved in 2 ml PBS (pH7.2). The mixture was then dialysed against 
carbonate buffer (0.1 M NaHCO3, pH 8.3) at 4°C overnight in 10 mm x 6 mm cellulose membrane 
dialysis tubing (Sigma Aldrich), with a buffer change after 5 hours. After overnight dialysis the 
volume of the mixture in the dialysis tubing was measured and the concentration measured at 280 
nm with a Nanodrop® ND 1000 spectrophotometer. 
The isolated immunoglobulin was diluted to a concentration of 5 mg/ml solution in 0.1 M NaHCO3 
(pH 8.3) in a pear bottom flask. A volume of Biotin reagent (2 mg Biotinamidocaproate N-
hydroxysuccinimide ester /ml N,N-Dimethylformamide (DMF)) which was one quarter of the total 
volume of the above dialysate, i.e. the isolated immunoglobulin, was added dropwise and gently 
stirred at room temperature for 2 hours. The mixture was then dialysed against PBS buffer (pH 7.2) 
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overnight at 4°C in 25 mm x 16 mm cellulose membrane dialysis tubing (Sigma Aldrich), with a 
buffer change after 5 hours. The biotinylated antibodies were then mixed with an equal volume of 
glycerol and stored at -20°C until use.  
4.2.3.4. Ostrich immune response measurement against OppA  
ELISA optimization: 
The immune response elicited in the ostriches was assessed by ELISA. Before this could be done, 
however, an optimization ELISA was performed using one immunized ostrich as follows. The wells 
of a 96-well ELISA plate (Maxisorp, Nunc) were prepared by coating columns 1 to 11 with OppA 
protein diluted in carbonate buffer (50 mM NaHCO3, pH 9.6). Rows A and B were coated with 1 
µg/ml OppA, rows C and D with 2 µg/ml OppA, rows E and F with 5 µg/ml OppA, rows G and H 
with 10 µg/ml OppA. Column 12 was left uncoated to test the specificity of the assay. The plate 
was incubated overnight at 4°C. Non-specific binding to the plate was then blocked with 200 µl 
caseïen buffer (154 mM NaCl, 10 mM Tris-HCl, 0.02% thiomersal and 0.5 % caseïen, pH 7.6) per 
well for 1-2 hours at 37°C. The wells were subsequently washed 6 times with PBS-tween 20 (PBS 
buffer (pH 7.2) containing 0.1% (v/v) tween 20). A 1:20 dilution of the ostrich serum was prepared 
in caseïen-tween 20 (caseïen buffer (pH 7.6) containing 0.1% (v/v) tween 20) and 200 µl pipetted 
into column 2 and 100 µl into column 12. To columns 1 and 3-11, 100 µl of caseïen-tween 20 (pH 
7.6) was added. To make a serial dilution from column 2 to 11, 100 µl of column 2 was mixed with 
column 3, then 100 µl of column 3 was mixed with column 4, this was done until column 11 was 
reached, after which 100 µl was discarded from each well in column 11 to leave only 100 µl in each 
well. The final volume in each well was therefore 100 µl. The plate was then incubated at 37°C for 
1 hour. After the plate was again washed 6 times with PBS-tween 20 (pH7.2), 100 µl of the 
biotinylated rabbit anti-ostrich antibodies prepared in section 4.2.3.2., that was diluted 1:100 in 
caseïen-tween 20, was added to each well and the plate incubated at 37°C for 1 hour. The plate 
was washed 6 times with PBS-tween 20 then incubated at 37°C for 1 hour with 100 µl Streptavidin 
Horseradish Peroxidase (HRP) Conjugate (Invitrogen) diluted 1:100 in caseïen-tween 20. A 1:40 
dilution of the Streptavidin-HRP was first prepared by mixing 2 ml of the Streptavidin-HRP ready 
made sample with 38 ml caseïen buffer (pH 7.6) and 40 ml glycerol, the mixture was stored at -
20°C until use. The plate was then washed again with PBS-tween 20  6 times before 100 µl of 
substrate (0.006 g ABTS, 12 ml citrate buffer (100 mM citric acid monohydrate and 100 mM tri-
sodium citrate dehydrate, pH 5) and 6 µl H2O2) was added and the plate incubated at 37°C. The 
absorbance was measured at 405 nm every 5 min for 30 min on a Labysystems Multiscan MS 
microtiter plate reader. The optimization ELISA was also done with coating concentrations of 0.1, 
0.2, 0.5 and 1 µg/ml OppA.  
 




The serum of a rabbit immunized with the OppA protein was used to test if the OppA used for 
coating can be recognised in the ELISA. The wells of a 96-well ELISA plate (Maxisorp, Nunc) were 
prepared by coating column 1 to 11 with 1 µg/ml of OppA protein diluted in carbonate buffer (50 
mM NaHCO3, pH 9.6). Column 12 was left uncoated to test the specificity of the assay. The plate 
was incubated overnight at 4°C. The plate was then blocked with 200 µl caseïen buffer (154 mM 
NaCl, 10 mM Tris-HCl, 0.02% thiomersal and 0.5% caseïen, pH 7.6) per well for 1-2 hours at 37°C. 
The wells were washed 3 times with PBS-tween 20 (PBS (pH 7.2) containing 0.1% (v/v) Tween 
20). A 1:20 dilution of the serum was prepared in caseïen-tween 20 (caseïen buffer (pH 7.6) 
containing 0.1% (v/v) Tween 20) and 200 µl pipetted into column 2; rows B, D and F; and 100 µl 
into column 12. To columns 1 and 3-11, 100 µl of caseïen-tween 20 was added. To make a serial 
dilution across columns 2 to 11, 100 µl of column 2; rows B, D and F; was mixed with column 3; 
rows B, D and F; then 100 µl of column 3; rows B, D and F; was mixed with column 4; rows B, D 
and F; this was done until column 11; rows B, D and F; was reached. The serial dilution was 
continued in rows C, E and G. The final volume in each well was 100 µl. The plate was then 
incubated at 37°C for 1 hour. After the plate washed again 3 times with PBS-tween 20 (pH 7.2), 
100 µl goat anti-rabbit antibodies were diluted 1:500 in caseïen-tween 20, and was added to each 
well and the plate incubated at 37°C for 1 hour. The plate was washed again 3 times with PBS-
tween 20 (pH 7.2) before 100 µl rabbit peroxydase anti-peroxidase (PAP) antibodies was diluted 
1:1000 in caseïen-tween 20, was added to each well and the plate incubated at 37°C for 1 hour. 
The plate was then washed again with PBS-tween 20 (pH 7.2) 3 times before 100 µl of substrate 
solution (0.006 g 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS), 12 ml citrate 
buffer (100 mM citric acid monohydrate and 100 mM tri-sodium citrate dehydrate, pH 5) and 6 µl 
H2O2) was added and the plate incubated at 37°C. The absorbance was measured at 405 nm 
every 5 min after addition for 30 min on a Labysystems Multiscan MS microtiter plate reader. The 
optimization ELISA was also done with coating concentrations of 0.1, 0.2, 0.5 and 1 µg/ml OppA.  
Humoral immune response of ostriches to Mycoplasma struthionis: 
To assess the humoral immune response of the ostriches to the OppA protein elicited by the DNA 
vaccines the following ELISA was used. The method is described above under “ELISA 
optimization” with the following modifications. Column 1 and Columns 2-12 rows A, C, E and G 
were coated with 1 µg/ml OppA and Columns 2-12 rows B, D, F, H were left uncoated. A serial 
dilution of the serum was not made across the plate, instead the serum collected at week 0, week 
3 and week 6 from each ostrich was only diluted 1:100 and 100 µl of this dilution pipetted into a 
coated wells in duplicate and in uncoated wells.      
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Mucosal immune response of ostriches to Mycoplasma struthionis:   
The second swab sample obtained from each ostriches in the vaccination trial was stored as 
described in section 4.2.1.3. but was then immersed in PBS (pH 7.2) containing 0.1%(w/v) Triton 
X-100. The immune responses of the ostriches against the OppA protein were assessed using the 
ELISA protocols described in section 4.2.3.3, with two exceptions. The ostrich swab samples were 
diluted 1:20 in caseïen-tween 20 for incubation instead of 1:100 used for the ostrich serum. The 
second change was that instead of biotinylated rabbit anti-ostrich immunoglobulin being used, 
biotinylated rabbit anti-ostrich IgA protein 1 and biotinylated rabbit anti-ostrich IgA protein 2 were 
used separately for each sample, respectively.   
4.2.3.5. Ostrich immune response measurement against Salmonella enterica serovar typhimurium 
SL3261 LPS  
ELISA optimization: 
The immune responses of the ostriches to the Salmonella enterica serovar typhimurium SL3261 
LPS was assessed by means of an ELISA very similar to that for the assessment of the immune 
response to OppA. The method described in section 4.2.3.3 was used with the following 
modifications. For Rows A and B, Column 1 to 5 was coated with 0.5 µg/ml LPS dissolved in PBS 
(pH 7.2) and Column 7 to 11 was coated with 0.5 µg/ml LPS dissolved in carbonate buffer (pH 
9.6). For Rows C and D, Column 1 to 5 was coated with 1.0 µg/ml LPS dissolved in PBS (pH 7.2) 
and Column 7 to 11 was coated with 0.5 µg/ml LPS dissolved in carbonate buffer (pH 9.6). For 
Rows E and F, Column 1 to 5 was coated with 3 µg/ml LPS dissolved in PBS (pH 7.2) and Column 
7 to 11 was coated with 0.5 µg/ml LPS dissolved in carbonate buffer (pH 9.6). For Rows G and H, 
Column 1 to 5 was coated with 5.0 µg/ml LPS dissolved in PBS (pH 7.2) and Columns 7 to 11 
were coated with 0.5 µg/ml LPS dissolved in carbonate buffer (pH 9.6). Columns 6 and 12 were left 
uncoated. A serial dilution of the serum was made from Column 2 to 5 and again in Columns 8 to 
11 starting with a dilution of 1/40. Rows A, C, E and G received sera from week 0 and Rows B, D, 
F and H received sera from week 3. The rest of the ELISA procedure was the same as described 
in section 4.2.3.3. 
Humoral immune response of the ostriches to Salmonella enterica serovar typhimurium SL3261: 
To test the immune response of the ostriches to Salmonella enterica serovar typhimurium SL3261 
an ELISA was used. The method in section 4.2.3.3 was used with the following modifications. 
Column 1 and Column 2-12 rows A, C, E and G was coated with 5 µg/ml Salmonella LPS and 
Columns 2-12 rows B, D, F, H was left uncoated. A serial dilution of the serum was not made 
across the plate, instead the serum of week 0, week 3 and week 6 for each ostrich was a diluted 
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1:100 and 100 µl pipetted into coated wells in duplicate and in uncoated wells. Biotinylated rabbit 
anti-ostrich immunoglobulin antibody was used as secondary antibody. 
Mucosal immune response of the ostriches to Salmonella enterica serovar typhimurium SL3261:   
The swab samples obtained from the ostriches in the vaccination trial were prepared as described 
in section 4.2.1.3., but the samples were immersed in PBS (pH 7.2) containing 0.1%(w/v) Triton X-
100. The immune responses of the ostriches against Salmonella enterica serovar typhimurium 
SL3261 were assessed using the ELISA protocols described in section 4.2.3.3, with two 
exceptions. The ostrich swab samples were diluted 1:20 in caseïen-tween 20 for incubation instead 
of the 1:100 used for the ostrich serum. The second change was that instead of biotinylated rabbit 
anti-ostrich immunoglobulins, biotinylated rabbit anti-ostrich IgA protein 1 and biotinylated rabbit 
anti-ostrich IgA protein 2 were used separately for each sample.   
4.2.3.6. Statistical analysis of ELISA data 
The immune responses as measured by ELISA after vaccination with the VR1020 naked DNA 
vaccine and the VR1020 mucosal DNA vaccine were analysed using ANOVA in the Statistical 
Analysis program Agrobase Generation II® (Agronomix Software Inc.). 
4.3. Results 
4.3.1. Analysis of samples collected during preliminary vaccine trial on a commercial 
ostrich farm in Oudtshoorn, Western Cape. 
The results of the tests for the detection of ostrich Mycoplasma and Salmonella infection in the 
ostriches prior to and during the vaccination trial are shown in table 4.4. All the ostriches showed 
the presence of Salmonella infections at week 0, which were cleared by week 6 after treatment 
with Tenaline® LA. Only a few Ms02 and Mycoplasma nasistruthionis infections were found.  
4.3.2. Evaluation of immune response elicited in preliminary vaccine trial 
4.3.2.1. Isolation of OppA protein for ELISA plate coating 
The agarose gel in figure 4.3 shows a band at approximately 3000 bp which corresponds with the 
expected size of the BL21(DE3)pLysS cells successfully transformed with pGEX containing the 
oppA gene and a band at appoximately 150 bp corresponding to the expected size of 
BL21(DE3)pLysS cells successfully transformed with the pGEX vector only. The concentrations of 
the fractions containing the isolated GST OppA fusion protein obtained from the glutathione 
agarose gel are shown in figure 4.4. The fraction with the highest protein concentration was 
fraction 6, with a concentration of 0.485 mg/ml. The results of of the SDS-PAGE separation of the 
fractions that contained the highest protein concentration are shown in figure 4.5. The SDS-PAGE 
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gel shows bands at approximately 150 kDa and 30 kDa which correspond to the expected size of 
the GST OppA fusion protein  (about 130 kDa) and the GST protein only (26 kDa), respectively 
(Brandt 2012).     
 
4.3.2.2. Isolation of Salmonella enterica serovar typhimurium SL3261 lipopolysaccharide (LPS) for 
ELISA plate coating 
The isolated Salmonella enterica serovar typhimurium SL3261 LPS was separated on an SDS-
PAGE gel and visualized with silver staining shown in figure 4.6A. In general, the staining of the 
bands was not very strong as a result of which the bands on the photograph are not all clearly 
visible. However, although the bands obtained in the lanes in which the isolated LPS samples were 
loaded was weaker, they were similar to those of the commercial Salmonella enterica serovar 
typhimurium LPS. The isolated LPS showed a ladder-like pattern in the low molecular weight range 
which is characteristic of LPS molecules, showing different amounts of repetitive O-antigen groups. 
Althought the commercial Salmonella enterica serovar typhimurium LPS shows different bands in 
the higher molecular weight range, it also shows the characteristic ladder-like banding in the low 
molecular weight range.       
4.3.2.3. Ostrich immune responses measured against OppA 
ELISA optimization: 
The optimal OppA protein coating concentration for coating was found to be 1 µg/ml. When this 
concentration of OppA was used for coating the highest absorbance value  in the ELISA of the 
serum sample from week 3 (1.658) was obtained whilst the absorbance value in the ELISA 
obtained with the serum sample from week 0 (0.479) remained relatively low. At a lower coating 
concentration, the week 3 values were too low whilst at a higher coating concentration the week 0 
absorbance values in the ELISA were too high. Results not shown. 
ELISA validation: 
The results of the ELISA validation showed that the ELISA can be used to measure an immune 
response against the OppA protein. Sera of a rabbit immunized with purified OppA protein were 
tested with the ELISA and the results obtained are shown in figure 4.7 showing an increase in titer 
over the period of 45 days.  
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Week 0 (kg) 
Infection 
Weight 
Week 3 (kg) 
Infection 
Weight 
Week 6 (kg) 
Infection 
Bacterial Control 
(Salmonella enterica  





















43 Salmonella 44 
Mycoplasma 
nasistruthionis 
2703 38 Salmonella 40.6 Salmonella 47.6 
 
2704 49 Salmonella 55.5 Ms02, Salmonella 63 
 








39.2 Salmonella 42.4 
 




















40.2 Salmonella 41.8 
 
2711 39 Salmonella 35.2 Salmonella 35.8 
 






2713 36 Salmonella 33.6 Ms02, Salmonella 32.8 
 






2715 39 Salmonella 35 Ms02 40.8 
 
2716 42 Salmonella 35.6 Salmonella 37.8 
 



















2720 51 Salmonella 56.5 Salmonella 64 
 
2721 40 Salmonella 39.2 Salmonella 41.2 
 
2722 39 Salmonella 43.6 Salmonella 45.8 
 
2723 42 Salmonella 40.2 Salmonella 42 
 
2724 43 Salmonella 42.8 Salmonella 48 
 






2726 39 Salmonella 40.8 Salmonella 47 
 
2727 49 Salmonella 49.6 Salmonella 59 
 
2728 47 Salmonella 44.4 Salmonella 46.6 
 
2729 39.8 Salmonella 41.6 Salmonella 43.2 
 
Mucosal vaccine 
(Salmonella enterica  
serovar typhimurium  
















2731 46 Salmonella 47.4 Salmonella 58 
 
2732 41 Salmonella 42.8 Salmonella - 
 
2733 45 Salmonella 46.8 Salmonella 51.5 
Mycoplasma 
nasistruthionis 
2734 47 Salmonella 52 Salmonella 62.5 
 
2735 35 Salmonella 30.4 Salmonella 35.4 
 
2736 40 Salmonella 38.8 Salmonella 45 
 






2738 34 Salmonella 36.4 Salmonella 35 
 






2740 48 Salmonella 49.2 Salmonella 61 
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2741 40 Salmonella 43.8 Salmonella 50.5 
 
2742 42 Salmonella 42.4 Salmonella 49.8 
 
2743 46 Salmonella 44.8 Salmonella 48.6 
 
2744 36 Salmonella 34.8 Salmonella 32 
Mycoplasma 
nasistruthionis 
2745 49 Salmonella 50.5 Salmonella 52 
 













2749 36 Salmonella 39.4 Salmonella 46.6 Ms02 
2750 38 
 
40.2 Salmonella 46 
 




2752 40 Salmonella 39 Ms02, Salmonella 47.6 
 




2754 44 Salmonella 40.6 Salmonella 47.8 
 
2755 44 Salmonella 44.4 Salmonella 46 Ms02 




40.6 Salmonella 45 
 
2758 36 Salmonella 40.2 Salmonella 47.4 
 




naked DNA vaccine) 
 
Week 0: 100 µg/ml 
Week 6: 100 µg/ml 
2760 40 Salmonella 39.4 Salmonella 42 
 
2761 40 Salmonella 42.6 Salmonella 44.8 Ms02 
2762 38 Salmonella 37 Salmonella 39.8 
 




41.2 Salmonella 49 
 
2765 37 Salmonella 37.8 Ms02, Salmonella 38.2 
 
2766 44 Salmonella 40.6 Salmonella 45.4 Ms02 
2767 40 Salmonella 43.2 Ms02, Salmonella 47.8 
 
2768 39 Salmonella 43.2 Ms02, Salmonella 46.8 
 
2769 39 Salmonella 38.8 Salmonella 39.2 
 
2770 37 Salmonella 43.8 Salmonella 42 
 
2771 48 Salmonella 41.4 Salmonella 42.8 
 
2772 37 Salmonella 40.8 Salmonella 40.4 Mycoplasma 




2773 37 Salmonella 37.6 Salmonella 33.4 
 
2774 43 Salmonella 46.6 Ms02, Salmonella 45.2 
 
2775 39 Salmonella 32 Salmonella 37.8 Ms02 
2776 37 Salmonella 37.8 Salmonella 40.3 Ms02 
2777 39 Salmonella 41.4 Salmonella 44.4 
 
2778 41 Salmonella 44.6 Salmonella 46 Ms02 
2779 37 Salmonella 38 Salmonella 37 
 
2780 40 Salmonella 41.8 Salmonella 44.2 Ms02 
2781 39 Salmonella 39.2 Salmonella 45.8 
 
2782 39 Salmonella 37.6 Salmonella - 
 
2783 40 Salmonella 35 Salmonella 38 
 
2784 41 Salmonella 40.8 Salmonella 43.4 
 
2785 41 Salmonella 42.4 Salmonella 48.4 
Mycoplasma 
nasistruthionis 
2786 41 Salmonella 41 Salmonella 42.6 
 
2787 39 Salmonella 36.2 Salmonella 36.6 
 
2788 39 Salmonella 44.4 Salmonella 46.6 
 




2790 38 Salmonella 37.8 Salmonella 42.4 
 
2791 40 Salmonella 36.8 Salmonella 44.4 
Mycoplasma 
nasistruthionis 
2792 36 Salmonella 32.4 Salmonella 35 
 
2793 38 Salmonella 34.2 Ms02, Salmonella 33.2 
 
























2798 36 Salmonella 41.4 Salmonella 48.6 Ms02 
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2801 37 Salmonella 33.2 Salmonella 38.4 Ms02 
















36.6 Salmonella 37.2 
 
2805 43 Salmonella 41 Salmonella 48.4 
 
2806 38 Salmonella 35.4 Salmonella 40.2 Ms02 
2807 38 Salmonella 38.2 Ms02, Salmonella 38.4 
 
2808 45 Salmonella 44.4 Salmonella 48 
 






2810 38 Salmonella 38.6 Salmonella 43.8 Ms02 
2811 38 Salmonella 40.2 Salmonella 40.2 
 
2812 40 Salmonella 43.4 Salmonella 43 
Mycoplasma 
nasistruthionis 
2813 38 Salmonella 37.4 Salmonella 38.8 
Ms02, Mycoplasma 
nasistruthionis 
2814 37 Salmonella 34 Salmonella 43 
 
2815 36 Salmonella 31 Salmonella 28.2 
Mycoplasma 
nasistruthionis 
2816 42 Salmonella 47 Salmonella 47.6 
 
2817 37 Salmonella 39.2 Salmonella 36 
Mycoplasma 
nasistruthionis 
2818 36 Salmonella 40 Salmonella 42.6 
 
2819 35 Salmonella 33 Salmonella 36.4 
Mycoplasma 
nasistruthionis 
[Blank]   No infections detected 
             No data available as ostriches died 






Figure 4.4: Graph of concentration of OppA in the fractions eluted from a glutathione agarose affinity 






























Concentration of OppA protein 
Figure 4.3: Diagnostic colony PCR of transformed cells. i. Lane 1: 5 μl DNA Ladder mix (Generuler
TM
, 
Fermentas). Lane 2-13: 10 μl PCR product from selected colonies on LB agar plates with BL21(DE3)pLysS 
transformed with pGEX only cells. Lane 14-24: 10 μl PCR product from selected colonies on LB agar plates 
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Figure 4.6: Silver stained SDS-PAGE gel to visualize isolated Salmonella enterica serovar typhimurium 
SL3261 LPS. Lane 1: 3 µg Salmonella enterica serovar typhimurium LPS control. Lane 2: 3 µg Salmonella 
enterica serovar typhimurium SL3261. Lane 3: 2.5 µg Salmonella enterica serovar typhimurium SL3261. 
Lane 4: 2 µg Salmonella enterica serovar typhimurium SL3261. Lane 5: 5 µl High range rainbow molecular 
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Figure 4.5: SDS PAGE gel of isolated OppA protein. Lane 1: Glutathione S-transferase (GST) Lane 2: 5 µl 
Protein Ladder (Unstained Pageruler
TM
) Lane 3 – 10: Fractions 4-11 collected during Glutathione agarose 
affinity chromatography.  
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Figure 4.7: Immune response elicited by a rabbit to isolated OppA protein as determined by an ELISA. The 
rabbit was immunized with purified OppA protein on day 0 and a booster injection was given on day 28. 
Serum samples collected on day 0, 28 and 42 were tested. 
Humoral and mucosal immune responses of ostriches to Mycoplasma struthionis  
The humoral and mucosal immune responses expressed as absorbance values obtained from the 
ELISA assessment of the serum and saliva samples were analysed by ANOVA. The results of the 
analysis are shown in Tables 4.5, 4.6 and 4.7. In view of the large biological variability to be 
expected from such trials a p-value of 0.05 was accepted as being significant. The ANOVA 
generates a least significant difference (LSD) value which indicates the smallest difference that is 
significant between any two points on the graphs. If the effect of a factor i.e., treatment or time was 
found to be statistically significant, the LSD of that interaction is indicated as a bar on the graphs 
depicting the averages of the immune response elicited by the ostriches (figures 4.8., 4.9 and 
4.10). The same goes for if the interaction between treatment and time was found to be statistically 
significant. The influence of the vaccine on the weights of the ostriches was also analysed and the 
results shown in table 4.8 and is shown graphically in figure 4.11. The raw data and a graphical 
presentation of the immune responses and weights of each bird are shown in Appendix B. 
It is a generally accepted rule in ANOVA analysis that if the R squared value is lower than 0.81 and 
the coefficient of variance (C. V.) is greater than 15%, the variability of the data is too great to 
make statistically significant deductions (Personal communication with Willem Burger). These 
values were used as a criterion upon which any deductions were made about the effect of the 
administration of the vaccines, the Salmonella control treatment or the control treatment caused on 
the observed changes in humoral or mucosal immunity. None of the results obtained from the 
analysis adhere to these criteria, which means that these results must be treated with caution. It 



















Immune response of rabbit 
Stellenbosch University  http://scholar.sun.ac.za
58 
 
as a result of vaccination with the VR1020 mucosal and VR1020 naked DNA vaccines. There are a 
number of reasons that can explain this and include: that the ostriches were influenced by previous 
infections with mycoplasmas and Salmonella; that the stress of handling has influenced the ability 
of the ostriches to elicit an immune response; and that the AI may have already compromised the 
ability of the birds to elicit an immune response. Although the analysis of data of the weights of the 
ostriches during the trial also has a low R squared value, the C.V. is 16% and this gives an 
indication that this data can be trusted. The weight increase of these birds was on average lower 
than what could have been expected for birds of this age so clearly they were influenced by 
environmental conditions. 
Table 4.5: Statistical analysis of humoral immune responses elicited against the different vaccines 
using anti-ostrich immunoglobulins as detection antibody. 
Source df SS MS Pr>F 
Total 359 57.063 
  
Treatment 3 5.919 1.973 0.0000 
Time 2 2.416 1.208 0.0002 
Treatment x Time interaction 6 1.361 0.227 0.1284 
Residual 348 47.367 0.136 
 
 
Figure 4.8: Averages of the humoral immune responses elicited in each vaccine group as determined by an 
ELISA using 1 µg/ml OppA for coating and anti-ostrich immunoglobulins as detection antibody. Group 1 (♦ 
Salmonella control) received 1 ml of a 10
9
 c.f.u./ml solution of Salmonella enterica serovar typhimurium 
SL3261. Group 2 (■ VR1020 mucosal DNA vaccine) received 1 ml of 10
9
 c.f.u./ml solution of the VR1020 
mucosal DNA vaccine. Group 3 (▲VR1020 naked DNA vaccine) received 1 ml of a 100 µg/ml solution of the 
naked VR1020 recombinant vaccine. Group 4 (Χ Control) received no immunizations. The ostriches were 




































LSDtreatment (0.5%) < 0.1082 
LSDtime (0.5%) < 0.0937  
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Table 4.6: Statistical analysis of mucosal immune response against the different vaccines using anti-
IgA protein 1 as the secondary antibody 
Source df SS MS Pr>F 
Total 359 0.050 
  
Treatment 3 0.003 0.001 0.0000 
Time 2 0.000 0.000 0.2474 
Treatment x Time interaction 6 0.001 0.000 0.3123 
Residual 348 0.046 0.000 
 
 
Figure 4.9: Averages of the mucosal immune responses elicited in each vaccine group as determined by an 
ELISA using 1 µg/ml OppA for coating, saliva collected and rabbit anti-ostrich IgA protein 1 as detection 
antibody. Group 1 (♦ Salmonella control) received 1 ml of a 109 c.f.u./ml solution of Salmonella enterica 
serovar typhimurium SL3261. Group 2 (■ mucosal VR1020 vaccine) received 1 ml of 10
9
 c.f.u./ml solution of 
the VR1020 mucosal DNA vaccine. Group 3 (▲VR1020 naked DNA vaccine) received 1 ml of a 100 µg/ml 
solution of the VR1020 naked DNA vaccine. Group 4 (Χ Control) received no immunizations. The ostriches 




































LSDtreatment (0.5%) < 0.0034 
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Table 4.7: Statistical analysis of mucosal immune response measured against the OppA protein 
using anti-IgA protein 2 as the secondary antibody 
Source df SS MS Pr>F 
Total 359 0.063 
  
Treatment 3 0.001 0.000 0.2527 
Time 2 0.000 0.000 0.5329 
Treatment x Time interaction 6 0.001 0.000 0.6294 
Residual 348 0.061 0.000 
 
 
Figure 4.10: Averages of the mucosal immune responses elicited in each vaccine group as determined by 
an ELISA using 1 µg/ml OppA for coating, saliva collected and rabbit anti-ostrich IgA protein 2 as the 
detector antibody. Group 1 (♦ Salmonella control) received 1 ml of a 109 c.f.u./ml solution of Salmonella 
enterica serovar typhimurium SL3261. Group 2 (■ VR1020 mucosal DNA vaccine) received 1 ml of 10
9
 
c.f.u./ml solution of the VR1020 mucosal DNA vaccine. Group 3 (▲VR1020 naked DNA vaccine) received 1 
ml of a 100 µg/ml solution of the VR1020 naked DNA vaccine. Group 4 (Χ Control) received no 
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Table 4.8: Statistical analysis of weight measured during the vaccine trial 
Source df SS MS Pr>F 
Total 359 17242.88 
  
Treatment 3 1543.189 514.396 0.0000 
Time 2 410.744 205.372 0.0096 
Treatment x Time interaction 6 101.732 16.955 0.8663 
Residual 348 15187.21 43.641 
 
 
Figure 4.11: Averages of the weights measured for each vaccination group. Group 1 (♦ Salmonella control) 
received 1 ml of a 10
9
 c.f.u./ml solution of Salmonella enterica serovar typhimurium SL3261. Group 2 (■ 
VR1020 mucosal DNA vaccine) received 1 ml of 10
9
 c.f.u./ml solution of the VR1020 mucosal DNA vaccine. 
Group 3 (▲VR1020 naked DNA vaccine) received 1 ml of a 100 µg/ml solution of the naked VR1020 
recombinant vaccine. Group 4 (Χ Control) received no immunizations. The ostriches were immunized on 
week 0 and received a booster immunization on week 6. 
4.3.2.4. Ostrich immune response against Salmonella enterica serovar typhimurium SL3261 LPS 
ELISA optimisation: 
The optimal coating concentration for the isolated Salmonella enterica serovar typhimurium 
SL3261 LPS was found to be 5.0 µg/ml. At this concentration the highest absorbance value in the 
ELISA of the serum sample from week 3 (2.126) was obtained and the absorbance value in the 
ELISA obtained with the serum sample from week 0 (1.838) remained relatively low. At a lower 
coating concentration, the week 3 values were too low and at a higher coating concentration, the 






























LSDtreatment (0.5%) < 1.9369 
LSDtime (0.5%) < 1.9369 
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Humoral and mucosal immune responses of the ostriches to Salmonella enterica serovar 
typhimurium SL3261: 
The humoral and mucosal immune responses expressed as absorbance values obtained from the 
ELISA assessment of the serum and saliva samples were analysed by ANOVA and the results are 
shown in tables 4.9, 4.10 and 4.11. LSD of the statistically sigificant relationships are shown in the 
graphs of the averages of the humoral and mucosal immune response of the ostriches to 
Salmonella enterica serovar typhimurium SL3261. The humoral immune response against 
Salmonella enterica serovar typhimurium SL3261 (figure 4.12) shows a decreasing trend in all of 
the groups and that the response measured of the control groups was higher than the vaccinated 
groups. The mucosal immune response measured using the secondary ostrich IgA protein 1 and 2, 
figure 4.13 and 4.14, respectively, show that no mucosal immune response was observed (figure 
4.13 and 4.14). The raw data and a graphical presentation of the immune responses and weights 
of each bird are shown in Appendix B. 
As in the analyses of the humoral and mucosal immune responses against OppA, the ANOVA 
analysis of the humoral and mucosal immune responses against Salmonella enterica serovar 
typhimurium SL3261 LPS gave too low R squared values and too high C.V. values. Thus 
deductions that the administration of the vaccines, the Salmonella control treatment or the control 
treatment caused the observed changes in humoral or mucosal immunity could not be made and 
must be treated with caution. Reasons for this may be the same as those listed previously. 
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Table 4.9: Statistical analysis of humoral immune response measured against Salmonella enterica 
serovar typhimurium SL3261 
Source df SS MS Pr>F 
Total 359 243.951 
  
Treatment 3 10.061 3.354 0.0011 
Time 2 19.620 9.810 0.0000 
Treatment x Time interaction 6 1.374 0.229 0.8951 
Residual 348 212.895 0.612 
 
 
Figure 4.12: Averages of the humoral immune responses elicited in each vaccine group as determined by 
an ELISA using 5 µg/ml Salmonella enterica serovar typhimurium SL3261 LPS for coating and serum 
collected. Group 1 (♦ Salmonella control) received 1 ml of a 10
9
 c.f.u./ml solution of Salmonella enterica 
serovar typhimurium SL3261. Group 2 (■ VR1020 mucosal DNA vaccine) received 1 ml of 10
9
 c.f.u./ml 
solution of the VR1020 mucosal DNA vaccine. Group 3 (▲VR1020 naked DNA vaccine) received 1 ml of a 
100 µg/ml solution of the VR1020 naked DNA vaccine. Group 4 (Χ Control) received no immunizations. The 



































LSDtreatment (0.5%) < 0.2293 
LSDtime (0.5%) < 0.1986 
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Table 4.10: Statistical analysis of mucosal immune response measured against the Salmonella 
enterica serovar typhimurium SL3261 using IgA protein 1 as the secondary antibody 
Source df SS MS Pr>F 
Total 359 0.068 
  
Treatment 3 0.003 0.001 0.0006 
Time 2 0.001 0.000 0.2275 
Treatment x Time interaction 6 0.001 0.000 0.7814 
Residual 348 0.063 0.000 
 
 
Figure 4.13: Averages of the mucosal immune responses elicited in each vaccine group as determined by 
an ELISA using 5 µg/ml Salmonella enterica serovar typhimurium SL3261 LPS for coating, saliva collected 
and biotinylated rabbit anti-ostrich IgA protein 1 as the biotinylated detector antibody. Group 1 (♦ Salmonella 
control) received 1 ml of a 10
9
 c.f.u./ml solution of Salmonella enterica serovar typhimurium SL3261. Group 2 
(■ VR1020 mucosal DNA vaccine) received 1 ml of 10
9
 c.f.u./ml solution of the VR1020 mucosal DNA 
vaccine. Group 3 (▲VR1020 naked DNA vaccine) received 1 ml of a 100 µg/ml solution of the VR1020 
naked DNA vaccine. Group 4 (Χ Control) received no immunizations. The ostriches were immunized on 




































LSDtreatment (0.5%) < 0.0040 
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Table 4.11: Statistical analysis of mucosal immune response measured against Salmonella enterica 
serovar typhimurium SL3261 using IgA protein 2 as the secondary antibody 
Source df SS MS Pr>F 
Total 359 0.114 
  
Treatment 3 0.005 0.002 0.0008 
Time 2 0.001 0.000 0.4364 
Treatment x Time interaction 6 0.002 0.000 0.5118 
Residual 348 0.107 0.000 
 
 
Figure 4.14: Averages of the mucosal immune responses elicited in each vaccine group as determined by 
an ELISA using 5 µg/ml Salmonella enterica serovar typhimurium SL3261 LPS for coating, saliva collected 
and biotinylated rabbit anti-ostrich IgA protein 2 as the biotinylated detector antibody. Group 1 (♦ Salmonella 
control) received 1 ml of a 10
9
 c.f.u./ml solution of Salmonella enterica serovar typhimurium SL3261. Group 2 
(■ VR1020 mucosal DNA vaccine) received 1 ml of 10
9
 c.f.u./ml solution of the VR1020 mucosal DNA 
vaccine. Group 3 (▲ VR1020 naked DNA vaccine) received 1 ml of a 100 µg/ml solution of the VR1020 
naked DNA vaccine. Group 4 (Χ Control) received no immunizations. The ostriches were immunized on 
week 0 and received a booster immunization on week 6. 
 
4.4. Discussion 
In general, it can be deduced from the results obtained from the controls used in this study, that the 
ELISA development for the assessment of the humoral and mucosal immune responses in 
ostriches against M. struthionis OppA and Salmonella enterica serovar typhimurium SL3261 LPS 
was successful.  
After expression of the cloned M. struthionis oppA gene in E. coli, the GST OppA fusion protein 
could be isolated from the bacterial lysate using a glutathione agarose gel. After the OppA sample 
was cleared of impurities, reduced glutathione was used to elute the GST-fused protein without 
denaturation, preserving the antigenicity and function of the protein. The 130 kDa GST-OppA 



































LSDtreatment (0.5%) < 0.0051 
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immunized rabbit. This indicated that the antigen is suitable for use in ELISAs to analyse the 
humoral and mucosal immune response of the ostriches against Mycoplasma struthionis OppA 
vaccines. Similarly, it was found that LPS could be isolated from Salmonella enterica serovar 
typhimurium SL3261. This isolated LPS could then beused as a coating antigen in ELISAs for the 
detection of humoral and mucosal immune responses to Salmonella enterica serovar typhimurium 
SL3261 and other Salmonella LPS‟ as deduced from the high humoral antibody levels measured in 
some of the ostriches that were used in the preliminary vaccine trial.  
In the saliva samples tested for Salmonella sp. type and ostrich mycoplasmas on weeks 0 and 3 
an overwhelming percentage of the ostriches showed the presence of one or more Salmonella sp. 
type, some Ms02 and M. nasistruthionis infections, but no M. struthionis infections. The reduction 
in Salmonella infection in week 6 can be attributed to the Tenaline® LA the ostriches received a 
week before the samples were collected. Tenaline® LA of which oxytetracycline is the active 
ingredient and reported to be active for a week after immunization (Adriaan Olivier, Personal 
communication), would have killed off the Salmonella present in these birds. After this treatment, 
the saliva samples still showed some Ms02 and M. nasistruthionis. It was surprising to find such a 
high incidence of Salmonella infections in these ostriches, although the frequent occurrence of 
ostrich mycoplasma infections was revealed previously in the study of Botes (2005a). This showed 
that most of the ostriches that were used in the vaccination trial, were already suffering from 
serious infections prior to the trial. This indicates that in future trials it may be beneficial to 
administer Tenaline® LA to ostriches two weeks before a vaccine trial is initiated to ensure that the 
ostriches are cleared of Salmonella infection. 
The ANOVA analysis of the humoral and mucosal immune responses against M struthionis OppA 
and Salmonella enterica serovar typhimurium SL3261 LPS showed that the results achieved were 
largely invalidated by far too high levels of variation in the data. Previous vaccine trials conducted 
from this laboratory against Newcastle Disease Virus (Botes et al., 2000) and Mycoplasma 
gallisepticum and Mycoplasma synoviae bacterins (Pretorius, 2009) were successful, but in these 
vaccination trials, the ostriches had no previous contact with the respective antigens and therefore 
could not have possessed prior immunity or background levels of antibodies against the antigens. 
However, in this trial, most of the ostriches had previous contact with Salmonella sp. and/or ostrich 
mycoplasmas. It can therefore be deduced that this was one of the factors contributing to the 
background values and the variation in the data. However, the low weight increase of the birds in 
the vaccination trial also indicated that stress may have played a role in reducing immune 
responses to the vaccines. Furthermore, the vaccine trial was terminated early due to an outbreak 
of AI in Oudsthoorn, which could have had an effect on these results as well.  
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For future trials, this means that the ostriches should be tested for Mycoplasma and Salmonella 
infection prior to the start of the trial and that an antibiotic, such as Tenaline® LA, should be 
administered to clear the ostriches of Salmonella infections. Mycoplasma infection in ostriches are 
mostly found during the winter months and when rapid changes in temperature occur, such as 
during changing of seasons, it might be better to plan vaccine trials for the months when the 
number of Mycoplasma infection observed in the ostriches is lower. Other factors that can be 
considered to increase the immune response elicited in the ostriches include studies to determine: 
if the dose of each vaccine administered is optimal for the ostriches to elicit an immune response 
and, if the immune response against the chosen protein, OppA, is able to confer protection of the 
ostriches against M. struthionis. 
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Chapter 5:  Dosing vaccine trial 
5.1. Introduction 
Attempts to develop an effective vaccine against this Mycoplasma struthionis, started with the 
isolation of the candidate gene, oppA, and its insertion into each of three plasmids to generate 
three DNA vaccines (Pretorius 2009). As M. struthionis infects the respiratory tract of ostriches, a 
mucosal immune response is required, and three mucosal vaccines were developed by inserting 
the DNA vaccines into the carrier bacterium, Salmonella enterica serovar typhimurium SL3261, 
using electroporation as described in Chapter 3. The VR1020 recombinant plasmid contains the 
tissue plasminogen activator (tPA) signal peptide that aids in secretion of the protein after 
expression (Coban et al. 2005). As the OppA protein of M. struthionis is a membrane protein it was 
thought that this vaccine would have a better chance of success and the immune response of the 
VR1020 mucosal DNA vaccine was therefore compared to the VR1020 naked DNA vaccine in a 
preliminary vaccine trial as described in Chapter 4. This trial was compromised by a variety of 
factors and prematurely terminated due to AI, but the serum and saliva samples collected were still 
analysed and a decision was reached that the dose chosen to immunise the ostriches with the 
mucosal vaccine may have been too low to elicit an immune response.  
In this chapter, the two mucosal vaccines that were shown to be the most stable, the VR1012 and 
VR1020 mucosal vaccines, were chosen to use in another vaccine trial in which the ostriches were 
immunised with various doses of the mucosal vaccines in an attempt to determine the effective 
dose needed to elicit an immune response in ostriches. The vaccine trial was performed at 
Kromme Rhee (Cape institute for agricultural training) in Stellenbosch, Western Cape, in an 
attempt to escape the threat of AI that was wide spread in Oudtshoorn at this time. Kromme Rhee 
is also much closer to Stellenbosch University and samples could be collected weekly in an 
attempt to measure the immune response of the ostriches more accurately. Swab samples were 
collected to test for the presence of Salmonella and Mycoplasma infections. As the chosen carrier 
bacterium, Salmonella enterica serovar typhimurium SL3261 is only capable of limited growth in 
vivo, cloacal swabs were collected once to test for bacterial shedding. The humoral and mucosal 
immune responses elicited against Mycoplasma struthionis OppA protein and Salmonella enterica 
serovar typhimurium SL3261 LPS were evaluated using the ELISAs developed in Chapter 4. An 
ANOVA analysis was used to analyse the data obtained.  
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5.2. Materials and Methods 
5.2.1. Dosing vaccine trial at Kromme Rhee farm in Stellenbosch, Western Cape. 
5.2.1.1. Vaccine trial design 
A vaccine trial to determine the optimal vaccine dose for ostriches to elicit an immune response 
was performed on 56 ostriches at Kromme Rhee (Cape institute for agricultural training) in 
Stellenbosch, Western Cape. The ostriches were bought from ostrich farms in the Malmesbury 
area moved to Kromme Rhee farm and held at for four weeks in feeding camps prior to the start of 
the vaccine trial. Two weeks before the trial started the ostriches were tested for Salmonella spp 
and Mycoplasma spp infection and all the ostriches were injected with Tenaline® LA at a dosage of 
1 ml/10 kg. Tenaline® LA, which is an antibiotic containing oxytetracycline, and was administered 
specifically because of the high level of infection of the ostriches used in the previous trial. 
Background Salmonella infections could be expected to influence the immune responses of the 
ostriches to the vaccines.   
The trial was designed so that there were 11 groups of ostriches. The first set of five groups 
consisted of five ostriches each that received different doses of the VR1012 mucosal vaccine and 
second set of five groups consisted of five ostriches each that received different doses of the 
VR1020 mucosal vaccine. The different doses were 109, 1010, 1011, 1012 and 1013 c.f.u/ml per 
ostrich for each of the two vaccines. The 11th group consisting of six ostriches that served as a 
control as they received no vaccinations. The vaccine trial was carried out over a period of 9 weeks 
with a vaccination at week 0 and a booster vaccination at week 6. Blood samples from ostriches 
were collected in 5 ml Serum sep clot activator tubes (Vacuette) using 18G x 1” needles 
(Vacuette); every week for the first three weeks and then every three weeks to minimize the stress 
caused by handling the ostriches. Two saliva samples were collected from the ostriches by 
swabbing the trachea with two sterile swabs (plain, Rayon tipped, sterile swabs with a plastic 
applicator, Copan) on weeks 0, 3, 6 and 9 and one saliva sample was collected on weeks 1 and 2. 
The weights of the ostriches were also determined prior to the trial, and at week 2 and week 9. 
Two cloacal swabs of each ostrich were also taken at week 6.  
5.2.1.2. Preparation of the recombinant VR1012 and VR1020 mucosal vaccine 
The mucosal vaccines were prepared as described in section 4.2.1.3. with the exception that each 
vaccine was prepared and diluted to 109, 1010, 1011, 1012 and 1013 c.f.u./ml less than 24 hours 
before vaccination in sterilized serum bottles, respectively.   
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5.2.2. Analysis of samples collected during dosing vaccine trial on ostriches on Kromme 
Rhee farm in Stellenbosch, Western Cape. 
5.2.2.1. Serum and saliva samples 
The serum sample and one saliva sample of each ostrich was processed as described in section 
4.2.2.1. and stored at -20°C. The second saliva sample collected at weeks 0, 3, 6 and 9 were 
analysed for ostrich Mycoplasma spp and Salmonella spp infections as described in section 
4.2.2.2. and 4.2.2.3.  
5.2.2.2. Cloacal samples 
The first swab was streaked directly onto a plastic Petri dishes containing XLD agar and incubated 
at 37°C for 24 hours. The second swab was first incubated in 2 ml Selenite enrichment broth 
(Merck) at 43°C for 24 hours. Using a loop the enriched sample was streaked onto a plastic Petri 
dish containing XLD agar and incubated at 37°C for 24 hours. The XLD and Selenite enrichment 
broth were prepared as per manufacturer‟s instructions.  
5.2.3. Evaluation of immune responses elicited in dosing vaccine trial against OppA  
The humoral and mucosal immune responses elicited by the VR1012 and VR1020 mucosal 
vaccines against OppA was measured by the ELISAs used to assess the immune response 
against the OppA protein of M. struthionis as described in section 4.2.3.4. The plate layout as well 
as the coating concentrations and dilutions used were the same as for the samples collected for 
the previous vaccine trial.   
5.2.4. Evaluation of immune responses elicited by dosing vaccine trial against Salmonella 
enterica serovar typhimurium SL3261 LPS 
The humoral and mucosal immune responses the ostriches elicited against the carrier bacteria 
Salmonella enterica serovar typhimurium SL3261 LPS were measured by ELISA described in 
section 4.2.3.5. The plate layout as well as the coating concentration and dilutions used were the 
same as for the samples collected during the preliminary vaccine trial. The results of antibody 
levels measured over time with the respective ELISAs for the two vaccines and the different doses 
they were administered at were analysed using an ANOVA in the Statistical Analysis program 
Agrobase Generation II® (Agronomix Software Inc.).   




5.3.1. Analysis of samples collected during vaccine trial on Kromme Rhee farm in 
Stellenbosch, Western Cape 
The results of the analysis of Mycoplasma spp and Salmonella spp infections in the ostriches are 
shown in Table 5.1. At Week 0 no Mycoplasma spp and Salmonella spp infections were found in 
any of the ostriches. Samples collected on week 3, 6 and 9, showed some Mycoplasma spp and 
Salmonella spp infections. The results of the cloacal swabs to test the excretion of Salmonella 
enterica serovar typhimurium SL3261 are shown in Table 5.2, followed by Table 5.3 showing a 
guideline to the species of microorganism found on the XLD medium after 24 hours. At week 6 it 
could therefore be shown that most of the ostriches had varying infections, E. coli, Enterobacter 
spp., Aeromonas, Serratia spp and Hafnia spp present in their cloacae with isolated occurrences of 
Citrobacter. The only Salmonella sp that could be detected was Salmonella typhosa. 




Weight (kg) Infections 
Prior Week 2 Week 9 
Week 
0 










2 44.6 41.8 48.0 
    
10 47.6 51.5 59.0 
    
12 50.4 47.0 47.8 
   
Mycoplasma 
struthionis 

















7 44.2 43.2 39.0 
    
9 46.8 - - 
 
- - - 
11 48.4 44.4 63.0 
    
13 50.0 44.4 - 
   
- 
14 47.0 40.6 53.0 














56 48.0 40.6 44.4 
    
57 47.6 44.2 44.4 
    




59 46.2 36.6 - 
 










44 48.2 40.0 39.2 
    
45 46.6 39.8 51.5 
  
Ms02 Ms02 




52 46.8 58.5 61.0 
   
Mycoplasma 
struthionis 

















23 51.6 47.6 - 
 
Ms02 - - 




35 50.4 47.8 53.0 
    
37 49.8 47.0 48.4 
   
Ms02 














20 52.4 47.4 38.6 
    
41 51.8 41.2 55.0 
    





























24 50.0 55.5 63.0 
    
26 52.8 42.8 - 
  
- - 
31 47.0 35.0 - 
 
- - - 
36 51.2 52.5 60.0 























30 50.0 48.2 54.0 
    


























82 50.8 46.2 57.5 
    
64 54.0 45.8 42.6 
   
Mycoplasma 
struthionis 
88 50.6 52.5 53.0 
    
91 50.8 37.2 52.5 

















71 44.8 - - 
 
- - - 




79 44.6 40.4 43.6 















65 50.4 - - 
 
- - - 
69 50.6 40.6 52.0 
 
Mycoplasma 
struthionis   
70 47.6 41.4 54.0 
    






78 46.2 - - 
 
- - - 
[blank]                   No infection detected            
       No data available as ostriches died 
Salmonella Multiplex PCR tested positive for a Salmonella sp. infection 




Cloacal swabs (Week 6) 












  Agar red 
No colonies 
  Agar red 
10 
No colonies 
  Agar red 
Yellow opaque colonies  
with yellow zones  
Agar yellow 
12 
Yellow opaque colonies  
with yellow zones  
Agar yellow 
Yellow opaque colonies  




  Agar red 
No colonies 
  Agar red 












  Agar red 
No colonies 
  Agar red 
9 - - 
11 
Yellow opaque colonies  
with yellow zones  
Agar red 
No colonies 
  Agar red 
13 
Yellow opaque colonies  
with yellow zones 
Agar yellow 
No colonies 
  Agar red 
14 
Yellow translucent colonies with 
yellow zones and  black centres 
Agar yellow 
No colonies 











Yellow opaque colonies  
with yellow zones 
Agar orange 
Yellow opaque colonies   
Agar red 
56 
Yellow opaque colonies with 
yellow zones, some colonies 
yellow opaque with black centres 
Agar yellow 
No colonies 
  Agar red 
57 
Yellow opaque colonies  
with yellow zones 
Agar orange 
No colonies 
  Agar red 
58 
Yellow opaque colonies  
with yellow zones 
Agar yellow 
Yellow opaque colonies   
Agar orange 
59 
Yellow translucent colonies with 
yellow zones and  black centres 
Agar yellow 
No colonies 
  Agar red 













Yellow opaque colonies  
with yellow zones 
Agar yellow 
No colonies 
  Agar red 
45 
No colonies 
  Agar red 
No colonies 
  Agar red 
51 
Yellow opaque colonies  
with yellow zones 
Agar red 
No colonies 
  Agar red 
52 
Yellow opaque colonies  
with yellow zones 
Agar yellow 
Orange opaque colonies 
Agar yellow 
54 
Yellow opaque colonies  
with yellow zones 
Agar yellow 











23 - - 
32 
No colonies 
  Agar red 
No colonies 
  Agar red 
35 
Yellow opaque colonies  
with yellow zones 
Agar yellow 
No colonies 
  Agar red 
37 
Yellow opaque colonies  
with yellow zones 
Agar orange 
No colonies 
  Agar red 
40 
No colonies 
  Agar red 
No colonies 
  Agar red 
Control  
 
(Nothing injected or 
given orally) 
3 
Yellow opaque colonies with 
yellow zones, some colonies 
yellow opaque with black centres 
Agar yellow 
No colonies 
  Agar red 
20 
Yellow opaque colonies  
with yellow zones 
Agar yellow 
Yellow opaque colonies  
with yellow zones  
Agar yellow 
41 
Yellow opaque colonies  
with yellow zones 
Agar yellow 
No colonies 
  Agar red 
47 
No colonies 
  Agar red 
No colonies 
  Agar red 
55 
Yellow opaque colonies  
with yellow zones 
Agar yellow 
No colonies 
  Agar red 
53 
Yellow opaque colonies  
with yellow zones 
Agar yellow 
No colonies 












  Agar red 
No colonies 
  Agar red 
24 
Yellow opaque colonies  
with yellow zones 
Agar yellow 
No colonies 
  Agar red 
26 - - 
31 - - 
36 
Yellow opaque colonies  
with yellow zones 
Agar red 
No colonies 
  Agar red 












25 - - 
29 
Yellow opaque colonies with 
yellow zones, some colonies 
yellow, opaque with black centres 
Agar yellow 
No colonies 
  Agar red 
30 
Yellow opaque colonies 
 with yellow zones 
Agar red 
Yellow opaque colonies  
with yellow zones  
Agar yellow 
33 
Yellow opaque colonies  
with yellow zones 
Agar yellow 
No colonies 
  Agar red 
89 
No colonies 
  Agar red 
No colonies 












  Agar red 
Yellow opaque colonies  
with yellow zones  
Agar yellow 
82 
Yellow opaque colonies  
with yellow zones 
Agar red 
No colonies 
  Agar red 
64 
Yellow opaque colonies  
with yellow zones 
Agar yellow 
No colonies 
  Agar red 
88 
Yellow opaque colonies  
with yellow zones 
Agar orange 
Yellow opaque colonies  
with yellow zones  
Agar yellow 
91 
Yellow opaque colonies  
with yellow zones 
Agar orange 
No colonies 










Yellow opaque colonies  
with yellow zones 
Agar orange 
No colonies 
  Agar red 
66 
Yellow opaque colonies  
with yellow zones 
Agar yellow 
No colonies 
  Agar red 
71 - - 
77 
No colonies 
  Agar red 
No colonies 
  Agar red 
79 
Yellow opaque colonies  
with yellow zones 
Agar yellow 











65 - - 
69 
No colonies 
  Agar red 
No colonies 
  Agar red 
70 
Yellow opaque colonies  
with yellow zones 
Agar red 
No colonies 
  Agar red 
76 
No colonies 
  Agar red 
No colonies 
  Agar red 
78 - - 
- No data available as ostriches died 
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Table 5.3: Guidelines from Merck for identification of microorganisms on selective XLD medium 
Colony appearance Microorganism 
Yellow surrounded by yellow zones,  
Opaque with precipitation zones 
E. coli, Enterobacter spp, Aeromonas spp 
Yellow surrounded by yellow zones,  
Opaque and mucoid with precipitation zones 
Klebsiella spp 
Yellow surrounded by yellow zones,  
Sometimes opaque with a black centre 
Citrobacter spp 
Yellow opaque colonies with yellow zones,  Serratia spp, Hafnia spp 
Yellow surrounded by yellow zones,  
Translucent with a black centre 
Proteus vulgaris 
Same colour as medium (red) 
Translucent with black centre 
Salmonella spp 
Same colour as medium (red) 
Translucent  





5.3.2. Evaluation of immune responses elicited in dosing vaccine trial elicited against OppA 
Humoral and mucosal immune responses of the ostriches: 
The results of the immune response of the ostriches that was measured against M. struthionis 
OppA were compiled and analysed using an ANOVA (Table 5.4, 5.5 and 5.6). The results of the 
ANOVA analysis of the weight data of the vaccinated ostriches are shown in Table 5.7. The 
respective LSD values are indicated on the graphs showing the average immune response against 
the various doses of the VR1012 and VR1020 mucosal vaccines over time, shown in figures 5.1 to 
5.6.  
In the ANOVA analysis of the humoral immune response of the dosing trial, the R squared value 
was much higher in comparison to the R squared values obtained in the ANOVA analysis of the 
humoral immune response results of the preliminary vaccine trial described in Chapter 4. Although 
the C. V. was also much lower (54.6%) it was still not 15% or lower, meaning that the differences in 
humoral immune responses seen between the different vaccine doses are not statistically 
significant. The results achieved can therefore only be viewed as trends. The trend seen was 
therefore that none of the doses of the VR1012 mucosal vaccine appeared to give an immune 
response. The groups that received a 1011 c.f.u./ml dose and 1012 c.f.u./ml dose of the VR1020 
mucosal vaccine tended to show a higher humoral response to OppA than all of the other groups 
including the control group.  
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In the ANOVA analysis of the mucosal immune response of the dosing trial, the R squared value 
was far too low and the C. V. much too high invalidating the data. There was no mucosal immune 
response measured to OppA. In general, the mucosal immune responses measured were 
extremely low which would also have had a negative effect on the statistical analysis. The mucosal 
vaccine responses against the mucosal VR1012 and VR1020 DNA vaccines using anti-ostrich IgA 
protein 1, are shown in figure 5.3 and 5.4, respectively, and using anti-ostrich IgA protein 2 are 
shown in figure 5.5 and 5.6, respectively.  
Table 5.4: Statistical analysis of humoral immune response elicited against different doses of the 
mucosal VR1012 and VR1020 DNA vaccines against the OppA protein using anti-ostrich 
immunoglobulin as detection antibody 
Source df SS MS Pr>F 
Total 329 80.023 
  
Treatment 10 24.964 2.496 0.0000 
Time 5 7.998 1.600 0.0000 
Treatment x Time interaction 50 7.607 0.152 0.4476 




Figure 5.1: Averages of the humoral immune responses elicited by various doses of the mucosal VR1012 
vaccine groups as determined by an ELISA using 1 µg/ml OppA for coating and anti-ostrich Ig as detection 
antibody. Group 1 (♦ VR1012 109 cfu) received 1 ml of a 109 c.f.u./ml solution of the VR1012 mucosal 
vaccine, group 2 (■ VR1012 10
10
 cfu) a 10
10













 c.f.u./ml, group 6 (● Control) received no 




























VR1012 10⁹ cfu 
VR1012 10¹⁰ cfu 
VR1012 10¹¹ cfu 
VR1012 10¹² cfu 
VR1012 10¹³ cfu 
Control 
LSDtreatment = 0.1965 
LSDtime = 0.1452 




Figure 5.2: Averages of the humoral immune responses elicited by various doses of the mucosal VR1020 
vaccine groups as determined by an ELISA using 1 µg/ml OppA for coating and anti-ostrich immunoglobulin 
as detection antibody. Group 1 (♦ VR1020 109 cfu) received 1 ml of a 109 c.f.u./ml solution of the VR1020 
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Table 5.5: Statistical analysis of mucosal immune response elicited against different doses of the 
mucosal VR1012 and VR1020 DNA vaccines using the OppA protein using anti-ostrich IgA protein 1 








Figure 5.3: Averages of the mucosal immune responses elicited by various doses of the mucosal VR1012 
vaccine groups as determined by an ELISA using 1 µg/ml OppA for coating and anti-ostrich IgA protein 1 as 
detection antibody. Group 1 (♦ VR1012 109 cfu) received 1 ml of a 109 c.f.u./ml solution of the VR1012 

















 c.f.u./ml, group 6 (● Control) 
received no immunizations. The ostriches were immunized at week 0 and received a booster immunization 
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Source df SS MS Pr>F 
Total 329 0.021 
  
Treatment 10 0.002 0.00 0.0023 
Time 5 0.000 0.00 0.8674 
Treatment x Time interaction 50 0.003 0.00 0.6448 
Residual 264 0.016 0.00  
LSDtreatment = 0.004 
 




Figure 5.4: Averages of the mucosal immune responses elicited by various doses of the mucosal VR1020 
vaccine groups as determined by an ELISA using 1 µg/ml OppA for coating and anti-ostrich IgA protein 1 as 
detection antibody. Group 1 (♦ VR1020 109 cfu) received 1 ml of a 109 c.f.u./ml solution of the VR1020 
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Table 5.6: Statistical analysis of mucosal immune response elicited against different doses of the 
mucosal VR1012 and VR1020 DNA vaccines using the OppA protein using anti-ostrich IgA protein 2 
as detection antibody 
Source df SS MS Pr>F 
Total 329 0.039 
  
Treatment 10 0.004 0.00 0.0005 
Time 5 0.001 0.00 0.4490 
Treatment x Time interaction 50 0.004 0.00 0.9675 
Residual 264 0.031 0.00  
 
 
Figure 5.5: Averages of the mucosal immune responses elicited by various doses of the mucosal VR1012 
vaccine groups as determined by an ELISA using 1 µg/ml OppA for coating and anti-ostrich IgA protein 2 as 
detection antibody. Group 1 (♦ VR1012 109 cfu) 109 c.f.u./ml solution of the VR1012 mucosal vaccine, group 
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Figure 5.6: Averages of the mucosal immune responses elicited by various doses of the mucosal VR1020 
vaccine groups as determined by an ELISA using 1 µg/ml OppA for coating and anti-ostrich IgA protein 2 as 
detection antibody. Group 1 (♦ VR1020 109 cfu) received 1 ml of a 109 c.f.u./ml solution of the VR1020 
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Table 5.7: Statistical analysis of weight measured during the vaccine trial 
Source df SS MS Pr>F 
Total 329 194151.098 
  
Treatment 10 1971.853 197.185 0.0705 
Time 5 157582.253 31516.451 0.0000 
Treatment x Time interaction 50 4810.577 96.212 0.7473 




Figure 5.7: Averages of the weights measured for each vaccination group. Group 1 (♦ VR1020 109 cfu) 
received 1 ml of a 10
9
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Figure 5.8: Averages of the weights measured for each vaccination group. Group 1 (♦ VR1020 109 cfu) 
received 1 ml of a 10
9


















 c.f.u./ml, group 6 (● Control) received no immunizations. The ostriches were 
immunized at week 0 and received a booster immunization at week 6. 
 
5.3.3. Evaluation of immune response elicited by dosing vaccine trial against Salmonella 
enterica serovar typhimurium SL3261 LPS 
Humoral and mucosal immune responses of the ostriches 
The immune responses against the carrier bacteria were compiled, analysed using an ANOVA and 
the results shown in Tables 5.8, 5.9 and 5.10. The graphs of the averages of the humoral and 
mucosal immune responses of the ostriches are shown in figures 5.9 to 5.14. In all of the ANOVA 
analyses of the respective data sets too low R squared values and too high C.V. values showed 
that there was a very high variation in the data which does not allow deductions that the 
administration of the vaccines are responsible for the observed immune responses. However, a 
reason for this can be seen in the immune response graphs of the individual birds shown in 
Addendum C. In many of the groups there were isolated birds with increased antibody levels. In 
most cases these elevated antibody levels were seen at the start of the trial, indicating that these 
birds may still have retained antibodies from previous contact with Salmonella bacteria prior to the 
trial. Thus although the antibiotic treatment at the start of the trial eliminated Salmonella infections, 
the antibodies remaining from previous contact may still have been present.  
Although it appears as though the group of animals that received the 1010 c.f.u./ml (figure 5.9) 
showed an increase at week 9 an examination of the titres of individual birds (figure C.10.B) show 
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therefore not significant. It was also observed that the humoral immune response values observed 
was generally higher than the mucosal immune response values. 
Table 5.8: Statistical analysis of humoral immune response elicited against different doses of the 
mucosal VR1012 and VR1020 DNA vaccines against the Salmonella enterica serovar typhimurium 
SL3261 LPS using anti-ostrich immunoglobulin as detection antibody  
Source df SS MS Pr>F 
Total 329 146.639 
  Treatment 10 30.985 3.099 0.0000 
Time 5 10.501 2.100 0.0000 
Treatment x Time interaction 50 20.993 0.420 0.0887 
Residual 264 84.159 0.319 
  
 
Figure 5.9: Averages of the humoral immune responses elicited by various doses of the mucosal VR1012 
vaccine groups as determined by an ELISA using 5 µg/ml Salmonella enterica serovar typhimurium SL3261 
LPS for coating and anti-ostrich immunoglobulin as detection antibody. Group 1 (♦ VR1012 109 cfu) received 
1 ml of a 10
9


















 c.f.u./ml, group 6 (● Control) received no immunizations. The ostriches were immunized at 
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Figure 5.10: Averages of the humoral immune responses elicited by various doses of the mucosal VR1020 
vaccine groups as determined by an ELISA using 5 µg/ml Salmonella enterica serovar typhimurium SL3261 
LPS for coating and anti-ostrich immunoglobulin as detection antibody. Group 1 (♦ VR1020 109 cfu) received 
1 ml of a 10
9


















 c.f.u./ml, group 6 (● Control) received no immunizations. The ostriches were immunized at 
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Table 5.9: Statistical analysis of humoral immune response elicited against different doses of the 
mucosal VR1012 and VR1020 DNA vaccines against the Salmonella enterica serovar typhimurium 
SL3261 LPS using anti-ostrich IgA protein 1 as detection antibody 
Source df SS MS Pr>F 
Total 329 0.034 
  
Treatment 10 0.004 0.000 0.0000 
Time 5 0.000 0.000 0.6805 
Treatment x Time interaction 50 0.003 0.000 0.9744 
Residual 264 0.026 0.000  
 
 
Figure 5.11: Averages of the mucosal immune responses elicited by various doses of the mucosal VR1012 
vaccine groups as determined by an ELISA using 5 µg/ml Salmonella enterica serovar typhimurium SL3261 
LPS for coating and anti-ostrich IgA protein 1 as detection antibody. Group 1 (♦ VR1012 109 cfu) received 1 
ml of a 10
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Figure 5.12: Averages of the mucosal immune responses elicited by various doses of the mucosal VR1020 
vaccine groups as determined by an ELISA using 5 µg/ml Salmonella enterica serovar typhimurium SL3261 
LPS for coating and anti-ostrich IgA protein 1 as detection antibody. Group 1 (♦ VR1020 109 cfu) received 1 
ml of a 10
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Table 5.10: Statistical analysis of humoral immune response elicited against different doses of the 
mucosal VR1012 and VR1020 DNA vaccines against the Salmonella enterica serovar typhimurium 
SL3261 LPS using anti-ostrich IgA protein 2 as detection antibody 
Source df SS MS Pr>F 
Total 329 0.083 
  Treatment 10 0.011 0.001 0.0000 
Time 5 0.001 0.000 0.3746 
Treatment x Time interaction 50 0.011 0.000 0.5942 
Residual 264 0.060 0.000  
 
 
Figure 5.13: Averages of the mucosal immune responses elicited by various doses of the mucosal VR1012 
vaccine groups as determined by an ELISA using 5 µg/ml Salmonella enterica serovar typhimurium SL3261 
LPS for coating and anti-ostrich IgA protein 2 as detection antibody. Group 1 (♦ VR1012 109 cfu) received 1 
ml of a 10
9


















 c.f.u./ml, group 6 (● Control) received no immunizations. The ostriches were immunized at 
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Figure 5.14: Averages of the mucosal immune responses elicited by various doses of the mucosal VR1020 
vaccine groups as determined by an ELISA using 5 µg/ml Salmonella enterica serovar typhimurium SL3261 
LPS for coating and anti-ostrich IgA protein 2 as detection antibody. Group 1 (♦ VR1020 109 cfu) received 1 
ml of a 10
9


















 c.f.u./ml., group 6 (● Control) received no immunizations. The ostriches were immunized at 
week 0 and received a booster immunization at week 6. 
5.4. Discussion 
Before the ability of the mucosal DNA vaccines to elicit a humoral and mucosal immune response 
could be evaluated further it was decided to determine the optimal dose required to elicit an 
immune response in ostriches. In the literature the dose mostly used was 1x109 c.f.u./ml, which 
includes various studies on mice (Benitez, McNair & Mead 2009, Poirier, Kehoe & Beachey 1988), 
and chickens (Pogonka et al. 2003). Some of the other doses found in literature include 5x1010 
c.f.u./2 ml in dogs (Chabalgoity et al. 2000), 1x1011 c.f.u./ml in mice (Barry et al. 1996), 5x1011 per 
cat (Tijhaar et al. 1997) and in rabbits doses between 106 and >1010 c.f.u./rabbit was evaluated to 
determine a target dose of 108-109 c.f.u./rabbit. With this in mind doses chosen were between 109 
and 1013 c.f.u./ml also taking into account the larger size of ostriches in comparison to chickens.  
In comparison to the preliminary vaccine trial, precautions were taken to prevent making the same 
mistakes. The injection of the ostriches with Tenaline® LA two weeks prior to the start of the trial, 
appeared to have brought all bacterial infections under control at the start of the dose range 
vaccine trial. Tenaline® LA is reported to be active for a week after immunization (Adriaan Olivier, 
Personal communication). As the birds were vaccinated two weeks after the Tenaline® LA 
administration it could not have inactivated the Salmonella enterica serovar typhimurium SL3261 
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Three weeks after the start of the trial isolated Salmonella infections were found, which the 
ostriches probably contracted from the environment, contaminated feedlots or neighbouring 
untreated ostriches. However, ostrich mycoplasma infections were found indicating that the birds 
had either carried these pathogens or had been infected from neighbouring untreated ostriches. 
However, a decrease in the weight of the ostriches was observed in week 2, indicating that the 
ostriches were very stressed and the ostriches that showed a large decline in their weight were 
given liver stimulant on week 3, which is a substance that aids in increasing the general condition 
of the ostriches. Furthermore, 13 ostriches died during the trial, which from their general behaviour, 
we deduced was due to the fact that they were not used to being kept in small feedlot camps 
causing high levels of stress. In general, we also observed that the vaccination and sample taking 
was very stressful for the ostriches. Taken together, these factors all must have contributed to the 
high levels of variation in the immune response data, which unfortunately invalidated the trial once 
again. 
However, a positive result of this trial was that the vaccine strain could not be detected either by 
direct plating or by enrichment of the cloacal swab in selenite broth before plating on XLD agar, 
thus the carrier bacteria could not be detected in the ostriches six weeks after immunization. This 
means that the chosen strain does not persist in vivo and will only affect the birds for a short period 
which is precisely what is aimed for in using these bacteria as carriers.  
At the end of the trial, the controlling veterinarian actually confirmed that some of the birds that 
were in the trial, had been tested at random for AI, and had tested positive. Thus this trial was also 
adversely influenced by AI and this must have contributed to the variation in the immune response 
results seen in the trial. The general conclusion that can therefore be drawn from this trial is that 
factors contributing to background levels of immunity need to be tightly regulated before any trials 
using mucosal DNA vaccines can be conducted in ostriches, as will be discussed in chapter 6.  
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Chapter 6: Discussion and future perspectives 
In this study, the three previously developed naked pCI-neo, VR1012 and VR1020 DNA vaccines 
were successfully electroporated into the carrier bacterial strain, Salmonella enterica serovar 
typhimurium SL3261, and three corresponding mucosal DNA vaccines were developed. The in 
vivo stability (figure 3.8) of the mucosal DNA vaccines showed that the VR1012 and VR1020 
mucosal DNA vaccines were more stable than the pCI-neo mucosal DNA vaccines and are 
therefore the best candidates for future use as mucosal DNA vaccines.  
Subsequently a preliminary vaccine trial using the VR1020 naked DNA vaccine and the mucosal 
VR1020 DNA was conducted. The VR1020 mucosal DNA vaccine was chosen due to the 
presence of a tPA signal peptide that aids in secretion of the expressed protein. The mucosal DNA 
vaccine was given orally and was viewed to be a less stressful method of administration than the 
intramuscular injection required for the naked DNA vaccine (Qu et al. 2008). The mucosal DNA 
vaccine is also easier and faster to produce than naked DNA vaccines (Schoen et al. 2004). The 
use of bacteria as carriers of DNA vaccines has another advantage in that it can act as a bivalent 
vaccine, conferring protection against the pathogen and the carrier bacteria, thus the immune 
responses of the ostriches were evaluated against M. struthionis OppA and Salmonella enterica 
serovar typhimurium SL3261 LPS.   
The ELISAs developed were successful for measuring the immune responses elicited by the 
ostriches in both the immunized groups and the control groups. However, the outbreak of AI in the 
Oudtshoorn district in 2011 ended the preliminary vaccine trial prematurely. This together with prior 
exposure to Salmonella and Mycoplasma infections caused a high amount of variation observed in 
the immune response data, which resulted in an inconclusive trial, an immune response to Opp A 
could not be detected in the vaccinated ostriches. It was concluded from the trial that prior testing 
for Mycoplasma and Salmonella infection is needed to assess the influence of these bacteria on 
the analysis of the immune response of the ostriches. Also the mucosal DNA vaccine dose of 109 
c.f.u./ml used to immunise the ostriches might not have been an effective dose to elicit an immune 
response.  
To determine an effective dose required to elicit an immune response in ostriches a second 
vaccine trial was performed, this time with various doses of the mucosal VR1012 and VR1020 
DNA vaccines. For this trial the antibiotic, Tenaline® LA, was administered to clear pre-existing 
Salmonella infections and aid in preventing these bacteria from influencing the immune responses 
of the ostriches to the DNA vaccine. The vaccine trial to determine the dose required to elicit an 
immune response gave results that again showed far too high levels of variation making the 
analysis of the statistical data for all the data sets invalid. The trend observed was that the VR1020 
mucosal DNA vaccine gave better immune responses than the VR1012 mucosal DNA vaccine, 
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possibly due to the tPA signal peptide encoded upstream of the Opp A gene in the VR1020 DNA 
vaccine plasmid. Another trend observed was that the 1011 c.f.u./ml and 1012 c.f.u./ml doses of the 
VR1020 mucosal DNA vaccine elicited better immune responses than the other doses and might 
be a good starting point for future vaccine trials using the mucosal DNA vaccine in ostriches. This 
trial was compromised by the severe stress observed in the ostriches, which was clear from the 
lack of weight gain and in some instances loss of weight observed in the first three weeks of the 
vaccine trial. This might have impaired the ability of the ostriches to elicit an effective immune 
response. Thus, further vaccine trials will have to be carried out to determine if the mucosal DNA 
vaccines can elicit immune responses.  
Even though the vaccine trials conducted in this study were not successful, the validity of the 
ELISAs developed could be confirmed and can be used for the analysis of future vaccine trials and 
a number of suggestions on how to improve the immune response elicited by ostriches could be 
made. In future trials steps should be taken to decrease the stress experienced by the ostriches, 
ostriches should not be moved prior to the start of a trial, and blood samples should not be 
collected and/or ostriches vaccinated at intervals less than three weeks. Furthermore the housing 
of ostriches in small feedlot enclosures should be avoided due to the stress that this housing 
causes. Another step that can be taken in the future to ensure better immune responses is to 
attempt vaccine trials on secluded ostrich farms, where the risk of avain influenza infection may be 
lower. A valuable consideration might also be to use a flock free of Salmonella infection. The 
antibodies levels present in the ostriches against both Mycopoplasma struthionis and Salmonella  
can be tested using the developed ELISAs prior to the start of the vaccine trial, and then the trial 
started only once the ELISA results are negative.  
With regard to the mucosal vaccines considerations for future studies might be to first test the 
ability of the Salmonella carrier to enter cells and to release the OppA gene containing plasmid as 
well as the expression of the OppA protein after its release from the Salmonella carrier in vitro 
(Guo et al. 2003). Guo et al. (2003) mixed Salmonella enterica serovar typhimurium SL3261 strain 
carrying a DNA vaccine plasmid containing a enhanced green florescent gene, with murine 
peritoneal macrophages. The expression of the enhanced green florescent gene was then 
observed using flow cytrometry and it was shown that the protein was expressed when viewed 
after 48 hours. Grillot-Courvalin et al. (2002) transfected COS-1 cells with Salmonella enterica 
serovar typhimurium SL7207 carrying a plasmid containing the green florescent gene to show 
gene transfer. Similar studies to test these vaccines for use in ostriches should be considered in 
chicken cells which are more commonly available as tissue culture cell lines. 
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Another consideration would be to perform a preliminary study on smaller animals before further 
trials on ostriches. Chickens may be a suitable species to use in preliminary trials because of the 
fact that they are domesticated and will not experience the stress that ostriches apparently do, and 
because of the relatedness to ostriches this may produce results which could indicate that 
ostriches would respond similarly. 
Also a heterologous prime-boost immunization strategy can be considered, where the mucosal 
vaccine is first used to prime the immune response of the host, followed by a booster immunization 
with recombinant OppA protein. The OppA protein that was expressed recombinantly for ELISA 
plate coating purposes in this study, could then be used as the booster protein.  
Apart from all the external factors that influenced the vaccine trials, mucosal DNA vaccines were 
developed that have the potential to elicit an immune response in ostriches, and the strategy can 
be applied to the vaccine development against the other two ostrich-specific mycoplasmas, Ms02 
and M. nasistruthionis. The use of bacteria as carriers of DNA vaccines also has the potential to be 
a multivalent vaccine, conferring protection against the carrier bacteria as well as more than one 
pathogen (Vindurampulle & Attridge 2003). Another potential future perspective for the project 
might be to insert the DNA vaccines for all three ostrich-specific Mycoplasmas into a single 
Salmonella enterica serovar typhimurium SL3261 bacterium to elicit immune responses against all 
three ostrich mycoplasmas simultaneously which would obviously have huge practical and 
economic advantages. 
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Figure A1. Day 1 of stability assessment of DNA vaccines in Salmonella enterica serovar typhimurium 
SL3261 tested with a diagnostic colony PCR. i. Mucosal pCIneo DNA vaccine. Lane 1-10: 10 µl of colony 
PCR from selected colonies on TSA plates without the antibiotic, ampicillin. Lane 11: 5 μl DNA Ladder mix 
(Generuler
TM
, Fermentas). Lane 12-21: 10 µl of colony PCR from selected colonies on TSA plates with the 
antibiotic, ampicillin. ii. VR1012 mucosal DNA vaccine. Lane 1-10: 10 µl of colony PCR from selected 
colonies on TSA plates without the antibiotic, kanamycin. Lane 11: 5 μl DNA Ladder mix (Generuler
TM
, 
Fermentas). Lane 12-21: 10 µl of colony PCR from selected colonies on TSA plates with the antibiotic, 
kanamycin. iii. VR1020 mucosal DNA vaccine. Lane 1-10: 10 µl of colony PCR from selected colonies on 
TSA plates without the antibiotic, kanamycin. Lane 12: 5 μl DNA Ladder mix (Generuler
TM
, Fermentas). 
Lane 11, 13-21: 10 µl of colony PCR from selected colonies on TSA plates with the antibiotic, kanamycin.            
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Figure A2: Day 2 of stability assessment of DNA vaccines in Salmonella enterica serovar typhimurium 
SL3261 tested with a diagnostic colony PCR. i. Mucosal pCIneo DNA vaccine. Lane 1-10: 10 µl of colony 
PCR from selected colonies on TSA plates without the antibiotic, ampicillin. Lane 11: 5 μl DNA Ladder mix 
(Generuler
TM
, Fermentas). Lane 12-21: 10 µl of colony PCR from selected colonies on TSA plates with the 
antibiotic, ampicillin. ii. VR1012 mucosal DNA vaccine. Lane 1-10: 10 µl of colony PCR from selected 
colonies on TSA plates without the antibiotic, kanamycin. Lane 11: 5 μl DNA Ladder mix (Generuler
TM
, 
Fermentas). Lane 12-21: 10 µl of colony PCR from selected colonies on TSA plates with the antibiotic, 
kanamycin. iii. VR1020 mucosal DNA vaccine. Lane 1-10: 10 µl of colony PCR from selected colonies on 
TSA plates without the antibiotic, kanamycin. Lane 11: 5 μl DNA Ladder mix (Generuler
TM
, Fermentas). 
Lane 12-21: 10 µl of colony PCR from selected colonies on TSA plates with the antibiotic, kanamycin.  
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Figure A3: Day 3 of stability assessment of DNA vaccines in Salmonella enterica serovar typhimurium 
SL3261 tested with a diagnostic colony PCR. i. Mucosal pCI-neo DNA vaccine. Lane 1-10: 10 µl of colony 
PCR from selected colonies on TSA plates without the antibiotic, ampicillin. Lane 11: 5 μl DNA Ladder mix 
(Generuler
TM
, Fermentas). Lane 12-21: 10 µl of colony PCR from selected colonies on TSA plates with 
the antibiotic, ampicillin. ii. VR1012 mucosal DNA vaccine. Lane 1-10: 10 µl of colony PCR from selected 
colonies on TSA plates without the antibiotic, kanamycin. Lane 11: 5 μl DNA Ladder mix (Generuler
TM
, 
Fermentas). Lane 12-21: 10 µl of colony PCR from selected colonies on TSA plates with the antibiotic, 
kanamycin. iii. VR1020 mucosal DNA vaccine. Lane 1-10: 10 µl of colony PCR from selected colonies on 
TSA plates without the antibiotic, kanamycin. Lane 11: 5 μl DNA Ladder mix (Generuler
TM
, Fermentas). 
Lane 12-21: 10 µl of colony PCR from selected colonies on TSA plates with the antibiotic, kanamycin.            
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Figure A4: Day 4 of stability assessment of recombinant plasmid vaccines in Salmonella enterica serovar 
typhimurium SL3261 tested with a diagnostic colony PCR. i. Mucosal pCI-neo DNA vaccine. Lane 1-10: 10 
µl of colony PCR from selected colonies on TSA plates without the antibiotic, ampicillin. Lane 11: 5 μl DNA 
Ladder mix (Generuler
TM
, Fermentas). Lane 12-21: 10 µl of colony PCR from selected colonies on TSA 
plates with the antibiotic, ampicillin. ii. VR1012 mucosal DNA vaccine. Lane 1-10: 10 µl of colony PCR from 
selected colonies on TSA plates without the antibiotic, kanamycin. Lane 11: 5 μl DNA Ladder mix 
(Generuler
TM
, Fermentas). Lane 12-21: 10 µl of colony PCR from selected colonies on TSA plates with the 
antibiotic, kanamycin. iii. VR1020 mucosal DNA vaccine. Lane 1-10: 10 µl of colony PCR from selected 
colonies on TSA plates without the antibiotic, kanamycin. Lane 11: 5 μl DNA Ladder mix (Generuler
TM
, 
Fermentas). Lane 12-21: 10 µl of colony PCR from selected colonies on TSA plates with the antibiotic, 
kanamycin. 
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Addendum B: Statistical analysis of ELISA results of the preliminary 
vaccine trial on a commercial ostrich farm in Oudtshoorn, Western Cape 
Humoral immune response of ostriches against OppA  
The immune response of the ostriches against the OppA protein was evaluated using ELISA as 
described in section 4.2.3.4 and the serum samples collected. An ANOVA was performed using 
the Statistical Analysis program Agrobase Generation II® (Agronomix Software Inc.). 
                   A N A L Y S I S   O F   V A R I A N C E                       
Serum - OppA 
Oudsthoorn 
Variable: RESP 
      
Source df SS MS F-value Pr>F 
Total 359 57.063 
  
  
Treatment 3 5.919 1.973 14.500 0.0000 
Time 2 2.416 1.208 8.880 0.0002 
Treatment x Time  6 1.361 0.227 1.670 0.1284 
Residual 348 47.367 0.136     
Grand mean = 0.728 R-squared = 0.1699 C.V. = 50.69% 
 
      
LSD for Treatment = 0.1082 S.E.D = 0.055  r = 90 
 
t (2-sided a=0.050, 348 df) = 1.9668 
 
MSE = 0.13611 
   
 
     
Treatment 
     
Averages 
     
Level --- Y --- Cv Rank Group 
 
1 0.93 49.7 1 Salmonella Control 
 
3 0.75 52.2 2 VR1020 Plasmid 
 4 0.63 51.6 3 Control 
 2 0.60 53.1 4 Salmonella + VR1020 
 
      LSD for Time = 0.0937 
 
S.E.D = 0.0476 r = 120 
 
t (2-sided a=0.050, 348 df) = 1.9668 
 
MSE = 0.13611 
   
 
     
Time 
     
Averages 
     
Level --- Y --- Cv Rank Week 
 
1 0.80 51.3 1 0 
 
2 0.77 53.4 2 3 
 
3 0.61 56.9 3 6 
 
      
LSD for Treatment*Time = 0.1874 
 
S.E.D = 0.0953 r = 30 
 
t (2-sided a=0.050, 348 df) = 1.9668 
 
MSE = 0.13611 
   
 
     
 Two-way table for Treatment*Time, n=30                                             
  
  1 2 3 
  
1 0.961 0.990 0.829 
  
2 0.750 0.590 0.453 
  
3 0.814 0.891 0.554 
  
4 0.687 0.596 0.621 
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                   A N A L Y S I S   O F   V A R I A N C E                       
Variable: WEIGHT 
      
Source df SS MS F-value Pr>F 
Total 359 17242.88 
  
  
Treatment  3 1543.189 514.396 11.79 0.0000 
Time  2 410.744 205.372 4.71 0.0096 
Treatment x Time  6 101.732 16.955 0.39 0.8663 
Residual 348 15187.21 43.641     
Grand mean = 41.192 
 
R-squared = 0.1192 
 
C.V. = 16.04% 
 
      
LSD for Treatment = 1.9369 S.E.D = 0.9848 r = 90 
 
t (2-sided a=0.050, 348 df) = 1.9668 
 
MSE =  43.64141    
   
      
Treatment 
     
Averages 
     
Level --- Y --- Cv Rank Group 
 
1 43.55 13.8 1 Salmonella control 
 
2 42.62 20.6 2 Salmonella + VR1020 
 
3 40.39 13.6 3 VR1020 Plasmid 
 
4 38.21 14.9 4 Control 
 
      
LSD for Time = 1.6774 S.E.D = 0.8529 r = 120 
 
t (2-sided a=0.050, 348 df) = 1.9668 
 
MSE =  43.64141    
   
      
Time      
Averages      
Level --- Y --- Cv Rank Time  
3 42.7 24 1 6  
2 40.52 11.7 2 3  
1 40.35 9.3 3 0  
      
LSD for Treatment*Time = 3.3548 S.E.D = 1.7057 r = 30  
t (2-sided a=0.050, 348 df) = 1.9668 MSE =  43.64141       
   
 Two-way table for Treatment*Time, n=30                                               
  1 2 3  
1 42.38 42.277 45.98  
2 41.337 41.91 44.627  
3 39.8 40.207 41.163  
4 37.9 37.963 39.027  
The following table contains the input data, and is arranged in two columns with the ostrich 
identification number, Treatment received (Trt), Time in weeks, the response as measured by 
ELISA (Resp) and weights of the ostriches, read from the top to the bottom and left to right. The 
Treatments consist of Salmonella enterica serovar typhimurium SL3261 control (1), mucosal 
VR1020 recombinant vaccine (2), intramuscular injected VR1020 recombinant vaccine (3) and the 
control group that received no vaccinations (4). Following the data are the graphs drawn for each 
ostrich depicting the immune response measured over time.  
  




Ostrich Trt Time Resp Weight 
2700 1 0 1.759 46.6 
2701 1 0 0.748 45.0 
2702 1 0 0.883 43.0 
2703 1 0 1.271 38.0 
2704 1 0 1.243 49.0 
2705 1 0 0.967 50.0 
2706 1 0 0.765 39.0 
2707 1 0 1.248 40.0 
2708 1 0 1.282 48.0 
2709 1 0 0.614 43.0 
2710 1 0 0.722 38.0 
2711 1 0 0.678 39.0 
2712 1 0 0.157 39.0 
2713 1 0 0.377 36.0 
2714 1 0 1.144 34.0 
2715 1 0 1.028 39.0 
2716 1 0 0.592 42.0 
2717 1 0 1.264 46.0 
2718 1 0 0.228 39.0 
2719 1 0 0.241 45.0 
2720 1 0 1.230 51.0 
2721 1 0 0.724 40.0 
2722 1 0 1.387 39.0 
2723 1 0 1.287 42.0 
2724 1 0 2.465 43.0 
2725 1 0 0.465 43.0 
2726 1 0 0.723 39.0 
2727 1 0 0.981 49.0 
2728 1 0 1.124 47.0 
2729 1 0 1.256 39.8 
2730 2 0 1.360 44.1 
2731 2 0 0.711 46.0 
2732 2 0 0.675 41.0 
2733 2 0 0.760 45.0 
2734 2 0 0.851 47.0 
2735 2 0 0.690 35.0 
2736 2 0 0.300 40.0 
2737 2 0 0.799 41.0 
2738 2 0 0.354 34.0 
2739 2 0 0.814 38.0 
2740 2 0 0.495 48.0 
2741 2 0 0.307 40.0 
2742 2 0 0.820 42.0 
2743 2 0 0.879 46.0 
2744 2 0 1.032 36.0 
2745 2 0 0.229 49.0 
2746 2 0 0.333 41.0 
2747 2 0 1.557 43.0 
2748 2 0 0.573 41.0 
2749 2 0 0.891 36.0 
2750 2 0 1.176 38.0 
2751 2 0 0.725 39.0 
2752 2 0 0.470 40.0 
2753 2 0 0.465 42.0 
2754 2 0 1.305 44.0 
2755 2 0 0.446 44.0 
2756 2 0 0.436 43.0 
2757 2 0 1.380 38.0 
2758 2 0 0.596 36.0 
2759 2 0 1.053 43.0 
2760 3 0 0.991 40.0 
2761 3 0 0.583 40.0 
2762 3 0 0.594 38.0 
2763 3 0 0.840 43.0 
2764 3 0 0.410 41.0 
2765 3 0 0.398 37.0 
2766 3 0 0.858 44.0 
2767 3 0 0.694 40.0 
2768 3 0 0.697 39.0 
2769 3 0 0.528 39.0 
2770 3 0 1.117 37.0 
2771 3 0 0.651 48.0 
2772 3 0 1.230 37.0 
2773 3 0 0.852 37.0 
2774 3 0 1.535 43.0 
2775 3 0 0.865 39.0 
2776 3 0 1.180 37.0 
2777 3 0 0.858 39.0 
2778 3 0 1.667 41.0 
2779 3 0 0.944 37.0 
2780 3 0 0.454 40.0 
2781 3 0 0.933 39.0 
2782 3 0 0.287 39.0 
2783 3 0 0.286 40.0 
2784 3 0 0.755 41.0 
2785 3 0 1.014 41.0 
2786 3 0 0.363 41.0 
2787 3 0 0.708 39.0 
2788 3 0 0.227 39.0 
2789 3 0 1.889 39.0 
2790 4 0 0.527 38.0 
2791 4 0 0.790 40.0 
2792 4 0 0.887 36.0 
2793 4 0 0.707 38.0 
2794 4 0 0.903 39.0 
2795 4 0 0.720 37.0 
2796 4 0 0.649 40.0 
2797 4 0 0.481 37.0 
2798 4 0 0.208 36.0 
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2799 4 0 1.273 36.0 
2800 4 0 1.002 37.0 
2801 4 0 0.720 37.0 
2802 4 0 0.887 36.0 
2803 4 0 0.682 37.0 
2804 4 0 0.372 35.0 
2805 4 0 0.615 43.0 
2806 4 0 1.645 38.0 
2807 4 0 0.348 38.0 
2808 4 0 0.639 45.0 
2809 4 0 0.897 37.0 
2810 4 0 1.308 38.0 
2811 4 0 0.431 38.0 
2812 4 0 0.570 40.0 
2813 4 0 0.646 38.0 
2814 4 0 1.292 37.0 
2815 4 0 0.480 36.0 
2816 4 0 0.111 42.0 
2817 4 0 0.147 37.0 
2818 4 0 0.492 36.0 
2819 4 0 0.177 35.0 
2700 1 3 1.938 50.5 
2701 1 3 1.049 45.4 
2702 1 3 1.186 43.0 
2703 1 3 0.951 40.6 
2704 1 3 1.736 55.5 
2705 1 3 0.861 46.0 
2706 1 3 1.566 39.2 
2707 1 3 1.097 37.8 
2708 1 3 0.511 42.0 
2709 1 3 0.538 44.8 
2710 1 3 0.404 40.2 
2711 1 3 0.540 35.2 
2712 1 3 0.482 37.2 
2713 1 3 0.160 33.6 
2714 1 3 1.150 34.4 
2715 1 3 0.543 35.0 
2716 1 3 0.640 35.6 
2717 1 3 1.090 39.8 
2718 1 3 0.322 43.8 
2719 1 3 0.675 44.6 
2720 1 3 0.849 56.5 
2721 1 3 1.273 39.2 
2722 1 3 1.279 43.6 
2723 1 3 1.046 40.2 
2724 1 3 1.097 42.8 
2725 1 3 0.818 45.4 
2726 1 3 1.158 40.8 
2727 1 3 1.916 49.6 
2728 1 3 1.602 44.4 
2729 1 3 1.202 41.6 
2730 2 3 1.106 43.2 
2731 2 3 0.495 47.4 
2732 2 3 0.540 42.8 
2733 2 3 0.371 46.8 
2734 2 3 0.656 52.0 
2735 2 3 0.791 30.4 
2736 2 3 0.437 38.8 
2737 2 3 0.394 46.4 
2738 2 3 0.371 36.4 
2739 2 3 0.782 38.2 
2740 2 3 0.390 49.2 
2741 2 3 0.181 43.8 
2742 2 3 0.739 42.4 
2743 2 3 0.756 44.8 
2744 2 3 0.974 34.8 
2745 2 3 0.175 50.5 
2746 2 3 0.172 41.2 
2747 2 3 1.088 44.4 
2748 2 3 0.746 36.8 
2749 2 3 0.373 39.4 
2750 2 3 0.531 40.2 
2751 2 3 1.024 34.8 
2752 2 3 0.857 39.0 
2753 2 3 0.510 41.6 
2754 2 3 0.262 40.6 
2755 2 3 0.401 44.4 
2756 2 3 0.357 45.2 
2757 2 3 0.779 40.6 
2758 2 3 0.703 40.2 
2759 2 3 0.718 41.0 
2760 3 3 1.140 39.4 
2761 3 3 0.535 42.6 
2762 3 3 0.747 37.0 
2763 3 3 1.247 39.8 
2764 3 3 1.039 41.2 
2765 3 3 0.671 37.8 
2766 3 3 0.855 40.6 
2767 3 3 0.794 43.2 
2768 3 3 0.740 43.2 
2769 3 3 0.786 38.8 
2770 3 3 1.074 43.8 
2771 3 3 1.179 41.4 
2772 3 3 1.970 40.8 
2773 3 3 1.333 37.6 
2774 3 3 0.833 46.6 
2775 3 3 1.582 32.0 
2776 3 3 1.352 37.8 
2777 3 3 0.523 41.4 
2778 3 3 0.745 44.6 
2779 3 3 1.048 38.0 
2780 3 3 0.430 41.8 
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2781 3 3 1.252 39.2 
2782 3 3 0.348 37.6 
2783 3 3 0.159 35.0 
2784 3 3 0.247 40.8 
2785 3 3 1.020 42.4 
2786 3 3 0.405 41.0 
2787 3 3 0.894 36.2 
2788 3 3 0.713 44.4 
2789 3 3 1.082 40.2 
2790 4 3 0.537 37.8 
2791 4 3 0.585 36.8 
2792 4 3 0.369 32.4 
2793 4 3 0.727 34.2 
2794 4 3 0.505 39.0 
2795 4 3 0.717 40.2 
2796 4 3 0.000 36.2 
2797 4 3 0.480 34.4 
2798 4 3 0.205 41.4 
2799 4 3 0.731 36.4 
2800 4 3 1.149 37.0 
2801 4 3 0.639 33.2 
2802 4 3 0.844 36.4 
2803 4 3 0.580 40.6 
2804 4 3 0.308 36.6 
2805 4 3 0.543 41.0 
2806 4 3 1.257 35.4 
2807 4 3 1.097 38.2 
2808 4 3 0.613 44.4 
2809 4 3 1.140 35.4 
2810 4 3 0.635 38.6 
2811 4 3 1.085 40.2 
2812 4 3 0.736 43.4 
2813 4 3 0.293 37.4 
2814 4 3 0.291 34.0 
2815 4 3 0.788 31.0 
2816 4 3 0.053 47.0 
2817 4 3 0.369 39.2 
2818 4 3 0.332 40.0 
2819 4 3 0.277 33.0 
2700 1 6 1.745 51.5 
2701 1 6 1.526 49.4 
2702 1 6 1.462 44.0 
2703 1 6 1.502 47.6 
2704 1 6 1.200 63.0 
2705 1 6 1.170 49.0 
2706 1 6 1.387 42.4 
2707 1 6 0.874 39.6 
2708 1 6 1.022 43.6 
2709 1 6 0.692 49.2 
2710 1 6 0.980 41.8 
2711 1 6 0.595 35.8 
2712 1 6 0.434 39.4 
2713 1 6 0.030 32.8 
2714 1 6 0.811 40.4 
2715 1 6 0.275 40.8 
2716 1 6 0.452 37.8 
2717 1 6 0.830 44.8 
2718 1 6 0.319 48.2 
2719 1 6 1.193 50.0 
2720 1 6 0.453 64.0 
2721 1 6 0.546 41.2 
2722 1 6 0.542 45.8 
2723 1 6 0.734 42.0 
2724 1 6 0.385 48.0 
2725 1 6 0.906 51.5 
2726 1 6 0.294 47.0 
2727 1 6 0.583 59.0 
2728 1 6 1.060 46.6 
2729 1 6 0.873 43.2 
2730 2 6 0.870 41.8 
2731 2 6 0.449 58.0 
2732 2 6 . . 
2733 2 6 0.675 51.5 
2734 2 6 0.210 62.5 
2735 2 6 0.675 35.4 
2736 2 6 0.201 45.0 
2737 2 6 0.813 50.0 
2738 2 6 0.283 35.0 
2739 2 6 0.729 46.6 
2740 2 6 0.293 61.0 
2741 2 6 0.240 50.5 
2742 2 6 0.603 49.8 
2743 2 6 0.368 48.6 
2744 2 6 0.488 32.0 
2745 2 6 0.274 52.0 
2746 2 6 0.321 53.5 
2747 2 6 0.751 53.5 
2748 2 6 . . 
2749 2 6 0.461 46.6 
2750 2 6 0.158 46.0 
2751 2 6 0.565 45.0 
2752 2 6 0.491 47.6 
2753 2 6 0.422 52.5 
2754 2 6 0.728 47.8 
2755 2 6 0.125 46.0 
2756 2 6 0.386 47.4 
2757 2 6 0.945 45.0 
2758 2 6 0.346 47.4 
2759 2 6 0.727 40.8 
2760 3 6 0.889 42.0 
2761 3 6 0.201 44.8 
2762 3 6 0.051 39.8 
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2763 3 6 1.321 39.2 
2764 3 6 0.352 49.0 
2765 3 6 0.646 38.2 
2766 3 6 0.414 45.4 
2767 3 6 0.613 47.8 
2768 3 6 0.824 46.8 
2769 3 6 0.605 39.2 
2770 3 6 0.654 42.0 
2771 3 6 0.374 42.8 
2772 3 6 0.779 40.4 
2773 3 6 0.474 33.4 
2774 3 6 0.255 45.2 
2775 3 6 0.562 37.8 
2776 3 6 0.704 40.3 
2777 3 6 0.820 44.4 
2778 3 6 0.305 46.0 
2779 3 6 0.404 37.0 
2780 3 6 0.693 44.2 
2781 3 6 0.897 45.8 
2782 3 6 . . 
2783 3 6 0.797 38.0 
2784 3 6 0.306 43.4 
2785 3 6 0.560 48.4 
2786 3 6 0.394 42.6 
2787 3 6 0.775 36.6 
2788 3 6 0.195 46.6 
2789 3 6 0.771 47.8 
2790 4 6 0.242 42.4 
2791 4 6 0.413 44.4 
2792 4 6 0.436 35.0 
2793 4 6 0.834 33.2 
2794 4 6 . . 
2795 4 6 0.512 46.6 
2796 4 6 0.654 36.0 
2797 4 6 0.731 35.8 
2798 4 6 0.440 48.6 
2799 4 6 0.849 38.6 
2800 4 6 0.747 46.2 
2801 4 6 0.431 38.4 
2802 4 6 0.783 35.6 
2803 4 6 1.233 39.4 
2804 4 6 0.557 37.2 
2805 4 6 0.603 48.4 
2806 4 6 0.775 40.2 
2807 4 6 0.745 38.4 
2808 4 6 1.084 48.0 
2809 4 6 0.759 38.8 
2810 4 6 0.476 43.8 
2811 4 6 0.960 40.2 
2812 4 6 0.973 43.0 
2813 4 6 0.638 38.8 
2814 4 6 1.041 43.0 
2815 4 6 0.606 28.2 
2816 4 6 0.213 47.6 
2817 4 6 0.574 36.0 
2818 4 6 0.135 42.6 

















































































































































































Figure B.1.: Immune responses elicited by ostriches that received 10
9
 c.f.u./ml of Salmonella enterica serovar typhimurium SL3261 control 
 















































































































































Figure B.2.: Immune responses elicited by ostriches that received 10
9
 c.f.u./ml of the mucosal VR1020 recombinant vaccine  
 















































































































































Figure B.3.: Immune responses elicited by ostriches that received 100 µg/ml of the intramuscular VR1020 recombinant vaccine 
 















































































































































Figure B.4.: Immune responses elicited by ostriches in the control group that received no vaccinations 
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Mucosal immune response of ostriches against OppA  
The mucosal immune response of the ostriches against the OppA protein was evaluated using 
ELISA as described in chapter 4.2.3.4 using the secondary antibody rabbit anti-ostrich IgA protein 
1. An ANOVA was performed using the Statistical Analysis program Agrobase Generation II® 
(Agronomix Software Inc.). 
                   A N A L Y S I S   O F   V A R I A N C E                       
Swab – OppA – IgA protein 1 
Oudsthoorn 
Variable: RESP 
      
Source df SS MS F-value Pr>F 
Total 359 0.050 
  
  
Treatment (Treatment) 3 0.003 0.001 8.67 0.0000 
Time (Time) 2 0.000 0.000 1.40 0.2474 
Treatment x Time  6 0.001 0.000 1.19 0.3123 
Residual 348 0.046 0.000     
Grand mean = 0.006 R-squared = 0.0936 C.V. = 203.9% 
 
      
LSD for Treatment = 0.0034 S.E.D = 0.0017  r = 90 
 
t (2-sided a=0.050, 348 df) = 1.9668 MSE = 0.00013 
   
 
     
Treatment 
     
Averages 
     
Level --- Y --- Cv Rank Group 
 
1 0.01 174.5 1 Salmonella Control 
 
3 0.01 184.7 2 VR1020 Plasmid 
 4 0.00 173.6 3 Control 
 2 0.00 303.4 4 Salmonella + VR1020 
 
      LSD for Time = 0.0029 S.E.D = 0.0015 r = 120 
 
t (2-sided a=0.050, 348 df) = 1.9668 MSE = 0.00013 
   
 
     
Time 
     
Averages 
     
Level --- Y --- Cv Rank Week 
 
1 0.01 233.6 1 0 
 
2 0.01 169.0 2 3 
 
3 0.00 206.1 3 6 
 
      
LSD for Treatment*Time = 0.0058 S.E.D = 0.0030 r = 30 
 
t (2-sided a=0.050, 348 df) = 1.9668 MSE = 0.00013 
   
 
     
 Two-way table for Treatment*Time, n=30                                             
  
  1 2 3 
  
1 0.015 0.008 0.008 
  
2 0.002 0.002 0.001 
  
3 0.005 0.007 0.006 
  
4 0.005 0.006 0.002 
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In the following table, the data is arranged in two columns with the ostrich identification number, 
Treatment received (Trt), Time in weeks, the response as measured by ELISA and weights of the 
ostriches, read from the top to the bottom and left to right. The Treatments consist of Salmonella 
enterica serovar typhimurium SL3261 control (1), mucosal VR1020 recombinant vaccine (2), 
intramuscular injected VR1020 recombinant vaccine (3) and the control group that received no 
vaccinations (4). Following the data are the graphs drawn for each ostrich depicting the immune 
response measured over time. 
 
Ostrich Trt Time Resp Weight 
2700 1 0 0.038 46.6 
2701 1 0 0.066 45.0 
2702 1 0 0.031 43.0 
2703 1 0 0.038 38.0 
2704 1 0 0.006 49.0 
2705 1 0 0.004 50.0 
2706 1 0 0.001 39.0 
2707 1 0 0.008 40.0 
2708 1 0 0.011 48.0 
2709 1 0 0.012 43.0 
2710 1 0 0.018 38.0 
2711 1 0 0.130 39.0 
2712 1 0 0.017 39.0 
2713 1 0 0.010 36.0 
2714 1 0 0.000 34.0 
2715 1 0 0.002 39.0 
2716 1 0 0.000 42.0 
2717 1 0 0.000 46.0 
2718 1 0 0.000 39.0 
2719 1 0 0.000 45.0 
2720 1 0 0.000 51.0 
2721 1 0 0.011 40.0 
2722 1 0 0.002 39.0 
2723 1 0 0.000 42.0 
2724 1 0 0.024 43.0 
2725 1 0 0.000 43.0 
2726 1 0 0.000 39.0 
2727 1 0 0.000 49.0 
2728 1 0 0.002 47.0 
2729 1 0 0.006 39.8 
2730 2 0 0.002 44.1 
2731 2 0 0.003 46.0 
2732 2 0 0.011 41.0 
2733 2 0 0.002 45.0 
2734 2 0 0.003 47.0 
2735 2 0 0.000 35.0 
2736 2 0 0.000 40.0 
2737 2 0 0.000 41.0 
2738 2 0 0.000 34.0 
2739 2 0 0.000 38.0 
2740 2 0 0.000 48.0 
2741 2 0 0.000 40.0 
2742 2 0 0.000 42.0 
2743 2 0 0.000 46.0 
2744 2 0 0.000 36.0 
2745 2 0 0.004 49.0 
2746 2 0 0.000 41.0 
2747 2 0 0.000 43.0 
2748 2 0 0.023 41.0 
2749 2 0 0.000 36.0 
2750 2 0 0.000 38.0 
2751 2 0 0.000 39.0 
2752 2 0 0.000 40.0 
2753 2 0 0.000 42.0 
2754 2 0 0.000 44.0 
2755 2 0 0.000 44.0 
2756 2 0 0.020 43.0 
2757 2 0 0.000 38.0 
2758 2 0 0.000 36.0 
2759 2 0 0.000 43.0 
2760 3 0 0.008 40.0 
2761 3 0 0.006 40.0 
2762 3 0 0.000 38.0 
2763 3 0 0.000 43.0 
2764 3 0 0.023 41.0 
2765 3 0 0.000 37.0 
2766 3 0 0.000 44.0 
2767 3 0 0.001 40.0 
2768 3 0 0.000 39.0 
2769 3 0 0.000 39.0 
2770 3 0 0.000 37.0 
2771 3 0 0.025 48.0 
2772 3 0 0.000 37.0 
2773 3 0 0.000 37.0 
2774 3 0 0.000 43.0 
2775 3 0 0.000 39.0 
2776 3 0 0.000 37.0 
2777 3 0 0.000 39.0 
2778 3 0 0.000 41.0 
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2779 3 0 0.000 37.0 
2780 3 0 0.000 40.0 
2781 3 0 0.000 39.0 
2782 3 0 0.023 39.0 
2783 3 0 0.008 40.0 
2784 3 0 0.002 41.0 
2785 3 0 0.037 41.0 
2786 3 0 0.003 41.0 
2787 3 0 0.012 39.0 
2788 3 0 0.000 39.0 
2789 3 0 0.006 39.0 
2790 4 0 0.015 38.0 
2791 4 0 0.000 40.0 
2792 4 0 0.008 36.0 
2793 4 0 0.003 38.0 
2794 4 0 0.008 39.0 
2795 4 0 0.012 37.0 
2796 4 0 0.001 40.0 
2797 4 0 0.015 37.0 
2798 4 0 0.013 36.0 
2799 4 0 0.001 36.0 
2800 4 0 0.000 37.0 
2801 4 0 0.011 37.0 
2802 4 0 0.012 36.0 
2803 4 0 0.000 37.0 
2804 4 0 0.000 35.0 
2805 4 0 0.013 43.0 
2806 4 0 0.000 38.0 
2807 4 0 0.000 38.0 
2808 4 0 0.019 45.0 
2809 4 0 0.000 37.0 
2810 4 0 0.000 38.0 
2811 4 0 0.004 38.0 
2812 4 0 0.006 40.0 
2813 4 0 0.000 38.0 
2814 4 0 0.001 37.0 
2815 4 0 0.000 36.0 
2816 4 0 0.025 42.0 
2817 4 0 0.012 37.0 
2818 4 0 0.000 36.0 
2819 4 0 0.000 35.0 
2700 1 3 0.011 50.5 
2701 1 3 0.012 45.4 
2702 1 3 0.004 43.0 
2703 1 3 0.009 40.6 
2704 1 3 0.041 55.5 
2705 1 3 0.019 46.0 
2706 1 3 0.019 39.2 
2707 1 3 0.007 37.8 
2708 1 3 0.009 42.0 
2709 1 3 0.012 44.8 
2710 1 3 0.013 40.2 
2711 1 3 0.016 35.2 
2712 1 3 0.014 37.2 
2713 1 3 0.014 33.6 
2714 1 3 0.000 34.4 
2715 1 3 0.006 35.0 
2716 1 3 0.004 35.6 
2717 1 3 0.000 39.8 
2718 1 3 0.000 43.8 
2719 1 3 0.000 44.6 
2720 1 3 0.000 56.5 
2721 1 3 0.000 39.2 
2722 1 3 0.000 43.6 
2723 1 3 0.000 40.2 
2724 1 3 0.019 42.8 
2725 1 3 0.000 45.4 
2726 1 3 0.000 40.8 
2727 1 3 0.000 49.6 
2728 1 3 0.004 44.4 
2729 1 3 0.017 41.6 
2730 2 3 0.005 43.2 
2731 2 3 0.005 47.4 
2732 2 3 0.010 42.8 
2733 2 3 0.000 46.8 
2734 2 3 0.000 52.0 
2735 2 3 0.010 30.4 
2736 2 3 0.000 38.8 
2737 2 3 0.000 46.4 
2738 2 3 0.000 36.4 
2739 2 3 0.000 38.2 
2740 2 3 0.000 49.2 
2741 2 3 0.000 43.8 
2742 2 3 0.000 42.4 
2743 2 3 0.000 44.8 
2744 2 3 0.010 34.8 
2745 2 3 0.004 50.5 
2746 2 3 0.016 41.2 
2747 2 3 0.000 44.4 
2748 2 3 0.005 36.8 
2749 2 3 0.001 39.4 
2750 2 3 0.000 40.2 
2751 2 3 0.000 34.8 
2752 2 3 0.000 39.0 
2753 2 3 0.000 41.6 
2754 2 3 0.000 40.6 
2755 2 3 0.000 44.4 
2756 2 3 0.004 45.2 
2757 2 3 0.000 40.6 
2758 2 3 0.000 40.2 
2759 2 3 0.000 41.0 
2760 3 3 0.009 39.4 
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2761 3 3 0.006 42.6 
2762 3 3 0.000 37.0 
2763 3 3 0.000 39.8 
2764 3 3 0.020 41.2 
2765 3 3 0.000 37.8 
2766 3 3 0.002 40.6 
2767 3 3 0.005 43.2 
2768 3 3 0.000 43.2 
2769 3 3 0.015 38.8 
2770 3 3 0.000 43.8 
2771 3 3 0.055 41.4 
2772 3 3 0.000 40.8 
2773 3 3 0.000 37.6 
2774 3 3 0.000 46.6 
2775 3 3 0.000 32.0 
2776 3 3 0.000 37.8 
2777 3 3 0.000 41.4 
2778 3 3 0.001 44.6 
2779 3 3 0.039 38.0 
2780 3 3 0.008 41.8 
2781 3 3 0.000 39.2 
2782 3 3 0.012 37.6 
2783 3 3 0.000 35.0 
2784 3 3 0.007 40.8 
2785 3 3 0.006 42.4 
2786 3 3 0.018 41.0 
2787 3 3 0.003 36.2 
2788 3 3 0.000 44.4 
2789 3 3 0.000 40.2 
2790 4 3 0.002 37.8 
2791 4 3 0.000 36.8 
2792 4 3 0.002 32.4 
2793 4 3 0.004 34.2 
2794 4 3 0.000 39.0 
2795 4 3 0.012 40.2 
2796 4 3 0.006 36.2 
2797 4 3 0.008 34.4 
2798 4 3 0.011 41.4 
2799 4 3 0.000 36.4 
2800 4 3 0.002 37.0 
2801 4 3 0.007 33.2 
2802 4 3 0.005 36.4 
2803 4 3 0.000 40.6 
2804 4 3 0.013 36.6 
2805 4 3 0.011 41.0 
2806 4 3 0.000 35.4 
2807 4 3 0.006 38.2 
2808 4 3 0.005 44.4 
2809 4 3 0.000 35.4 
2810 4 3 0.007 38.6 
2811 4 3 0.008 40.2 
2812 4 3 0.004 43.4 
2813 4 3 0.000 37.4 
2814 4 3 0.002 34.0 
2815 4 3 0.012 31.0 
2816 4 3 0.011 47.0 
2817 4 3 0.055 39.2 
2818 4 3 0.000 40.0 
2819 4 3 0.000 33.0 
2700 1 6 0.014 51.5 
2701 1 6 0.011 49.4 
2702 1 6 0.015 44.0 
2703 1 6 0.005 47.6 
2704 1 6 0.014 63.0 
2705 1 6 0.016 49.0 
2706 1 6 0.027 42.4 
2707 1 6 0.006 39.6 
2708 1 6 0.006 43.6 
2709 1 6 0.007 49.2 
2710 1 6 0.015 41.8 
2711 1 6 0.030 35.8 
2712 1 6 0.029 39.4 
2713 1 6 0.014 32.8 
2714 1 6 0.000 40.4 
2715 1 6 0.000 40.8 
2716 1 6 0.000 37.8 
2717 1 6 0.000 44.8 
2718 1 6 0.000 48.2 
2719 1 6 0.000 50.0 
2720 1 6 0.000 64.0 
2721 1 6 0.000 41.2 
2722 1 6 0.000 45.8 
2723 1 6 0.006 42.0 
2724 1 6 0.001 48.0 
2725 1 6 0.000 51.5 
2726 1 6 0.000 47.0 
2727 1 6 0.000 59.0 
2728 1 6 0.000 46.6 
2729 1 6 0.006 43.2 
2730 2 6 0.000 41.8 
2731 2 6 0.000 58.0 
2732 2 6 . . 
2733 2 6 0.000 51.5 
2734 2 6 0.000 62.5 
2735 2 6 0.020 35.4 
2736 2 6 0.000 45.0 
2737 2 6 0.000 50.0 
2738 2 6 0.000 35.0 
2739 2 6 0.000 46.6 
2740 2 6 0.000 61.0 
2741 2 6 0.000 50.5 
2742 2 6 0.001 49.8 
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2743 2 6 0.000 48.6 
2744 2 6 0.000 32.0 
2745 2 6 0.000 52.0 
2746 2 6 0.000 53.5 
2747 2 6 0.000 53.5 
2748 2 6 . . 
2749 2 6 0.001 46.6 
2750 2 6 0.000 46.0 
2751 2 6 0.000 45.0 
2752 2 6 0.000 47.6 
2753 2 6 0.000 52.5 
2754 2 6 0.000 47.8 
2755 2 6 0.000 46.0 
2756 2 6 0.004 47.4 
2757 2 6 0.004 45.0 
2758 2 6 0.000 47.4 
2759 2 6 0.000 40.8 
2760 3 6 0.000 42.0 
2761 3 6 0.002 44.8 
2762 3 6 0.012 39.8 
2763 3 6 0.056 39.2 
2764 3 6 0.024 49.0 
2765 3 6 0.000 38.2 
2766 3 6 0.011 45.4 
2767 3 6 0.005 47.8 
2768 3 6 0.000 46.8 
2769 3 6 0.005 39.2 
2770 3 6 0.011 42.0 
2771 3 6 0.002 42.8 
2772 3 6 0.000 40.4 
2773 3 6 0.000 33.4 
2774 3 6 0.000 45.2 
2775 3 6 0.000 37.8 
2776 3 6 0.000 40.3 
2777 3 6 0.000 44.4 
2778 3 6 0.000 46.0 
2779 3 6 0.031 37.0 
2780 3 6 0.015 44.2 
2781 3 6 0.000 45.8 
2782 3 6 . . 
2783 3 6 0.000 38.0 
2784 3 6 0.009 43.4 
2785 3 6 0.010 48.4 
2786 3 6 0.000 42.6 
2787 3 6 0.009 36.6 
2788 3 6 0.000 46.6 
2789 3 6 0.000 47.8 
2790 4 6 0.000 42.4 
2791 4 6 0.001 44.4 
2792 4 6 0.001 35.0 
2793 4 6 0.007 33.2 
2794 4 6 . . 
2795 4 6 0.004 46.6 
2796 4 6 0.000 36.0 
2797 4 6 0.000 35.8 
2798 4 6 0.007 48.6 
2799 4 6 0.000 38.6 
2800 4 6 0.006 46.2 
2801 4 6 0.000 38.4 
2802 4 6 0.000 35.6 
2803 4 6 0.000 39.4 
2804 4 6 0.000 37.2 
2805 4 6 0.000 48.4 
2806 4 6 0.000 40.2 
2807 4 6 0.000 38.4 
2808 4 6 0.000 48.0 
2809 4 6 0.000 38.8 
2810 4 6 0.003 43.8 
2811 4 6 0.007 40.2 
2812 4 6 0.007 43.0 
2813 4 6 0.008 38.8 
2814 4 6 0.007 43.0 
2815 4 6 0.000 28.2 
2816 4 6 0.001 47.6 
2817 4 6 0.000 36.0 
2818 4 6 0.003 42.6 
2819 4 6 0.000 36.4 

















































































































































Figure B.5.: Immune responses elicited by ostriches that received 10
9
 c.f.u./ml of Salmonella enterica serovar typhimurium SL3261 control 
 



















































































































































Figure B.6.: Immune responses elicited by ostriches that received 10
9
 c.f.u./ml of the mucosal VR1020 recombinant vaccine  
 

















































































































































Figure B.7.: Immune responses elicited by ostriches that received 100 µg/ml of the intramuscular VR1020 recombinant vaccine 
 



















































































































































Figure B.8.: Immune responses elicited by ostriches in the control group that received no vaccinations 
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Mucosal immune response of ostriches against OppA  
The mucosal immune response of the ostriches against the OppA protein was evaluated using 
ELISA as described in chapter 4.2.3.4 using the swab samples collected and rabbit anti-ostrich IgA 
protein 2 as the biotinylated secondary antibody. An ANOVA was performed using the Statistical 
Analysis program Agrobase Generation II® (Agronomix Software Inc.). 
                   A N A L Y S I S   O F   V A R I A N C E                       
Swab – OppA – IgA protein 2 
Oudsthoorn 
Variable: RESP 
      
Source df SS MS F-value Pr>F 
Total 359 0.063 
   
Treatment (Treatment) 3 0.001 0.000 1.37 0.2527 
Time (Time) 2 0.000 0.000 0.63 0.5329 
Treatment x Time  6 0.001 0.000 0.73 0.6294 
Residual 348 0.061 0.000 
  
Grand mean = 0.007 R-squared = 0.0272 C.V. = 191.7% 
 
   
  
 
LSD for Treatment = 0.0039 S.E.D = 0.0020  r = 90 
 
t (2-sided a=0.050, 348 df) = 1.9668 
 
MSE = 0.00018 






    
 Averages 
     
Level --- Y --- Cv Rank Group 
 
1 0.01 191.1 1 Salmonella Control 
 
4 0.01 183.5 2 Control 
 3 0.01 157.9 3 VR1020 Plasmid 
 2 0.00 230.0 4 Salmonella + VR1020 
 
   
   LSD for Time = 0.0034 S.E.D = 0.0017 r = 120 
 
t (2-sided a=0.050, 348 df) = 1.9668 
 
MSE = 0.00018 
   
 
     
Time 
     
Averages 
     
Level --- Y --- Cv Rank Week 
 
1 0.01 205.5 1 0 
 
2 0.01 152.3 2 3 
 
3 0.01 209.6 3 6 
 
      
LSD for Treatment*Time = 0.0067 S.E.D = 0.0034 r = 30 
 
t (2-sided a=0.050, 348 df) = 1.9668 
 
MSE = 0.00018 
   
 
     
 Two-way table for Treatment*Time, n=30                                             
  
  1 2 3 
  
1 0.012 0.008 0.006 
  
2 0.006 0.006 0.002 
  
3 0.006 0.008 0.007 
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The following table the data is arranged in two columns with the ostrich identification number, 
Treatment received (Trt), Time in weeks, the response as measured by ELISA and weights of the 
ostriches, read from the top to the bottom and left to right. The Treatments consist of Salmonella 
enterica serovar typhimurium SL3261 control (1), mucosal VR1020 recombinant vaccine (2), 
intramuscular injected VR1020 recombinant vaccine (3) and the control group that received no 
vaccinations (4). Following the data are the graphs drawn for each ostrich depicting the immune 
response measured over time. 
 
Ostrich Trt Time Resp Weight 
2700 1 0 0.011 46.6 
2701 1 0 0.021 45.0 
2702 1 0 0.030 43.0 
2703 1 0 0.002 38.0 
2704 1 0 0.000 49.0 
2705 1 0 0.000 50.0 
2706 1 0 0.013 39.0 
2707 1 0 0.000 40.0 
2708 1 0 0.000 48.0 
2709 1 0 0.024 43.0 
2710 1 0 0.015 38.0 
2711 1 0 0.022 39.0 
2712 1 0 0.106 39.0 
2713 1 0 0.029 36.0 
2714 1 0 0.002 34.0 
2715 1 0 0.008 39.0 
2716 1 0 0.000 42.0 
2717 1 0 0.000 46.0 
2718 1 0 0.000 39.0 
2719 1 0 0.001 45.0 
2720 1 0 0.010 51.0 
2721 1 0 0.010 40.0 
2722 1 0 0.069 39.0 
2723 1 0 0.000 42.0 
2724 1 0 0.000 43.0 
2725 1 0 0.000 43.0 
2726 1 0 0.000 39.0 
2727 1 0 0.000 49.0 
2728 1 0 0.000 47.0 
2729 1 0 0.000 39.8 
2730 2 0 0.012 44.1 
2731 2 0 0.003 46.0 
2732 2 0 0.009 41.0 
2733 2 0 0.077 45.0 
2734 2 0 0.003 47.0 
2735 2 0 0.002 35.0 
2736 2 0 0.000 40.0 
2737 2 0 0.000 41.0 
2738 2 0 0.000 34.0 
2739 2 0 0.000 38.0 
2740 2 0 0.000 48.0 
2741 2 0 0.000 40.0 
2742 2 0 0.000 42.0 
2743 2 0 0.019 46.0 
2744 2 0 0.000 36.0 
2745 2 0 0.000 49.0 
2746 2 0 0.000 41.0 
2747 2 0 0.008 43.0 
2748 2 0 0.019 41.0 
2749 2 0 0.000 36.0 
2750 2 0 0.000 38.0 
2751 2 0 0.000 39.0 
2752 2 0 0.000 40.0 
2753 2 0 0.012 42.0 
2754 2 0 0.000 44.0 
2755 2 0 0.000 44.0 
2756 2 0 0.000 43.0 
2757 2 0 0.000 38.0 
2758 2 0 0.016 36.0 
2759 2 0 0.000 43.0 
2760 3 0 0.017 40.0 
2761 3 0 0.000 40.0 
2762 3 0 0.013 38.0 
2763 3 0 0.019 43.0 
2764 3 0 0.001 41.0 
2765 3 0 0.000 37.0 
2766 3 0 0.000 44.0 
2767 3 0 0.005 40.0 
2768 3 0 0.000 39.0 
2769 3 0 0.000 39.0 
2770 3 0 0.000 37.0 
2771 3 0 0.002 48.0 
2772 3 0 0.000 37.0 
2773 3 0 0.000 37.0 
2774 3 0 0.004 43.0 
2775 3 0 0.000 39.0 
2776 3 0 0.000 37.0 
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2777 3 0 0.000 39.0 
2778 3 0 0.000 41.0 
2779 3 0 0.008 37.0 
2780 3 0 0.000 40.0 
2781 3 0 0.000 39.0 
2782 3 0 0.028 39.0 
2783 3 0 0.000 40.0 
2784 3 0 0.000 41.0 
2785 3 0 0.037 41.0 
2786 3 0 0.036 41.0 
2787 3 0 0.002 39.0 
2788 3 0 0.003 39.0 
2789 3 0 0.009 39.0 
2790 4 0 0.001 38.0 
2791 4 0 0.000 40.0 
2792 4 0 0.000 36.0 
2793 4 0 0.000 38.0 
2794 4 0 0.021 39.0 
2795 4 0 0.013 37.0 
2796 4 0 0.006 40.0 
2797 4 0 0.000 37.0 
2798 4 0 0.002 36.0 
2799 4 0 0.000 36.0 
2800 4 0 0.000 37.0 
2801 4 0 0.000 37.0 
2802 4 0 0.006 36.0 
2803 4 0 0.000 37.0 
2804 4 0 0.000 35.0 
2805 4 0 0.000 43.0 
2806 4 0 0.005 38.0 
2807 4 0 0.021 38.0 
2808 4 0 0.008 45.0 
2809 4 0 0.002 37.0 
2810 4 0 0.027 38.0 
2811 4 0 0.000 38.0 
2812 4 0 0.000 40.0 
2813 4 0 0.011 38.0 
2814 4 0 0.000 37.0 
2815 4 0 0.000 36.0 
2816 4 0 0.000 42.0 
2817 4 0 0.025 37.0 
2818 4 0 0.019 36.0 
2819 4 0 0.017 35.0 
2700 1 3 0.009 50.5 
2701 1 3 0.031 45.4 
2702 1 3 0.041 43.0 
2703 1 3 0.006 40.6 
2704 1 3 0.011 55.5 
2705 1 3 0.042 46.0 
2706 1 3 0.015 39.2 
2707 1 3 0.000 37.8 
2708 1 3 0.013 42.0 
2709 1 3 0.005 44.8 
2710 1 3 0.017 40.2 
2711 1 3 0.000 35.2 
2712 1 3 0.011 37.2 
2713 1 3 0.008 33.6 
2714 1 3 0.000 34.4 
2715 1 3 0.004 35.0 
2716 1 3 0.007 35.6 
2717 1 3 0.000 39.8 
2718 1 3 0.000 43.8 
2719 1 3 0.001 44.6 
2720 1 3 0.005 56.5 
2721 1 3 0.000 39.2 
2722 1 3 0.000 43.6 
2723 1 3 0.000 40.2 
2724 1 3 0.004 42.8 
2725 1 3 0.000 45.4 
2726 1 3 0.000 40.8 
2727 1 3 0.000 49.6 
2728 1 3 0.000 44.4 
2729 1 3 0.002 41.6 
2730 2 3 0.006 43.2 
2731 2 3 0.000 47.4 
2732 2 3 0.001 42.8 
2733 2 3 0.040 46.8 
2734 2 3 0.000 52.0 
2735 2 3 0.000 30.4 
2736 2 3 0.000 38.8 
2737 2 3 0.000 46.4 
2738 2 3 0.000 36.4 
2739 2 3 0.000 38.2 
2740 2 3 0.000 49.2 
2741 2 3 0.000 43.8 
2742 2 3 0.000 42.4 
2743 2 3 0.031 44.8 
2744 2 3 0.000 34.8 
2745 2 3 0.011 50.5 
2746 2 3 0.000 41.2 
2747 2 3 0.000 44.4 
2748 2 3 0.024 36.8 
2749 2 3 0.000 39.4 
2750 2 3 0.000 40.2 
2751 2 3 0.000 34.8 
2752 2 3 0.015 39.0 
2753 2 3 0.025 41.6 
2754 2 3 0.000 40.6 
2755 2 3 0.000 44.4 
2756 2 3 0.012 45.2 
2757 2 3 0.007 40.6 
2758 2 3 0.014 40.2 
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2759 2 3 0.014 41.0 
2760 3 3 0.000 39.4 
2761 3 3 0.009 42.6 
2762 3 3 0.014 37.0 
2763 3 3 0.000 39.8 
2764 3 3 0.003 41.2 
2765 3 3 0.000 37.8 
2766 3 3 0.005 40.6 
2767 3 3 0.003 43.2 
2768 3 3 0.012 43.2 
2769 3 3 0.025 38.8 
2770 3 3 0.000 43.8 
2771 3 3 0.020 41.4 
2772 3 3 0.000 40.8 
2773 3 3 0.000 37.6 
2774 3 3 0.000 46.6 
2775 3 3 0.000 32.0 
2776 3 3 0.000 37.8 
2777 3 3 0.000 41.4 
2778 3 3 0.000 44.6 
2779 3 3 0.008 38.0 
2780 3 3 0.025 41.8 
2781 3 3 0.014 39.2 
2782 3 3 0.024 37.6 
2783 3 3 0.005 35.0 
2784 3 3 0.040 40.8 
2785 3 3 0.006 42.4 
2786 3 3 0.033 41.0 
2787 3 3 0.000 36.2 
2788 3 3 0.003 44.4 
2789 3 3 0.004 40.2 
2790 4 3 0.002 37.8 
2791 4 3 0.000 36.8 
2792 4 3 0.044 32.4 
2793 4 3 0.000 34.2 
2794 4 3 0.020 39.0 
2795 4 3 0.003 40.2 
2796 4 3 0.008 36.2 
2797 4 3 0.000 34.4 
2798 4 3 0.000 41.4 
2799 4 3 0.000 36.4 
2800 4 3 0.015 37.0 
2801 4 3 0.010 33.2 
2802 4 3 0.000 36.4 
2803 4 3 0.000 40.6 
2804 4 3 0.000 36.6 
2805 4 3 0.000 41.0 
2806 4 3 0.003 35.4 
2807 4 3 0.000 38.2 
2808 4 3 0.006 44.4 
2809 4 3 0.006 35.4 
2810 4 3 0.000 38.6 
2811 4 3 0.002 40.2 
2812 4 3 0.000 43.4 
2813 4 3 0.000 37.4 
2814 4 3 0.000 34.0 
2815 4 3 0.007 31.0 
2816 4 3 0.000 47.0 
2817 4 3 0.016 39.2 
2818 4 3 0.018 40.0 
2819 4 3 0.012 33.0 
2700 1 6 0.000 51.5 
2701 1 6 0.000 49.4 
2702 1 6 0.047 44.0 
2703 1 6 0.001 47.6 
2704 1 6 0.000 63.0 
2705 1 6 0.004 49.0 
2706 1 6 0.000 42.4 
2707 1 6 0.009 39.6 
2708 1 6 0.040 43.6 
2709 1 6 0.016 49.2 
2710 1 6 0.012 41.8 
2711 1 6 0.033 35.8 
2712 1 6 0.019 39.4 
2713 1 6 0.001 32.8 
2714 1 6 0.000 40.4 
2715 1 6 0.002 40.8 
2716 1 6 0.000 37.8 
2717 1 6 0.000 44.8 
2718 1 6 0.000 48.2 
2719 1 6 0.003 50.0 
2720 1 6 0.000 64.0 
2721 1 6 0.000 41.2 
2722 1 6 0.000 45.8 
2723 1 6 0.000 42.0 
2724 1 6 0.007 48.0 
2725 1 6 0.000 51.5 
2726 1 6 0.000 47.0 
2727 1 6 0.000 59.0 
2728 1 6 0.000 46.6 
2729 1 6 0.001 43.2 
2730 2 6 0.018 41.8 
2731 2 6 0.001 58.0 
2732 2 6 . . 
2733 2 6 0.008 51.5 
2734 2 6 0.000 62.5 
2735 2 6 0.000 35.4 
2736 2 6 0.000 45.0 
2737 2 6 0.000 50.0 
2738 2 6 0.000 35.0 
2739 2 6 0.002 46.6 
2740 2 6 0.000 61.0 
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2741 2 6 0.000 50.5 
2742 2 6 0.000 49.8 
2743 2 6 0.000 48.6 
2744 2 6 0.000 32.0 
2745 2 6 0.000 52.0 
2746 2 6 0.000 53.5 
2747 2 6 0.000 53.5 
2748 2 6 . . 
2749 2 6 0.000 46.6 
2750 2 6 0.002 46.0 
2751 2 6 0.000 45.0 
2752 2 6 0.005 47.6 
2753 2 6 0.010 52.5 
2754 2 6 0.000 47.8 
2755 2 6 0.000 46.0 
2756 2 6 0.013 47.4 
2757 2 6 0.000 45.0 
2758 2 6 0.000 47.4 
2759 2 6 0.014 40.8 
2760 3 6 0.003 42.0 
2761 3 6 0.009 44.8 
2762 3 6 0.030 39.8 
2763 3 6 0.020 39.2 
2764 3 6 0.005 49.0 
2765 3 6 0.000 38.2 
2766 3 6 0.000 45.4 
2767 3 6 0.002 47.8 
2768 3 6 0.003 46.8 
2769 3 6 0.001 39.2 
2770 3 6 0.010 42.0 
2771 3 6 0.014 42.8 
2772 3 6 0.000 40.4 
2773 3 6 0.003 33.4 
2774 3 6 0.033 45.2 
2775 3 6 0.000 37.8 
2776 3 6 0.000 40.3 
2777 3 6 0.000 44.4 
2778 3 6 0.000 46.0 
2779 3 6 0.003 37.0 
2780 3 6 0.004 44.2 
2781 3 6 0.023 45.8 
2782 3 6 . . 
2783 3 6 0.013 38.0 
2784 3 6 0.008 43.4 
2785 3 6 0.031 48.4 
2786 3 6 0.000 42.6 
2787 3 6 0.000 36.6 
2788 3 6 0.009 46.6 
2789 3 6 0.007 47.8 
2790 4 6 0.069 42.4 
2791 4 6 0.007 44.4 
2792 4 6 0.005 35.0 
2793 4 6 0.004 33.2 
2794 4 6 . . 
2795 4 6 0.000 46.6 
2796 4 6 0.007 36.0 
2797 4 6 0.019 35.8 
2798 4 6 0.004 48.6 
2799 4 6 0.000 38.6 
2800 4 6 0.011 46.2 
2801 4 6 0.017 38.4 
2802 4 6 0.000 35.6 
2803 4 6 0.000 39.4 
2804 4 6 0.000 37.2 
2805 4 6 0.000 48.4 
2806 4 6 0.000 40.2 
2807 4 6 0.000 38.4 
2808 4 6 0.012 48.0 
2809 4 6 0.000 38.8 
2810 4 6 0.000 43.8 
2811 4 6 0.000 40.2 
2812 4 6 0.001 43.0 
2813 4 6 0.000 38.8 
2814 4 6 0.007 43.0 
2815 4 6 0.000 28.2 
2816 4 6 0.000 47.6 
2817 4 6 0.008 36.0 
2818 4 6 0.071 42.6 
2819 4 6 0.005 36.4 



















































































































































Figure B.9.: Immune responses elicited by ostriches that received 10
9
 c.f.u./ml of Salmonella enterica serovar typhimurium SL3261 control 
 



















































































































































Figure B.10.: Immune responses elicited by ostriches that received 10
9
 c.f.u./ml of the mucosal VR1020 recombinant vaccine  
 



















































































































































Figure B.11.: Immune responses elicited by ostriches that received 100 µg/ml of the intramuscular VR1020 recombinant vaccine 
 



















































































































































Figure B.12.: Immune responses elicited by ostriches in the control group that received no vaccinations 
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Humoral immune response of ostriches against Salmonella entrica serovar typhimurium 
SL3261 LPS  
The humoral immune response of the ostriches against Salmonella entrica serovar typhimurium 
SL3261 LPS was evaluated using ELISA as described in chapter as described in chapter 4.2.3.5 
and the serum samples collected. An ANOVA was performed using the Statistical Analysis 
program Agrobase Generation II® (Agronomix Software Inc.). 
                   A N A L Y S I S   O F   V A R I A N C E                       
Serum - LPS 
Oudsthoorn 
Variable: RESP 
      
Source df SS MS F-value Pr>F 
Total 359 243.951 
   
Treatment (Treatment) 3 10.061 3.354 5.48 0.0011 
Time (Time) 2 19.620 9.810 16.04 0.0000 
Treatment x Time  6 1.374 0.229 0.37 0.8951 
Residual 348 212.895 0.612 
  
Grand mean = 1.317 R-squared = 0.1273 C.V. = 59.40% 
 
   
  
 
LSD for Treatment = 0.2293 S.E.D = 0.1166  r = 90 
 
t (2-sided a=0.050, 348 df) = 1.9668 MSE = 0.61177 






    
 Averages 
     
Level --- Y --- Cv Rank Group 
 
1 1.58 54.3 1 Salmonella Control 
 
4 1.31 66.6 2 Control 
 3 1.25 62.6 3 VR1020 Plasmid 
 2 1.13 63.9 4 Salmonella + VR1020 
 
      LSD for Time = 0.1986 S.E.D = 0.1010 r = 120 
 
t (2-sided a=0.050, 348 df) = 1.9668 MSE = 0.61177 
   
 
     
Time 
     
Averages 
     
Level --- Y --- Cv Rank Week 
 
1 1.60 52.6 1 0 
 
2 1.32 58.9 2 3 
 
3 1.03 73.3 3 6 
 
      
LSD for Treatment*Time = 0.3972 S.E.D = 0.2020 r = 30 
 
t (2-sided a=0.050, 348 df) = 1.9668 MSE = 0.61177 
   
 
     
 Two-way table for Treatment*Time, n=30                                             
  
  1 2 3 
  
1 1.886 1.624 1.243 
  
2 1.519 1.069 0.798 
  
3 1.468 1.317 0.961 
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The following table the data is arranged in two columns with the ostrich identification number, 
Treatment received (Trt), Time in weeks, the response as measured by ELISA and weights of the 
ostriches, read from the top to the bottom and left to right. The Treatments consist of Salmonella 
enterica serovar typhimurium SL3261 control (1), mucosal VR1020 recombinant vaccine (2), 
intramuscular injected VR1020 recombinant vaccine (3) and the control group that received no 
vaccinations (4). Following the data are the graphs drawn for each ostrich depicting the immune 
response measured over time. 
 
Ostrich Trt Time Resp Weight 
2700 1 0 2.559 46.6 
2701 1 0 2.299 45.0 
2702 1 0 2.031 43.0 
2703 1 0 1.936 38.0 
2704 1 0 2.823 49.0 
2705 1 0 1.421 50.0 
2706 1 0 2.901 39.0 
2707 1 0 2.641 40.0 
2708 1 0 1.441 48.0 
2709 1 0 0.928 43.0 
2710 1 0 0.825 38.0 
2711 1 0 2.763 39.0 
2712 1 0 0.520 39.0 
2713 1 0 0.390 36.0 
2714 1 0 0.820 34.0 
2715 1 0 2.804 39.0 
2716 1 0 2.318 42.0 
2717 1 0 1.690 46.0 
2718 1 0 1.637 39.0 
2719 1 0 2.951 45.0 
2720 1 0 1.590 51.0 
2721 1 0 0.598 40.0 
2722 1 0 2.886 39.0 
2723 1 0 1.670 42.0 
2724 1 0 2.766 43.0 
2725 1 0 1.609 43.0 
2726 1 0 1.037 39.0 
2727 1 0 0.816 49.0 
2728 1 0 3.070 47.0 
2729 1 0 2.824 39.8 
2730 2 0 2.288 44.1 
2731 2 0 2.519 46.0 
2732 2 0 0.499 41.0 
2733 2 0 1.211 45.0 
2734 2 0 1.871 47.0 
2735 2 0 0.000 35.0 
2736 2 0 0.324 40.0 
2737 2 0 1.782 41.0 
2738 2 0 2.586 34.0 
2739 2 0 2.128 38.0 
2740 2 0 1.868 48.0 
2741 2 0 0.425 40.0 
2742 2 0 1.220 42.0 
2743 2 0 2.750 46.0 
2744 2 0 1.961 36.0 
2745 2 0 1.613 49.0 
2746 2 0 1.290 41.0 
2747 2 0 1.886 43.0 
2748 2 0 1.145 41.0 
2749 2 0 1.353 36.0 
2750 2 0 1.204 38.0 
2751 2 0 1.486 39.0 
2752 2 0 0.613 40.0 
2753 2 0 2.845 42.0 
2754 2 0 2.479 44.0 
2755 2 0 0.838 44.0 
2756 2 0 0.366 43.0 
2757 2 0 1.139 38.0 
2758 2 0 2.801 36.0 
2759 2 0 1.094 43.0 
2760 3 0 0.818 40.0 
2761 3 0 0.599 40.0 
2762 3 0 1.501 38.0 
2763 3 0 2.535 43.0 
2764 3 0 0.381 41.0 
2765 3 0 0.598 37.0 
2766 3 0 1.332 44.0 
2767 3 0 1.363 40.0 
2768 3 0 0.833 39.0 
2769 3 0 1.262 39.0 
2770 3 0 1.517 37.0 
2771 3 0 3.020 48.0 
2772 3 0 2.025 37.0 
2773 3 0 1.688 37.0 
2774 3 0 1.440 43.0 
2775 3 0 1.132 39.0 
2776 3 0 2.190 37.0 
2777 3 0 1.208 39.0 
2778 3 0 2.432 41.0 
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2779 3 0 1.891 37.0 
2780 3 0 2.523 40.0 
2781 3 0 3.115 39.0 
2782 3 0 0.486 39.0 
2783 3 0 0.358 40.0 
2784 3 0 1.784 41.0 
2785 3 0 1.649 41.0 
2786 3 0 0.722 41.0 
2787 3 0 0.832 39.0 
2788 3 0 0.583 39.0 
2789 3 0 2.206 39.0 
2790 4 0 2.180 38.0 
2791 4 0 1.867 40.0 
2792 4 0 1.620 36.0 
2793 4 0 1.086 38.0 
2794 4 0 1.289 39.0 
2795 4 0 0.865 37.0 
2796 4 0 1.213 40.0 
2797 4 0 2.512 37.0 
2798 4 0 0.604 36.0 
2799 4 0 1.913 36.0 
2800 4 0 2.682 37.0 
2801 4 0 1.166 37.0 
2802 4 0 3.171 36.0 
2803 4 0 0.776 37.0 
2804 4 0 2.901 35.0 
2805 4 0 0.722 43.0 
2806 4 0 2.091 38.0 
2807 4 0 1.418 38.0 
2808 4 0 2.868 45.0 
2809 4 0 2.733 37.0 
2810 4 0 1.731 38.0 
2811 4 0 0.643 38.0 
2812 4 0 0.748 40.0 
2813 4 0 2.351 38.0 
2814 4 0 1.182 37.0 
2815 4 0 2.450 36.0 
2816 4 0 0.381 42.0 
2817 4 0 0.284 37.0 
2818 4 0 0.474 36.0 
2819 4 0 0.201 35.0 
2700 1 3 2.351 50.5 
2701 1 3 1.892 45.4 
2702 1 3 1.665 43.0 
2703 1 3 1.335 40.6 
2704 1 3 2.637 55.5 
2705 1 3 1.604 46.0 
2706 1 3 2.419 39.2 
2707 1 3 1.888 37.8 
2708 1 3 0.557 42.0 
2709 1 3 0.634 44.8 
2710 1 3 0.508 40.2 
2711 1 3 1.114 35.2 
2712 1 3 0.662 37.2 
2713 1 3 0.169 33.6 
2714 1 3 1.213 34.4 
2715 1 3 0.883 35.0 
2716 1 3 1.057 35.6 
2717 1 3 1.370 39.8 
2718 1 3 1.748 43.8 
2719 1 3 3.062 44.6 
2720 1 3 0.951 56.5 
2721 1 3 1.290 39.2 
2722 1 3 2.905 43.6 
2723 1 3 1.470 40.2 
2724 1 3 1.462 42.8 
2725 1 3 1.796 45.4 
2726 1 3 2.415 40.8 
2727 1 3 1.891 49.6 
2728 1 3 3.009 44.4 
2729 1 3 2.774 41.6 
2730 2 3 1.020 43.2 
2731 2 3 2.201 47.4 
2732 2 3 0.489 42.8 
2733 2 3 0.588 46.8 
2734 2 3 1.121 52.0 
2735 2 3 0.831 30.4 
2736 2 3 0.648 38.8 
2737 2 3 2.089 46.4 
2738 2 3 0.740 36.4 
2739 2 3 1.681 38.2 
2740 2 3 0.912 49.2 
2741 2 3 0.206 43.8 
2742 2 3 0.939 42.4 
2743 2 3 1.893 44.8 
2744 2 3 1.307 34.8 
2745 2 3 0.470 50.5 
2746 2 3 0.464 41.2 
2747 2 3 0.990 44.4 
2748 2 3 2.002 36.8 
2749 2 3 0.319 39.4 
2750 2 3 0.687 40.2 
2751 2 3 1.730 34.8 
2752 2 3 0.949 39.0 
2753 2 3 0.864 41.6 
2754 2 3 1.793 40.6 
2755 2 3 0.696 44.4 
2756 2 3 0.636 45.2 
2757 2 3 0.554 40.6 
2758 2 3 2.405 40.2 
2759 2 3 0.847 41.0 
2760 3 3 0.768 39.4 
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2761 3 3 0.573 42.6 
2762 3 3 1.092 37.0 
2763 3 3 2.178 39.8 
2764 3 3 0.626 41.2 
2765 3 3 0.810 37.8 
2766 3 3 1.064 40.6 
2767 3 3 1.337 43.2 
2768 3 3 0.817 43.2 
2769 3 3 1.246 38.8 
2770 3 3 1.360 43.8 
2771 3 3 2.960 41.4 
2772 3 3 2.800 40.8 
2773 3 3 1.922 37.6 
2774 3 3 0.783 46.6 
2775 3 3 1.935 32.0 
2776 3 3 1.553 37.8 
2777 3 3 1.085 41.4 
2778 3 3 1.000 44.6 
2779 3 3 1.909 38.0 
2780 3 3 2.045 41.8 
2781 3 3 2.921 39.2 
2782 3 3 0.368 37.6 
2783 3 3 0.230 35.0 
2784 3 3 0.677 40.8 
2785 3 3 1.078 42.4 
2786 3 3 0.526 41.0 
2787 3 3 1.530 36.2 
2788 3 3 0.966 44.4 
2789 3 3 1.321 40.2 
2790 4 3 1.772 37.8 
2791 4 3 0.736 36.8 
2792 4 3 0.463 32.4 
2793 4 3 1.324 34.2 
2794 4 3 0.801 39.0 
2795 4 3 1.424 40.2 
2796 4 3 0.000 36.2 
2797 4 3 2.090 34.4 
2798 4 3 0.553 41.4 
2799 4 3 1.160 36.4 
2800 4 3 2.466 37.0 
2801 4 3 0.889 33.2 
2802 4 3 2.860 36.4 
2803 4 3 0.726 40.6 
2804 4 3 2.614 36.6 
2805 4 3 1.004 41.0 
2806 4 3 1.441 35.4 
2807 4 3 1.339 38.2 
2808 4 3 2.893 44.4 
2809 4 3 2.492 35.4 
2810 4 3 0.617 38.6 
2811 4 3 1.497 40.2 
2812 4 3 0.787 43.4 
2813 4 3 1.870 37.4 
2814 4 3 0.299 34.0 
2815 4 3 2.489 31.0 
2816 4 3 0.122 47.0 
2817 4 3 0.376 39.2 
2818 4 3 0.374 40.0 
2819 4 3 0.339 33.0 
2700 1 6 2.100 51.5 
2701 1 6 1.775 49.4 
2702 1 6 1.355 44.0 
2703 1 6 1.575 47.6 
2704 1 6 1.768 63.0 
2705 1 6 1.494 49.0 
2706 1 6 2.007 42.4 
2707 1 6 1.346 39.6 
2708 1 6 0.835 43.6 
2709 1 6 0.805 49.2 
2710 1 6 0.812 41.8 
2711 1 6 1.983 35.8 
2712 1 6 0.705 39.4 
2713 1 6 0.044 32.8 
2714 1 6 0.639 40.4 
2715 1 6 0.362 40.8 
2716 1 6 0.496 37.8 
2717 1 6 0.941 44.8 
2718 1 6 2.707 48.2 
2719 1 6 2.776 50.0 
2720 1 6 0.350 64.0 
2721 1 6 0.468 41.2 
2722 1 6 0.696 45.8 
2723 1 6 1.107 42.0 
2724 1 6 0.387 48.0 
2725 1 6 1.240 51.5 
2726 1 6 0.380 47.0 
2727 1 6 0.536 59.0 
2728 1 6 2.769 46.6 
2729 1 6 2.781 43.2 
2730 2 6 0.738 41.8 
2731 2 6 0.770 58.0 
2732 2 6 . . 
2733 2 6 0.856 51.5 
2734 2 6 0.280 62.5 
2735 2 6 0.856 35.4 
2736 2 6 0.423 45.0 
2737 2 6 1.411 50.0 
2738 2 6 0.328 35.0 
2739 2 6 0.934 46.6 
2740 2 6 0.474 61.0 
2741 2 6 2.392 50.5 
2742 2 6 0.732 49.8 
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2743 2 6 0.681 48.6 
2744 2 6 0.566 32.0 
2745 2 6 0.420 52.0 
2746 2 6 0.662 53.5 
2747 2 6 0.980 53.5 
2748 2 6 . . 
2749 2 6 0.373 46.6 
2750 2 6 0.219 46.0 
2751 2 6 1.161 45.0 
2752 2 6 0.611 47.6 
2753 2 6 1.091 52.5 
2754 2 6 0.983 47.8 
2755 2 6 0.451 46.0 
2756 2 6 1.541 47.4 
2757 2 6 2.080 45.0 
2758 2 6 1.052 47.4 
2759 2 6 0.888 40.8 
2760 3 6 0.862 42.0 
2761 3 6 0.575 44.8 
2762 3 6 0.373 39.8 
2763 3 6 1.753 39.2 
2764 3 6 0.328 49.0 
2765 3 6 0.767 38.2 
2766 3 6 0.578 45.4 
2767 3 6 0.817 47.8 
2768 3 6 0.681 46.8 
2769 3 6 0.473 39.2 
2770 3 6 0.703 42.0 
2771 3 6 2.823 42.8 
2772 3 6 2.148 40.4 
2773 3 6 0.653 33.4 
2774 3 6 0.250 45.2 
2775 3 6 0.557 37.8 
2776 3 6 0.556 40.3 
2777 3 6 0.511 44.4 
2778 3 6 0.769 46.0 
2779 3 6 1.410 37.0 
2780 3 6 1.083 44.2 
2781 3 6 3.094 45.8 
2782 3 6 . . 
2783 3 6 2.247 38.0 
2784 3 6 0.435 43.4 
2785 3 6 0.950 48.4 
2786 3 6 0.565 42.6 
2787 3 6 1.681 36.6 
2788 3 6 0.287 46.6 
2789 3 6 0.889 47.8 
2790 4 6 1.052 42.4 
2791 4 6 0.441 44.4 
2792 4 6 0.484 35.0 
2793 4 6 0.732 33.2 
2794 4 6 . . 
2795 4 6 0.790 46.6 
2796 4 6 0.842 36.0 
2797 4 6 1.686 35.8 
2798 4 6 0.596 48.6 
2799 4 6 1.258 38.6 
2800 4 6 1.297 46.2 
2801 4 6 0.513 38.4 
2802 4 6 2.962 35.6 
2803 4 6 1.477 39.4 
2804 4 6 2.806 37.2 
2805 4 6 0.952 48.4 
2806 4 6 1.355 40.2 
2807 4 6 0.955 38.4 
2808 4 6 2.992 48.0 
2809 4 6 1.210 38.8 
2810 4 6 0.540 43.8 
2811 4 6 1.317 40.2 
2812 4 6 1.579 43.0 
2813 4 6 2.783 38.8 
2814 4 6 0.842 43.0 
2815 4 6 0.972 28.2 
2816 4 6 0.174 47.6 
2817 4 6 0.611 36.0 
2818 4 6 0.237 42.6 


















































































































































Figure B.13.: Immune responses elicited by ostriches that received 10
9
 c.f.u./ml of Salmonella enterica serovar typhimurium SL3261 control 
 













































































































































Figure B.14.: Immune responses elicited by ostriches that received 10
9
 c.f.u./ml of the mucosal VR1020 recombinant vaccine  
 













































































































































Figure B.15: Immune responses elicited by ostriches that received 100 µg/ml of the intramuscular VR1020 recombinant vaccine 
 















































































































































Figure B.16.: Immune responses elicited by ostriches in the control group that received no vaccinations 
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Mucosal immune response of ostriches against Salmonella entrica serovar typhimurium 
SL3261 LPS  
The mucosal immune response of the ostriches against Salmonella entrica serovar typhimurium 
SL3261 LPS was evaluated using ELISA as described in chapter 4.2.3.5 using the swab samples 
collected and rabbit anti-ostrich IgA protein 1 as the biotinylated secondary antibody. An ANOVA 
was performed using the Statistical Analysis program Agrobase Generation II® (Agronomix 
Software Inc.). 
                   A N A L Y S I S   O F   V A R I A N C E                       
Swab – LPS – IgA Protein 1 
Oudsthoorn 
Variable: RESP 
      
Source df SS MS F-value Pr>F 
Total 359 0.068 
   
Treatment (Treatment) 3 0.003 0.001 5.89 0.0006 
Time (Time) 2 0.001 0.000 1.49 0.2275 
Treatment x Time  6 0.001 0.000 0.54 0.7814 
Residual 348 0.063 0.000 
  
Grand mean = 0.008 R-squared = 0.0642 C.V. = 170.5% 
 
   
  
 
LSD for Treatment = 0.0040 S.E.D = 0.0020  r = 90 
 
t (2-sided a=0.050, 348 df) = 1.9668 MSE = 0.00018 






    
 Averages 
     
Level --- Y --- Cv Rank Group 
 
3 0.01 132.3 1 VR1020 Plasmid 
 
1 0.01 201.0 2 Salmonella Control 
 2 0.01 152.6 3 Salmonella + VR1020 
 4 0.00 207.9 4 Control 
 
   
   LSD for Time = 0.0034 S.E.D = 0.0017 r = 120 
 
t (2-sided a=0.050, 348 df) = 1.9668 MSE = 0.00018 
   
 
     
Time 
     
Averages 
     
Level --- Y --- Cv Rank Week 
 
2 0.01 184.2 1 3 
 
3 0.01 167.1 2 6 
 
1 0.01 148.2 3 0 
 
      
LSD for Treatment*Time = 0.0069 
 
S.E.D = 0.0035 
 
r = 30 
 
t (2-sided a=0.050, 348 df) = 1.9668 
 
MSE = 0.00018 
   
 
     
 Two-way table for Treatment*Time, n=30                                             
  
  1 2 3 
  
1 0.006 0.011 0.007 
  
2 0.005 0.010 0.009 
  
3 0.010 0.011 0.015 
  
4 0.003 0.004 0.003 
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The following table the data is arranged in two columns with the ostrich identification number, 
Treatment received (Trt), Time in weeks, the response as measured by ELISA and weights of the 
ostriches, read from the top to the bottom and left to right. The Treatments consist of Salmonella 
enterica serovar typhimurium SL3261 control (1), mucosal VR1020 recombinant vaccine (2), 
intramuscular injected VR1020 recombinant vaccine (3) and the control group that received no 
vaccinations (4). Following the data are the graphs drawn for each ostrich depicting the immune 
response measured over time. 
 
Ostrich Trt Time Resp Weight 
2700 1 0 0.000 46.6 
2701 1 0 0.011 45.0 
2702 1 0 0.006 43.0 
2703 1 0 0.006 38.0 
2704 1 0 0.000 49.0 
2705 1 0 0.003 50.0 
2706 1 0 0.000 39.0 
2707 1 0 0.000 40.0 
2708 1 0 0.019 48.0 
2709 1 0 0.022 43.0 
2710 1 0 0.012 38.0 
2711 1 0 0.000 39.0 
2712 1 0 0.000 39.0 
2713 1 0 0.000 36.0 
2714 1 0 0.004 34.0 
2715 1 0 0.010 39.0 
2716 1 0 0.009 42.0 
2717 1 0 0.005 46.0 
2718 1 0 0.001 39.0 
2719 1 0 0.007 45.0 
2720 1 0 0.025 51.0 
2721 1 0 0.013 40.0 
2722 1 0 0.000 39.0 
2723 1 0 0.005 42.0 
2724 1 0 0.000 43.0 
2725 1 0 0.001 43.0 
2726 1 0 0.009 39.0 
2727 1 0 0.014 49.0 
2728 1 0 0.002 47.0 
2729 1 0 0.002 39.8 
2730 2 0 0.009 44.1 
2731 2 0 0.004 46.0 
2732 2 0 0.021 41.0 
2733 2 0 0.000 45.0 
2734 2 0 0.012 47.0 
2735 2 0 0.013 35.0 
2736 2 0 0.000 40.0 
2737 2 0 0.000 41.0 
2738 2 0 0.000 34.0 
2739 2 0 0.000 38.0 
2740 2 0 0.000 48.0 
2741 2 0 0.000 40.0 
2742 2 0 0.000 42.0 
2743 2 0 0.000 46.0 
2744 2 0 0.001 36.0 
2745 2 0 0.018 49.0 
2746 2 0 0.010 41.0 
2747 2 0 0.000 43.0 
2748 2 0 0.006 41.0 
2749 2 0 0.013 36.0 
2750 2 0 0.010 38.0 
2751 2 0 0.000 39.0 
2752 2 0 0.000 40.0 
2753 2 0 0.001 42.0 
2754 2 0 0.000 44.0 
2755 2 0 0.000 44.0 
2756 2 0 0.022 43.0 
2757 2 0 0.026 38.0 
2758 2 0 0.000 36.0 
2759 2 0 0.000 43.0 
2760 3 0 0.000 40.0 
2761 3 0 0.000 40.0 
2762 3 0 0.000 38.0 
2763 3 0 0.016 43.0 
2764 3 0 0.032 41.0 
2765 3 0 0.000 37.0 
2766 3 0 0.000 44.0 
2767 3 0 0.006 40.0 
2768 3 0 0.001 39.0 
2769 3 0 0.000 39.0 
2770 3 0 0.000 37.0 
2771 3 0 0.000 48.0 
2772 3 0 0.015 37.0 
2773 3 0 0.006 37.0 
2774 3 0 0.004 43.0 
2775 3 0 0.006 39.0 
2776 3 0 0.020 37.0 
2777 3 0 0.022 39.0 
2778 3 0 0.001 41.0 
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2779 3 0 0.006 37.0 
2780 3 0 0.026 40.0 
2781 3 0 0.034 39.0 
2782 3 0 0.000 39.0 
2783 3 0 0.039 40.0 
2784 3 0 0.000 41.0 
2785 3 0 0.013 41.0 
2786 3 0 0.042 41.0 
2787 3 0 0.000 39.0 
2788 3 0 0.010 39.0 
2789 3 0 0.000 39.0 
2790 4 0 0.000 38.0 
2791 4 0 0.006 40.0 
2792 4 0 0.000 36.0 
2793 4 0 0.000 38.0 
2794 4 0 0.003 39.0 
2795 4 0 0.012 37.0 
2796 4 0 0.000 40.0 
2797 4 0 0.008 37.0 
2798 4 0 0.000 36.0 
2799 4 0 0.003 36.0 
2800 4 0 0.000 37.0 
2801 4 0 0.000 37.0 
2802 4 0 0.011 36.0 
2803 4 0 0.003 37.0 
2804 4 0 0.000 35.0 
2805 4 0 0.000 43.0 
2806 4 0 0.016 38.0 
2807 4 0 0.009 38.0 
2808 4 0 0.016 45.0 
2809 4 0 0.000 37.0 
2810 4 0 0.000 38.0 
2811 4 0 0.000 38.0 
2812 4 0 0.000 40.0 
2813 4 0 0.000 38.0 
2814 4 0 0.000 37.0 
2815 4 0 0.011 36.0 
2816 4 0 0.005 42.0 
2817 4 0 0.000 37.0 
2818 4 0 0.000 36.0 
2819 4 0 0.000 35.0 
2700 1 3 0.000 50.5 
2701 1 3 0.007 45.4 
2702 1 3 0.000 43.0 
2703 1 3 0.017 40.6 
2704 1 3 0.005 55.5 
2705 1 3 0.000 46.0 
2706 1 3 0.000 39.2 
2707 1 3 0.000 37.8 
2708 1 3 0.008 42.0 
2709 1 3 0.143 44.8 
2710 1 3 0.028 40.2 
2711 1 3 0.000 35.2 
2712 1 3 0.000 37.2 
2713 1 3 0.000 33.6 
2714 1 3 0.003 34.4 
2715 1 3 0.009 35.0 
2716 1 3 0.006 35.6 
2717 1 3 0.012 39.8 
2718 1 3 0.004 43.8 
2719 1 3 0.009 44.6 
2720 1 3 0.020 56.5 
2721 1 3 0.005 39.2 
2722 1 3 0.002 43.6 
2723 1 3 0.000 40.2 
2724 1 3 0.003 42.8 
2725 1 3 0.001 45.4 
2726 1 3 0.016 40.8 
2727 1 3 0.007 49.6 
2728 1 3 0.000 44.4 
2729 1 3 0.022 41.6 
2730 2 3 0.039 43.2 
2731 2 3 0.026 47.4 
2732 2 3 0.018 42.8 
2733 2 3 0.000 46.8 
2734 2 3 0.013 52.0 
2735 2 3 0.038 30.4 
2736 2 3 0.005 38.8 
2737 2 3 0.000 46.4 
2738 2 3 0.000 36.4 
2739 2 3 0.000 38.2 
2740 2 3 0.000 49.2 
2741 2 3 0.000 43.8 
2742 2 3 0.000 42.4 
2743 2 3 0.001 44.8 
2744 2 3 0.026 34.8 
2745 2 3 0.014 50.5 
2746 2 3 0.011 41.2 
2747 2 3 0.000 44.4 
2748 2 3 0.011 36.8 
2749 2 3 0.003 39.4 
2750 2 3 0.048 40.2 
2751 2 3 0.000 34.8 
2752 2 3 0.009 39.0 
2753 2 3 0.003 41.6 
2754 2 3 0.000 40.6 
2755 2 3 0.010 44.4 
2756 2 3 0.005 45.2 
2757 2 3 0.022 40.6 
2758 2 3 0.000 40.2 
2759 2 3 0.000 41.0 
2760 3 3 0.000 39.4 
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2761 3 3 0.014 42.6 
2762 3 3 0.000 37.0 
2763 3 3 0.022 39.8 
2764 3 3 0.018 41.2 
2765 3 3 0.000 37.8 
2766 3 3 0.000 40.6 
2767 3 3 0.000 43.2 
2768 3 3 0.005 43.2 
2769 3 3 0.000 38.8 
2770 3 3 0.000 43.8 
2771 3 3 0.015 41.4 
2772 3 3 0.017 40.8 
2773 3 3 0.012 37.6 
2774 3 3 0.009 46.6 
2775 3 3 0.012 32.0 
2776 3 3 0.042 37.8 
2777 3 3 0.004 41.4 
2778 3 3 0.011 44.6 
2779 3 3 0.000 38.0 
2780 3 3 0.026 41.8 
2781 3 3 0.040 39.2 
2782 3 3 0.011 37.6 
2783 3 3 0.010 35.0 
2784 3 3 0.000 40.8 
2785 3 3 0.050 42.4 
2786 3 3 0.028 41.0 
2787 3 3 0.000 36.2 
2788 3 3 0.005 44.4 
2789 3 3 0.000 40.2 
2790 4 3 0.000 37.8 
2791 4 3 0.000 36.8 
2792 4 3 0.000 32.4 
2793 4 3 0.000 34.2 
2794 4 3 0.006 39.0 
2795 4 3 0.001 40.2 
2796 4 3 0.000 36.2 
2797 4 3 0.000 34.4 
2798 4 3 0.000 41.4 
2799 4 3 0.002 36.4 
2800 4 3 0.001 37.0 
2801 4 3 0.000 33.2 
2802 4 3 0.022 36.4 
2803 4 3 0.009 40.6 
2804 4 3 0.002 36.6 
2805 4 3 0.000 41.0 
2806 4 3 0.005 35.4 
2807 4 3 0.020 38.2 
2808 4 3 0.013 44.4 
2809 4 3 0.000 35.4 
2810 4 3 0.007 38.6 
2811 4 3 0.000 40.2 
2812 4 3 0.021 43.4 
2813 4 3 0.000 37.4 
2814 4 3 0.000 34.0 
2815 4 3 0.029 31.0 
2816 4 3 0.000 47.0 
2817 4 3 0.000 39.2 
2818 4 3 0.000 40.0 
2819 4 3 0.000 33.0 
2700 1 6 0.000 51.5 
2701 1 6 0.000 49.4 
2702 1 6 0.001 44.0 
2703 1 6 0.000 47.6 
2704 1 6 0.000 63.0 
2705 1 6 0.000 49.0 
2706 1 6 0.004 42.4 
2707 1 6 0.000 39.6 
2708 1 6 0.000 43.6 
2709 1 6 0.018 49.2 
2710 1 6 0.037 41.8 
2711 1 6 0.000 35.8 
2712 1 6 0.000 39.4 
2713 1 6 0.000 32.8 
2714 1 6 0.008 40.4 
2715 1 6 0.010 40.8 
2716 1 6 0.006 37.8 
2717 1 6 0.002 44.8 
2718 1 6 0.011 48.2 
2719 1 6 0.014 50.0 
2720 1 6 0.006 64.0 
2721 1 6 0.000 41.2 
2722 1 6 0.018 45.8 
2723 1 6 0.003 42.0 
2724 1 6 0.025 48.0 
2725 1 6 0.030 51.5 
2726 1 6 0.009 47.0 
2727 1 6 0.004 59.0 
2728 1 6 0.000 46.6 
2729 1 6 0.012 43.2 
2730 2 6 0.009 41.8 
2731 2 6 0.035 58.0 
2732 2 6 . . 
2733 2 6 0.007 51.5 
2734 2 6 0.009 62.5 
2735 2 6 0.005 35.4 
2736 2 6 0.000 45.0 
2737 2 6 0.000 50.0 
2738 2 6 0.000 35.0 
2739 2 6 0.000 46.6 
2740 2 6 0.000 61.0 
2741 2 6 0.000 50.5 
2742 2 6 0.018 49.8 
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2743 2 6 0.000 48.6 
2744 2 6 0.016 32.0 
2745 2 6 0.031 52.0 
2746 2 6 0.024 53.5 
2747 2 6 0.008 53.5 
2748 2 6 . . 
2749 2 6 0.050 46.6 
2750 2 6 0.010 46.0 
2751 2 6 0.000 45.0 
2752 2 6 0.003 47.6 
2753 2 6 0.000 52.5 
2754 2 6 0.000 47.8 
2755 2 6 0.000 46.0 
2756 2 6 0.023 47.4 
2757 2 6 0.023 45.0 
2758 2 6 0.000 47.4 
2759 2 6 0.000 40.8 
2760 3 6 0.007 42.0 
2761 3 6 0.009 44.8 
2762 3 6 0.010 39.8 
2763 3 6 0.080 39.2 
2764 3 6 0.000 49.0 
2765 3 6 0.000 38.2 
2766 3 6 0.000 45.4 
2767 3 6 0.000 47.8 
2768 3 6 0.000 46.8 
2769 3 6 0.003 39.2 
2770 3 6 0.000 42.0 
2771 3 6 0.022 42.8 
2772 3 6 0.019 40.4 
2773 3 6 0.019 33.4 
2774 3 6 0.005 45.2 
2775 3 6 0.010 37.8 
2776 3 6 0.011 40.3 
2777 3 6 0.010 44.4 
2778 3 6 0.024 46.0 
2779 3 6 0.000 37.0 
2780 3 6 0.067 44.2 
2781 3 6 0.049 45.8 
2782 3 6 . . 
2783 3 6 0.019 38.0 
2784 3 6 0.030 43.4 
2785 3 6 0.017 48.4 
2786 3 6 0.011 42.6 
2787 3 6 0.011 36.6 
2788 3 6 0.002 46.6 
2789 3 6 0.000 47.8 
2790 4 6 0.000 42.4 
2791 4 6 0.000 44.4 
2792 4 6 0.000 35.0 
2793 4 6 0.000 33.2 
2794 4 6 . . 
2795 4 6 0.000 46.6 
2796 4 6 0.000 36.0 
2797 4 6 0.000 35.8 
2798 4 6 0.000 48.6 
2799 4 6 0.000 38.6 
2800 4 6 0.000 46.2 
2801 4 6 0.003 38.4 
2802 4 6 0.013 35.6 
2803 4 6 0.001 39.4 
2804 4 6 0.006 37.2 
2805 4 6 0.001 48.4 
2806 4 6 0.037 40.2 
2807 4 6 0.007 38.4 
2808 4 6 0.011 48.0 
2809 4 6 0.000 38.8 
2810 4 6 0.000 43.8 
2811 4 6 0.000 40.2 
2812 4 6 0.009 43.0 
2813 4 6 0.002 38.8 
2814 4 6 0.000 43.0 
2815 4 6 0.000 28.2 
2816 4 6 0.000 47.6 
2817 4 6 0.000 36.0 
2818 4 6 0.000 42.6 




































































































































































Figure B-17: Immune responses elicited by ostriches that received 10
9
 c.f.u./ml of Salmonella enterica serovar typhimurium SL3261 control 
 

















































































































































Figure B.18.: Immune responses elicited by ostriches that received 10
9
 c.f.u./ml of the mucosal VR1020 recombinant vaccine  
 

















































































































































Figure B.19.: Immune responses elicited by ostriches that received 100 µg/ml of the intramuscular VR1020 recombinant vaccine 
 



















































































































































Figure B.20.: Immune responses elicited by ostriches in the control group that received no vaccinations 
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Mucosal immune response of ostriches against Salmonella entrica serovar typhimurium 
SL3261 LPS  
The mucosal immune response of the ostriches against Salmonella entrica serovar typhimurium 
SL3261 LPS was evaluated using ELISA as described in chapter 4.2.3.5 using the swab samples 
collected and rabbit anti-ostrich IgA protein 2 as the biotinylated secondary antibody. An ANOVA 
was performed using the Statistical Analysis program Agrobase Generation II® (Agronomix 
Software Inc.). 
                   A N A L Y S I S   O F   V A R I A N C E                       
Swab – LPS – IgA Protein 2 
Oudsthoorn 
Variable: RESP 
      
Source df SS MS F-value Pr>F 
Total 359 0.114 
   
Treatment (Treatment) 3 0.005 0.002 5.66 0.0008 
Time (Time) 2 0.001 0.000 0.83 0.4364 
Treatment x Time  6 0.002 0.000 0.88 0.5118 
Residual 348 0.107 0.000 
  
Grand mean = 0.009 R-squared = 0.0643 C.V. = 200.9% 
 
      
LSD for Treatment = 0.0051 S.E.D = 0.0026  r = 90 
 
t (2-sided a=0.050, 348 df) = 1.9668 MSE = 0.00031 
   
 
     
Treatment 
    
 Averages 
     
Level --- Y --- Cv Rank Group 
 
3 0.02 163.4 1 VR1020 Plasmid 
 
4 0.01 284.6 2 Control 
 1 0.01 151.4 3 Salmonella  Control 
 2 0.01 145.6 4 Salmonella + VR1020 
 
      LSD for Time = 0.0044 S.E.D = 0.0023 r = 120 
 
t (2-sided a=0.050, 348 df) = 1.9668 MSE = 0.00031 
  
 
     
Time 
     
Averages 
     
Level --- Y --- Cv Rank Week 
 
2 0.01 204.4 1 3 
 
1 0.01 193.5 2 0 
 
3 0.01 212.3 3 6 
 
      
LSD for Treatment*Time = 0.0089 S.E.D = 0.0045 r = 30 
 
t (2-sided a=0.050, 348 df) = 1.9668 MSE = 0.00031 
   
 
     
 Two-way table for Treatment*Time, n=30                                             
  
  1 2 3 
  
1 0.007 0.008 0.005 
  
2 0.006 0.006 0.004 
  
3 0.016 0.013 0.016 
  
4 0.006 0.013 0.003 
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The following table the data is arranged in two columns with the ostrich identification number, 
Treatment received (Trt), Time in weeks, the response as measured by ELISA and weights of the 
ostriches, read from the top to the bottom and left to right. The Treatments consist of Salmonella 
enterica serovar typhimurium SL3261 control (1), mucosal VR1020 recombinant vaccine (2), 
intramuscular injected VR1020 recombinant vaccine (3) and the control group that received no 
vaccinations (4). Following the data are the graphs drawn for each ostrich depicting the immune 
response measured over time. 
 
Ostrich Trt Time Resp Weight 
2700 1 0 0.011 46.6 
2701 1 0 0.000 45.0 
2702 1 0 0.009 43.0 
2703 1 0 0.000 38.0 
2704 1 0 0.000 49.0 
2705 1 0 0.000 50.0 
2706 1 0 0.000 39.0 
2707 1 0 0.000 40.0 
2708 1 0 0.003 48.0 
2709 1 0 0.008 43.0 
2710 1 0 0.017 38.0 
2711 1 0 0.000 39.0 
2712 1 0 0.000 39.0 
2713 1 0 0.015 36.0 
2714 1 0 0.006 34.0 
2715 1 0 0.011 39.0 
2716 1 0 0.009 42.0 
2717 1 0 0.000 46.0 
2718 1 0 0.021 39.0 
2719 1 0 0.036 45.0 
2720 1 0 0.012 51.0 
2721 1 0 0.003 40.0 
2722 1 0 0.005 39.0 
2723 1 0 0.002 42.0 
2724 1 0 0.001 43.0 
2725 1 0 0.013 43.0 
2726 1 0 0.010 39.0 
2727 1 0 0.006 49.0 
2728 1 0 0.006 47.0 
2729 1 0 0.011 39.8 
2730 2 0 0.007 44.1 
2731 2 0 0.011 46.0 
2732 2 0 0.000 41.0 
2733 2 0 0.008 45.0 
2734 2 0 0.009 47.0 
2735 2 0 0.007 35.0 
2736 2 0 0.004 40.0 
2737 2 0 0.001 41.0 
2738 2 0 0.000 34.0 
2739 2 0 0.000 38.0 
2740 2 0 0.000 48.0 
2741 2 0 0.007 40.0 
2742 2 0 0.000 42.0 
2743 2 0 0.010 46.0 
2744 2 0 0.000 36.0 
2745 2 0 0.008 49.0 
2746 2 0 0.000 41.0 
2747 2 0 0.013 43.0 
2748 2 0 0.022 41.0 
2749 2 0 0.000 36.0 
2750 2 0 0.000 38.0 
2751 2 0 0.000 39.0 
2752 2 0 0.002 40.0 
2753 2 0 0.002 42.0 
2754 2 0 0.000 44.0 
2755 2 0 0.042 44.0 
2756 2 0 0.018 43.0 
2757 2 0 0.000 38.0 
2758 2 0 0.013 36.0 
2759 2 0 0.003 43.0 
2760 3 0 0.012 40.0 
2761 3 0 0.001 40.0 
2762 3 0 0.127 38.0 
2763 3 0 0.000 43.0 
2764 3 0 0.017 41.0 
2765 3 0 0.001 37.0 
2766 3 0 0.000 44.0 
2767 3 0 0.003 40.0 
2768 3 0 0.000 39.0 
2769 3 0 0.000 39.0 
2770 3 0 0.000 37.0 
2771 3 0 0.000 48.0 
2772 3 0 0.005 37.0 
2773 3 0 0.004 37.0 
2774 3 0 0.005 43.0 
2775 3 0 0.000 39.0 
2776 3 0 0.000 37.0 
2777 3 0 0.000 39.0 
2778 3 0 0.000 41.0 
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2779 3 0 0.045 37.0 
2780 3 0 0.074 40.0 
2781 3 0 0.037 39.0 
2782 3 0 0.015 39.0 
2783 3 0 0.017 40.0 
2784 3 0 0.034 41.0 
2785 3 0 0.064 41.0 
2786 3 0 0.026 41.0 
2787 3 0 0.005 39.0 
2788 3 0 0.000 39.0 
2789 3 0 0.000 39.0 
2790 4 0 0.000 38.0 
2791 4 0 0.000 40.0 
2792 4 0 0.000 36.0 
2793 4 0 0.000 38.0 
2794 4 0 0.009 39.0 
2795 4 0 0.000 37.0 
2796 4 0 0.000 40.0 
2797 4 0 0.000 37.0 
2798 4 0 0.000 36.0 
2799 4 0 0.000 36.0 
2800 4 0 0.000 37.0 
2801 4 0 0.000 37.0 
2802 4 0 0.001 36.0 
2803 4 0 0.000 37.0 
2804 4 0 0.011 35.0 
2805 4 0 0.000 43.0 
2806 4 0 0.007 38.0 
2807 4 0 0.016 38.0 
2808 4 0 0.015 45.0 
2809 4 0 0.011 37.0 
2810 4 0 0.000 38.0 
2811 4 0 0.000 38.0 
2812 4 0 0.000 40.0 
2813 4 0 0.035 38.0 
2814 4 0 0.000 37.0 
2815 4 0 0.007 36.0 
2816 4 0 0.000 42.0 
2817 4 0 0.009 37.0 
2818 4 0 0.022 36.0 
2819 4 0 0.008 35.0 
2700 1 3 0.000 50.5 
2701 1 3 0.008 45.4 
2702 1 3 0.010 43.0 
2703 1 3 0.000 40.6 
2704 1 3 0.000 55.5 
2705 1 3 0.000 46.0 
2706 1 3 0.000 39.2 
2707 1 3 0.000 37.8 
2708 1 3 0.001 42.0 
2709 1 3 0.013 44.8 
2710 1 3 0.074 40.2 
2711 1 3 0.000 35.2 
2712 1 3 0.000 37.2 
2713 1 3 0.015 33.6 
2714 1 3 0.005 34.4 
2715 1 3 0.009 35.0 
2716 1 3 0.012 35.6 
2717 1 3 0.000 39.8 
2718 1 3 0.025 43.8 
2719 1 3 0.012 44.6 
2720 1 3 0.012 56.5 
2721 1 3 0.010 39.2 
2722 1 3 0.010 43.6 
2723 1 3 0.003 40.2 
2724 1 3 0.001 42.8 
2725 1 3 0.011 45.4 
2726 1 3 0.005 40.8 
2727 1 3 0.005 49.6 
2728 1 3 0.005 44.4 
2729 1 3 0.016 41.6 
2730 2 3 0.014 43.2 
2731 2 3 0.011 47.4 
2732 2 3 0.000 42.8 
2733 2 3 0.002 46.8 
2734 2 3 0.007 52.0 
2735 2 3 0.021 30.4 
2736 2 3 0.007 38.8 
2737 2 3 0.000 46.4 
2738 2 3 0.000 36.4 
2739 2 3 0.000 38.2 
2740 2 3 0.000 49.2 
2741 2 3 0.003 43.8 
2742 2 3 0.000 42.4 
2743 2 3 0.006 44.8 
2744 2 3 0.007 34.8 
2745 2 3 0.009 50.5 
2746 2 3 0.000 41.2 
2747 2 3 0.009 44.4 
2748 2 3 0.020 36.8 
2749 2 3 0.003 39.4 
2750 2 3 0.000 40.2 
2751 2 3 0.003 34.8 
2752 2 3 0.009 39.0 
2753 2 3 0.011 41.6 
2754 2 3 0.000 40.6 
2755 2 3 0.043 44.4 
2756 2 3 0.014 45.2 
2757 2 3 0.000 40.6 
2758 2 3 0.004 40.2 
2759 2 3 0.000 41.0 
2760 3 3 0.014 39.4 
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2761 3 3 0.018 42.6 
2762 3 3 0.024 37.0 
2763 3 3 0.025 39.8 
2764 3 3 0.038 41.2 
2765 3 3 0.000 37.8 
2766 3 3 0.000 40.6 
2767 3 3 0.002 43.2 
2768 3 3 0.000 43.2 
2769 3 3 0.000 38.8 
2770 3 3 0.000 43.8 
2771 3 3 0.002 41.4 
2772 3 3 0.005 40.8 
2773 3 3 0.004 37.6 
2774 3 3 0.010 46.6 
2775 3 3 0.000 32.0 
2776 3 3 0.001 37.8 
2777 3 3 0.004 41.4 
2778 3 3 0.003 44.6 
2779 3 3 0.030 38.0 
2780 3 3 0.048 41.8 
2781 3 3 0.034 39.2 
2782 3 3 0.054 37.6 
2783 3 3 0.008 35.0 
2784 3 3 0.041 40.8 
2785 3 3 0.043 42.4 
2786 3 3 0.018 41.0 
2787 3 3 0.004 36.2 
2788 3 3 0.000 44.4 
2789 3 3 0.000 40.2 
2790 4 3 0.000 37.8 
2791 4 3 0.000 36.8 
2792 4 3 0.002 32.4 
2793 4 3 0.000 34.2 
2794 4 3 0.132 39.0 
2795 4 3 0.000 40.2 
2796 4 3 0.000 36.2 
2797 4 3 0.000 34.4 
2798 4 3 0.000 41.4 
2799 4 3 0.000 36.4 
2800 4 3 0.000 37.0 
2801 4 3 0.000 33.2 
2802 4 3 0.003 36.4 
2803 4 3 0.000 40.6 
2804 4 3 0.001 36.6 
2805 4 3 0.000 41.0 
2806 4 3 0.005 35.4 
2807 4 3 0.019 38.2 
2808 4 3 0.009 44.4 
2809 4 3 0.028 35.4 
2810 4 3 0.003 38.6 
2811 4 3 0.003 40.2 
2812 4 3 0.000 43.4 
2813 4 3 0.019 37.4 
2814 4 3 0.000 34.0 
2815 4 3 0.017 31.0 
2816 4 3 0.000 47.0 
2817 4 3 0.022 39.2 
2818 4 3 0.139 40.0 
2819 4 3 0.000 33.0 
2700 1 6 0.000 51.5 
2701 1 6 0.000 49.4 
2702 1 6 0.003 44.0 
2703 1 6 0.000 47.6 
2704 1 6 0.000 63.0 
2705 1 6 0.000 49.0 
2706 1 6 0.000 42.4 
2707 1 6 0.001 39.6 
2708 1 6 0.013 43.6 
2709 1 6 0.000 49.2 
2710 1 6 0.016 41.8 
2711 1 6 0.001 35.8 
2712 1 6 0.000 39.4 
2713 1 6 0.000 32.8 
2714 1 6 0.001 40.4 
2715 1 6 0.010 40.8 
2716 1 6 0.017 37.8 
2717 1 6 0.000 44.8 
2718 1 6 0.005 48.2 
2719 1 6 0.014 50.0 
2720 1 6 0.006 64.0 
2721 1 6 0.014 41.2 
2722 1 6 0.011 45.8 
2723 1 6 0.000 42.0 
2724 1 6 0.002 48.0 
2725 1 6 0.009 51.5 
2726 1 6 0.002 47.0 
2727 1 6 0.022 59.0 
2728 1 6 0.011 46.6 
2729 1 6 0.014 43.2 
2730 2 6 0.000 41.8 
2731 2 6 0.006 58.0 
2732 2 6 . . 
2733 2 6 0.019 51.5 
2734 2 6 0.000 62.5 
2735 2 6 0.006 35.4 
2736 2 6 0.000 45.0 
2737 2 6 0.002 50.0 
2738 2 6 0.001 35.0 
2739 2 6 0.000 46.6 
2740 2 6 0.000 61.0 
2741 2 6 0.000 50.5 
2742 2 6 0.000 49.8 
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2743 2 6 0.003 48.6 
2744 2 6 0.000 32.0 
2745 2 6 0.008 52.0 
2746 2 6 0.003 53.5 
2747 2 6 0.000 53.5 
2748 2 6 . . 
2749 2 6 0.005 46.6 
2750 2 6 0.009 46.0 
2751 2 6 0.007 45.0 
2752 2 6 0.018 47.6 
2753 2 6 0.010 52.5 
2754 2 6 0.000 47.8 
2755 2 6 0.014 46.0 
2756 2 6 0.010 47.4 
2757 2 6 0.014 45.0 
2758 2 6 0.000 47.4 
2759 2 6 0.000 40.8 
2760 3 6 0.023 42.0 
2761 3 6 0.015 44.8 
2762 3 6 0.002 39.8 
2763 3 6 0.031 39.2 
2764 3 6 0.005 49.0 
2765 3 6 0.000 38.2 
2766 3 6 0.000 45.4 
2767 3 6 0.000 47.8 
2768 3 6 0.000 46.8 
2769 3 6 0.000 39.2 
2770 3 6 0.000 42.0 
2771 3 6 0.003 42.8 
2772 3 6 0.000 40.4 
2773 3 6 0.022 33.4 
2774 3 6 0.012 45.2 
2775 3 6 0.000 37.8 
2776 3 6 0.000 40.3 
2777 3 6 0.000 44.4 
2778 3 6 0.008 46.0 
2779 3 6 0.040 37.0 
2780 3 6 0.057 44.2 
2781 3 6 0.064 45.8 
2782 3 6 . . 
2783 3 6 0.013 38.0 
2784 3 6 0.120 43.4 
2785 3 6 0.037 48.4 
2786 3 6 0.045 42.6 
2787 3 6 0.001 36.6 
2788 3 6 0.000 46.6 
2789 3 6 0.000 47.8 
2790 4 6 0.000 42.4 
2791 4 6 0.000 44.4 
2792 4 6 0.000 35.0 
2793 4 6 0.000 33.2 
2794 4 6 . . 
2795 4 6 0.000 46.6 
2796 4 6 0.000 36.0 
2797 4 6 0.000 35.8 
2798 4 6 0.000 48.6 
2799 4 6 0.000 38.6 
2800 4 6 0.000 46.2 
2801 4 6 0.000 38.4 
2802 4 6 0.005 35.6 
2803 4 6 0.000 39.4 
2804 4 6 0.002 37.2 
2805 4 6 0.006 48.4 
2806 4 6 0.008 40.2 
2807 4 6 0.009 38.4 
2808 4 6 0.011 48.0 
2809 4 6 0.001 38.8 
2810 4 6 0.000 43.8 
2811 4 6 0.000 40.2 
2812 4 6 0.007 43.0 
2813 4 6 0.006 38.8 
2814 4 6 0.010 43.0 
2815 4 6 0.000 28.2 
2816 4 6 0.000 47.6 
2817 4 6 0.009 36.0 
2818 4 6 0.014 42.6 




































































































































































Figure B.21: Immune responses elicited by ostriches that received 10
9
 c.f.u./ml of Salmonella enterica serovar typhimurium SL3261 control 
 


















































































































































Figure B.22.: Immune responses elicited by ostriches that received 10
9
 c.f.u./ml of the mucosal VR1020 recombinant vaccine  
 

















































































































































Figure B.23.: Immune responses elicited by ostriches that received 100 µg/ml of the intramuscular VR1020 recombinant vaccine 
 
















































































































































Figure B.24.: Immune responses elicited by ostriches in the control group that received no vaccinations 
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Addendum C: Statistical analysis of ELISA results of the dosing vaccine 
trial on Kromme Rhee farm in Stellenbosch, Western Cape 
Humoral immune response of ostriches against Mycoplasma struthionis 
The humoral immune response of the ostriches against the OppA protein was evaluated using 
ELISA as described in section 5.2.3. and the serum samples collected. An ANOVA was performed 
using the Statistical Analysis program Agrobase Generation II® (Agronomix Software Inc.). 
                   A N A L Y S I S   O F   V A R I A N C E                       
Serum - OppA 
Kromme Rhee 
Variable: RESP 
      
Source df SS MS F-value Pr>F 
Total 329 80.023 
   
Treatment 10 24.964 2.496 16.70 0.0000 
Time 5 7.998 1.600 10.70 0.0000 
Treatment x Time  50 7.607 0.152 1.020 0.4476 
Residual 264 39.454 0.149     
Grand mean = 0.708 R-squared = 0.5070 C.V. = 54.60% 
 
      
LSD for Treatment = 0.1965 S.E.D = 0.0998  r = 30 
 
t (2-sided a=0.050, 264 df) = 1.9690 
 
MSE = 0.14945 
   
 
     
Treatment 
     
Averages 
     
Level --- Y --- Cv Rank Group 
 
9 1.24 31.1 1 VR1020 10^11 
 
10 0.96 64.5 2 VR1020 10^12 
 
8 0.91 60 3 VR1020 10^10 
 
6 0.88 43 4 Control 
 
11 0.77 76 5 VR1020 10^13 
 
7 0.74 62.6 6 VR1020 10^9 
 
5 0.73 50.8 7 VR1012 10^13 
 
3 0.47 60.8 8 VR1012 10^11 
 4 0.41 58.2 9 VR1012 10^12 
 1 0.36 54.2 10 VR1012 10^9 
 2 0.31 76.2 11 VR1012 10^10 
 
      LSD for Time = 0.1452 
 
S.E.D = 0.0737 r = 55 
 
t (2-sided a=0.050, 264 df) = 1.9690 
 
MSE = 0.14945 
   
 
     
Time 
     
Averages 
     
Level --- Y --- Cv Rank Week 
 
1 0.88 54.1 1 0 
 
2 0.86 61.6 2 1 
 
4 0.78 67.8 3 3 
 
3 0.74 65.1 4 2 
 
5 0.51 79.7 5 6 
 
6 0.49 80.9 6 9 
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LSD for Treatment*Time = 0.4814 
 
S.E.D = 0.2445 r = 5 
 
t (2-sided a=0.050, 264 df) = 1.9690 
 
MSE = 0.14945 
   
 
     
 Two-way table for Treatment*Time, n=5                                             
  
 
1 2 3 4 5 6 
1 0.462 0.292 0.334 0.462 0.264 0.368 
2 0.446 0.224 0.284 0.386 0.248 0.3 
3 0.472 0.476 0.436 0.438 0.582 0.426 
4 0.438 0.402 0.38 0.548 0.378 0.342 
5 0.878 1.01 0.692 0.706 0.624 0.496 
6 0.92 1.138 1.136 1.064 0.54 0.5 
7 0.966 1.074 0.892 0.73 0.392 0.38 
8 1.222 1.158 1.1 1.092 0.354 0.51 
9 1.326 1.476 1.152 1.372 1.09 1.01 
10 1.078 1.226 1.116 1.11 0.732 0.472 
11 1.422 0.954 0.67 0.632 0.37 0.56 
 
1 2 3 4 5 6 
 
                   A N A L Y S I S   O F   V A R I A N C E                       
Variable: WEIGHT 
      
Source df SS MS F-value Pr>F 
Total 329 194151.1 
   
Treatment  10 1971.853 197.185 1.75 0.0705 
Time  5 157582.3 31546.45 279.33 0.0000 
Treatment x Time  50 4810.577 96.212 0.85 0.7473 
Residual 264 29786.42 112.827     
Grand mean = 21.664 
 
R-squared = 0.8466 
 
C.V. = 49.03% 
 
      
LSD for Treatment = 5.4001 S.E.D = 2.7426 r = 30 
 
t (2-sided a=0.050, 264 df) = 1.9690 
 
MSE = 112.82733 
   
      
Treatment 
     
Averages 
     
Level --- Y --- Cv Rank Group 
 
6 25.24 103.2 1 Control 
 
9 24.26 102.9 2 VR1020 10^11 
 
8 26.93 110.4 3 VR1020 10^10 
 
4 22.93 104 4 VR1020 10^12 
 
5 22.9 109.6 5 VR1020 10^13 
 
1 21.79 110 6 VR1020 10^9 
 
3 21.07 109.7 7 VR1012 10^11 
 
10 20.53 118.5 8 VR1012 10^12 
 
7 20.32 126.5 9 VR1012 10^9 
 
2 18.8 126.3 10 VR1012 10^10 
 
11 16.53 135.8 11 VR1012 10^13 
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LSD for Time = 3.9883 S.E.D = 2.0255 r = 55 
 
t (2-sided a=0.050, 264 df) = 1.9690  MSE = 112.82733    
      
Time      
Averages      
Level --- Y --- Cv Rank Time  
1 48.98 6.2 1 0  
3 41.26 31.2 2 2  
6 39.74 56.4 3 9  
2 0.00 -9.0 4 1  
4 0.00 -9.0 5 3  
5 0.00 -9.0 6 6  
      
LSD for Treatment*Time = 13.2276 S.E.D = 6.718 r = 55  
t (2-sided a=0.050, 264 df) = 1.9690 MSE = 112.82733    
   
 Two-way table for Treatment*Time, n=30                                               
 1 2 3 4 5 6 
1 47.120 0.000 43.340 0.000 0.000 40.280 
2 47.280 0.000 34.520 0.000 0.000 31.000 
3 47.600 0.000 40.880 0.000 0.000 37.960 
4 47.640 0.000 44.060 0.000 0.000 45.900 
5 49.120 0.000 45.760 0.000 0.000 42.540 
6 53.440 0.000 47.820 0.000 0.000 50.160 
7 49.960 0.000 47.360 0.000 0.000 24.600 
8 50.400 0.000 46.560 0.000 0.000 46.600 
9 50.040 0.000 45.700 0.000 0.000 49.800 
10 48.440 0.000 34.240 0.000 0.000 40.520 
11 47.760 0.000 23.640 0.000 0.000 27.800 
 
The following table contains the input data for the ANOVA, and is arranged in two columns with the 
ostrich identification number, treatment received (Trt), Time in weeks, the response as measured 
by ELISA and weights of the ostriches, read from the top to the bottom and left to right. The 
treatments i.e. vaccine doses, consisted of VR1012 mucosal DNA vaccine administered at various 
doses; 1x109 c.f.u./ml (1), 1x1010 c.f.u./ml (2), 1x1011 c.f.u./ml (3), 1x1012 c.f.u./ml (4) and 1x1013 
c.f.u./ml (5); Salmonella enterica serovar typhimurium SL3261 control (6), VR1020 mucosal DNA 
vaccine administered at various doses; 1x109 c.f.u./ml (7), 1x1010 c.f.u./ml (8), 1x1011 c.f.u./ml (9), 
1x1012 c.f.u./ml (10) and 1x1013 c.f.u./ml (11). Following the data arethe graphs drawn for each 
ostrich depicting the absorbance measured over time.  
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Ostrich Trt Time Resp Weight 
2 1 0 0.560 44.6 
10 1 0 0.397 47.6 
12 1 0 0.346 50.4 
18 1 0 0.597 45.2 
19 1 0 0.402 47.8 
7 2 0 0.535 44.2 
9 2 0 0.028 46.8 
11 2 0 0.575 48.4 
13 2 0 0.402 50 
14 2 0 0.682 47 
48 3 0 0.153 48.6 
56 3 0 1.062 48 
57 3 0 0.439 47.6 
58 3 0 0.526 47.6 
59 3 0 0.184 46.2 
44 4 0 0.421 48.2 
45 4 0 0.676 46.6 
51 4 0 0.258 45.6 
52 4 0 0.464 46.8 
54 4 0 0.369 51 
23 5 0 1.107 51.6 
32 5 0 1.468 46.6 
35 5 0 0.614 50.4 
37 5 0 0.481 49.8 
40 5 0 0.721 47.2 
3 6 0 1.028 52.4 
20 6 0 1.141 52.4 
41 6 0 0.760 51.8 
47 6 0 0.510 54.8 
55 6 0 1.162 55.8 
53 6 0 0.534 55.4 
21 7 0 1.081 48.8 
24 7 0 0.667 50 
26 7 0 1.439 52.8 
31 7 0 0.803 47 
36 7 0 0.838 51.2 
25 8 0 2.159 48.2 
29 8 0 0.758 46.8 
30 8 0 1.081 50 
33 8 0 1.602 53.8 
89 8 0 0.511 53.2 
81 9 0 1.778 44 
82 9 0 1.688 50.8 
64 9 0 0.863 54 
88 9 0 1.354 50.6 
91 9 0 0.954 50.8 
74 10 0 1.075 55.6 
66 10 0 0.658 48.2 
71 10 0 1.268 44.8 
77 10 0 1.483 49 
79 10 0 0.904 44.6 
65 11 0 1.397 50.4 
69 11 0 1.402 50.6 
70 11 0 1.244 47.6 
76 11 0 1.533 44 
78 11 0 1.544 46.2 
2 1 1 0.213 . 
10 1 1 0.263 . 
12 1 1 0.349 . 
18 1 1 0.344 . 
19 1 1 0.295 . 
7 2 1 0.213 . 
9 2 1 . . 
11 2 1 0.263 . 
13 2 1 0.295 . 
14 2 1 0.349 . 
48 3 1 0.277 . 
56 3 1 0.772 . 
57 3 1 0.585 . 
58 3 1 0.485 . 
59 3 1 0.252 . 
44 4 1 0.344 . 
45 4 1 0.783 . 
51 4 1 0.195 . 
52 4 1 0.342 . 
54 4 1 0.347 . 
23 5 1 0.898 . 
32 5 1 1.596 . 
35 5 1 1.074 . 
37 5 1 0.635 . 
40 5 1 0.836 . 
3 6 1 1.039 . 
20 6 1 1.292 . 
41 6 1 0.598 . 
47 6 1 1.482 . 
55 6 1 1.280 . 
53 6 1 0.896 . 
21 7 1 1.278 . 
24 7 1 0.889 . 
26 7 1 1.133 . 
31 7 1 1.256 . 
36 7 1 0.805 . 
25 8 1 1.544 . 
29 8 1 0.858 . 
30 8 1 0.607 . 
33 8 1 1.797 . 
89 8 1 0.980 . 
81 9 1 1.141 . 
82 9 1 1.733 . 
64 9 1 1.152 . 
88 9 1 1.601 . 
91 9 1 1.760 . 
74 10 1 0.851 . 
66 10 1 0.898 . 
71 10 1 1.182 . 
77 10 1 2.249 . 
79 10 1 0.950 . 
65 11 1 . . 
69 11 1 1.232 . 
70 11 1 0.714 . 
76 11 1 1.301 . 
78 11 1 1.527 . 
2 1 2 0.370 41.8 
10 1 2 0.244 51.5 
12 1 2 0.555 47 
18 1 2 0.288 40.2 
19 1 2 0.206 36.2 
7 2 2 0.370 43.2 
9 2 2 . . 
11 2 2 0.244 44.4 
13 2 2 0.254 44.4 
14 2 2 0.555 40.6 
48 3 2 0.220 47 
56 3 2 0.683 40.6 
57 3 2 0.546 44.2 
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58 3 2 0.480 36 
59 3 2 0.247 36.6 
44 4 2 0.288 40 
45 4 2 0.649 39.8 
51 4 2 0.307 40 
52 4 2 0.375 58.5 
54 4 2 0.272 42 
23 5 2 0.762 47.6 
32 5 2 1.027 45 
35 5 2 0.665 47.8 
37 5 2 0.451 47 
40 5 2 0.552 41.4 
3 6 2 0.874 53 
20 6 2 1.357 47.4 
41 6 2 0.871 41.2 
47 6 2 1.532 47 
55 6 2 1.048 50.5 
53 6 2 1.153 47.2 
21 7 2 0.847 51 
24 7 2 1.277 55.5 
26 7 2 1.294 42.8 
31 7 2 0.489 35 
36 7 2 0.550 52.5 
25 8 2 1.399 34.6 
29 8 2 1.097 45 
30 8 2 0.814 48.2 
33 8 2 1.624 51 
89 8 2 0.566 54 
81 9 2 1.349 46.8 
82 9 2 1.314 46.2 
64 9 2 0.796 45.8 
88 9 2 1.147 52.5 
91 9 2 1.150 37.2 
74 10 2 1.443 49 
66 10 2 0.757 42.6 
71 10 2 . . 
77 10 2 2.117 39.2 
79 10 2 1.263 40.4 
65 11 2 . . 
69 11 2 1.129 40.6 
70 11 2 1.179 41.4 
76 11 2 1.043 36.2 
78 11 2 . . 
2 1 3 0.657 . 
10 1 3 0.290 . 
12 1 3 0.868 . 
18 1 3 0.305 . 
19 1 3 0.178 . 
7 2 3 0.633 . 
9 2 3 . . 
11 2 3 0.314 . 
13 2 3 0.220 . 
14 2 3 0.774 . 
48 3 3 0.204 . 
56 3 3 0.400 . 
57 3 3 0.937 . 
58 3 3 0.425 . 
59 3 3 0.220 . 
44 4 3 0.160 . 
45 4 3 0.793 . 
51 4 3 1.040 . 
52 4 3 0.554 . 
54 4 3 0.203 . 
23 5 3 0.752 . 
32 5 3 0.983 . 
35 5 3 0.463 . 
37 5 3 0.466 . 
40 5 3 0.869 . 
3 6 3 1.343 . 
20 6 3 1.309 . 
41 6 3 0.454 . 
47 6 3 1.016 . 
55 6 3 1.204 . 
53 6 3 0.989 . 
21 7 3 0.840 . 
24 7 3 1.118 . 
26 7 3 1.200 . 
31 7 3 . . 
36 7 3 0.492 . 
25 8 3 1.657 . 
29 8 3 1.041 . 
30 8 3 0.817 . 
33 8 3 1.405 . 
89 8 3 0.529 . 
81 9 3 0.966 . 
82 9 3 1.097 . 
64 9 3 1.257 . 
88 9 3 1.682 . 
91 9 3 1.846 . 
74 10 3 1.574 . 
66 10 3 0.626 . 
71 10 3 . . 
77 10 3 2.323 . 
79 10 3 1.029 . 
65 11 3 . . 
69 11 3 1.410 . 
70 11 3 0.749 . 
76 11 3 1.002 . 
78 11 3 . . 
2 1 6 0.354 . 
10 1 6 0.301 . 
12 1 6 0.473 . 
18 1 6 0.204 . 
19 1 6 . . 
7 2 6 0.354 . 
9 2 6 . . 
11 2 6 0.301 . 
13 2 6 0.118 . 
14 2 6 0.473 . 
48 3 6 0.185 . 
56 3 6 0.628 . 
57 3 6 1.139 . 
58 3 6 0.658 . 
59 3 6 0.287 . 
44 4 6 0.204 . 
45 4 6 0.847 . 
51 4 6 0.187 . 
52 4 6 0.499 . 
54 4 6 0.145 . 
23 5 6 . . 
32 5 6 0.689 . 
35 5 6 1.073 . 
37 5 6 0.655 . 
40 5 6 0.700 . 
3 6 6 0.688 . 
20 6 6 0.284 . 
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41 6 6 0.317 . 
47 6 6 0.680 . 
55 6 6 0.729 . 
53 6 6 0.705 . 
21 7 6 0.215 . 
24 7 6 0.794 . 
26 7 6 . . 
31 7 6 . . 
36 7 6 0.945 . 
25 8 6 . . 
29 8 6 0.516 . 
30 8 6 0.294 . 
33 8 6 0.560 . 
89 8 6 0.396 . 
81 9 6 1.243 . 
82 9 6 0.481 . 
64 9 6 0.579 . 
88 9 6 1.517 . 
91 9 6 1.626 . 
74 10 6 0.639 . 
66 10 6 0.592 . 
71 10 6 . . 
77 10 6 1.404 . 
79 10 6 1.029 . 
65 11 6 . . 
69 11 6 0.853 . 
70 11 6 0.454 . 
76 11 6 0.548 . 
78 11 6 . . 
2 1 9 0.524 48 
10 1 9 0.205 59 
12 1 9 0.774 47.8 
18 1 9 0.337 46.6 
19 1 9 . . 
7 2 9 0.524 39 
9 2 9 . . 
11 2 9 0.205 63 
13 2 9 . . 
14 2 9 0.774 53 
48 3 9 0.214 53 
56 3 9 0.337 44.4 
57 3 9 0.805 44.4 
58 3 9 0.766 48 
59 3 9 . . 
44 4 9 0.337 39.2 
45 4 9 0.522 51.5 
51 4 9 0.100 39.4 
52 4 9 0.649 61 
54 4 9 0.098 38.4 
23 5 9 . . 
32 5 9 1.259 49.8 
35 5 9 0.666 53 
37 5 9 0.383 48.4 
40 5 9 0.173 61.5 
3 6 9 0.795 44.8 
20 6 9 0.332 38.6 
41 6 9 0.335 55 
47 6 9 0.653 64 
55 6 9 0.381 48.4 
53 6 9 . . 
21 7 9 . . 
24 7 9 0.854 63 
26 7 9 . . 
31 7 9 . . 
36 7 9 1.054 60 
25 8 9 . . 
29 8 9 0.329 59 
30 8 9 0.789 54 
33 8 9 0.991 60.5 
89 8 9 0.438 59.5 
81 9 9 1.313 43.4 
82 9 9 1.271 57.5 
64 9 9 0.641 42.6 
88 9 9 0.594 53 
91 9 9 1.239 52.5 
74 10 9 0.582 57.5 
66 10 9 0.376 62.5 
71 10 9 . . 
77 10 9 0.801 39 
79 10 9 0.602 43.6 
65 11 9 . . 
69 11 9 0.820 52 
70 11 9 1.313 54 
76 11 9 0.672 33 




































































































































































Figure C.1: Humoral immune responses elicited in ostriches during the dosing vaccine trial at Kromme Rhee farm in Stellenbosch, Western Cape. Various doses 
of the mucosal vaccines were evaluated. A. 10
9
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine, B. 10
10
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine, 
C. 10
11
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine, D. Received a 10
12
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine. 
 












































































































































Figure C.2: Humoral immune responses elicited in ostriches during the dosing vaccine trial at Kromme Rhee farm in Stellenbosch, Western Cape. Various doses 
of the mucosal vaccines were evaluated. A. 10
13
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine, B. Control group, C. 10
9
 c.f.u./ml dose of the VR1020 
mucosal DNA vaccine, D. Received a 10
10
 c.f.u./ml dose of the VR1020 mucosal DNA vaccine. 
 

















































































































Figure C.3: Humoral immune responses elicited in ostriches during the dosing vaccine trial at Kromme Rhee farm in Stellenbosch, Western Cape. Various doses 
of the mucosal vaccines were evaluated. A. 10
11
 c.f.u./ml dose of the VR1020 mucosal DNA vaccine, B. 10
12
 c.f.u./ml dose of the VR1020 mucosal DNA vaccine, 
C. 10
13
 c.f.u./ml dose of the VR1020 mucosal DNA vaccine. 
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Mucosal immune response of ostriches against Mycoplasma struthionis  
The mucosal immune response of ostriches against the OppA protein was evaluated using ELISA 
as described in section 5.2.3, using the secondary antibody rabbit anti-ostrich IgA protein 1. An 
ANOVA was performed using the Statistical Analysis program Agrobase Generation II® 
(Agronomix Software Inc.). 
                   A N A L Y S I S   O F   V A R I A N C E                       
Swab – OppA – IgA Protein 1 
Kromme Rhee 
Variable: RESP 
      
Source df SS MS F-value Pr>F 
Total 329 0.021 
   
Treatment 10 0.002 0.000 2.83 0.0023 
Time 5 0.000 0.000 0.37 0.8674 
Treatment x Time  50 0.003 0.000 0.91 0.6448 
Residual 264 0.016 0.000 
  
Grand mean = 0.003 R-squared = 0.2230 C.V. = 266.50% 
 
      
LSD for Treatment = 0.004 S.E.D = 0.0020  r = 30 
 
t (2-sided a=0.050, 264 df) = 1.9690 
 
MSE = 0.00006 
   
 
     
Treatment 
     
Averages 
     
Level --- Y --- Cv Rank Group 
 
6 0.01 243.5 1 Control 
 
9 0.01 173.4 2 VR1020 10^11 
 
7 0.01 212.6 3 VR1020 10^9 
 
4 0.00 124.6 4 VR1012 10^12 
 
3 0.00 178.3 5 VR1012 10^11 
 
10 0.00 243.6 6 VR1020 10^12 
 
5 0.00 242.1 7 VR1012 10^13 
 
11 0.00 325.6 8 VR1020 10^13 
 8 0.00 380.6 9 VR1020 10^10 
 2 0.00 547.7 10 VR1012 10^10 
 1 0.00 -9.0 11 VR1012 10^9 
 
      LSD for Time = 0.0029 
 
S.E.D = 0.0015 r = 55 
 
t (2-sided a=0.050, 264 df) = 1.9690 
 
MSE = 0.00006 
   
 
     
Time 
     
Averages 
     
Level --- Y --- Cv Rank Week 
 
4 0 312.7 1 3 
 
5 0 226.8 2 6 
 
3 0 249 3 2 
 
6 0 205.2 4 9 
 
1 0 274.9 5 0 
 
2 0 314.2 6 1 
 
      
      
      
LSD for Treatment*Time = 0.0098 
 
S.E.D = 0.0050 r = 5 
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t (2-sided a=0.050, 264 df) = 1.9690 
 
MSE = 0.00006 
   
   
 Two-way table for Treatment*Time, n=5                                             
  
 
1 2 3 4 5 6 
1 0.000 0.000 0.000 0.000 0.000 0.000 
2 0.000 0.000 0.000 0.002 0.000 0.000 
3 0.000 0.000 0.004 0.006 0.004 0.004 
4 0.004 0.002 0.006 0.004 0.004 0.004 
5 0.000 0.000 0.006 0.004 0.002 0.000 
6 0.004 0.004 0.000 0.016 0.010 0.004 
7 0.012 0.014 0.008 0.000 0.000 0.002 
8 0.000 0.000 0.000 0.000 0.002 0.002 
9 0.002 0.004 0.002 0.008 0.014 0.008 
10 0.002 0.000 0.002 0.000 0.004 0.006 
11 0.004 0.000 0.002 0.002 0.000 0.000 
 
The following table contains the input data for the ANOVA and is arranged in two columns with the 
ostrich identification number, treatment received (Trt), Time in weeks, the response as measured 
by ELISA and weights of the ostriches, read from the top to the bottom and left to right. The 
treatments consist of VR1012 mucosal DNA vaccine administered at various doses; 1x109 c.f.u./ml 
(1), 1x1010 c.f.u./ml (2), 1x1011 c.f.u./ml (3), 1x1012 c.f.u./ml (4) and 1x1013 c.f.u./ml (5); Salmonella 
enterica serovar typhimurium SL3261 control (6), VR1020 naked DNA vaccine administered at 
various doses; 1x109 c.f.u./ml (7), 1x1010 c.f.u./ml (8), 1x1011 c.f.u./ml (9), 1x1012 c.f.u./ml (10) and 
1x1013 c.f.u./ml (11). Following the data are the graphs drawn for each ostrich depicting the 
absorbance measured over time.  
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Ostrich Trt Time Resp Weight 
2 1 0 0.000 44.6 
10 1 0 0.000 47.6 
12 1 0 0.000 50.4 
18 1 0 0.000 45.2 
19 1 0 0.000 47.8 
7 2 0 0.002 44.2 
9 2 0 0.000 46.8 
11 2 0 0.000 48.4 
13 2 0 0.000 50 
14 2 0 0.000 47 
48 3 0 0.000 48.6 
56 3 0 0.000 48 
57 3 0 0.000 47.6 
58 3 0 0.004 47.6 
59 3 0 0.004 46.2 
44 4 0 0.006 48.2 
45 4 0 0.003 46.6 
51 4 0 0.009 45.6 
52 4 0 0.000 46.8 
54 4 0 0.003 51 
23 5 0 0.002 51.6 
32 5 0 0.000 46.6 
35 5 0 0.000 50.4 
37 5 0 0.000 49.8 
40 5 0 0.000 47.2 
3 6 0 0.000 52.4 
20 6 0 0.000 52.4 
41 6 0 0.008 51.8 
47 6 0 0.000 54.8 
55 6 0 0.009 55.8 
53 6 0 0.000 55.4 
21 7 0 0.000 48.8 
24 7 0 0.000 50 
26 7 0 0.000 52.8 
31 7 0 0.043 47 
36 7 0 0.018 51.2 
25 8 0 0.000 48.2 
29 8 0 0.000 46.8 
30 8 0 0.000 50 
33 8 0 0.000 53.8 
89 8 0 0.000 53.2 
81 9 0 0.002 44 
82 9 0 0.001 50.8 
64 9 0 0.000 54 
88 9 0 0.006 50.6 
91 9 0 0.000 50.8 
74 10 0 0.000 55.6 
66 10 0 0.000 48.2 
71 10 0 0.000 44.8 
77 10 0 0.000 49 
79 10 0 0.009 44.6 
65 11 0 0.000 50.4 
69 11 0 0.020 50.6 
70 11 0 0.000 47.6 
76 11 0 0.000 44 
78 11 0 0.000 46.2 
2 1 1 0.000 . 
10 1 1 0.000 . 
12 1 1 0.000 . 
18 1 1 0.000 . 
19 1 1 0.000 . 
7 2 1 0.000 . 
9 2 1 . . 
11 2 1 0.000 . 
13 2 1 0.000 . 
14 2 1 0.000 . 
48 3 1 0.000 . 
56 3 1 0.000 . 
57 3 1 0.000 . 
58 3 1 0.003 . 
59 3 1 0.003 . 
44 4 1 0.008 . 
45 4 1 0.004 . 
51 4 1 0.000 . 
52 4 1 0.000 . 
54 4 1 0.000 . 
23 5 1 0.004 . 
32 5 1 0.000 . 
35 5 1 0.000 . 
37 5 1 0.000 . 
40 5 1 0.000 . 
3 6 1 0.000 . 
20 6 1 0.000 . 
41 6 1 0.022 . 
47 6 1 0.000 . 
55 6 1 0.000 . 
53 6 1 0.000 . 
21 7 1 0.000 . 
24 7 1 0.000 . 
26 7 1 0.008 . 
31 7 1 0.021 . 
36 7 1 0.043 . 
25 8 1 0.000 . 
29 8 1 0.000 . 
30 8 1 0.000 . 
33 8 1 0.000 . 
89 8 1 0.004 . 
81 9 1 0.008 . 
82 9 1 0.001 . 
64 9 1 0.000 . 
88 9 1 0.011 . 
91 9 1 0.000 . 
74 10 1 0.000 . 
66 10 1 0.000 . 
71 10 1 0.000 . 
77 10 1 0.001 . 
79 10 1 0.000 . 
65 11 1 . . 
69 11 1 0.000 . 
70 11 1 0.000 . 
76 11 1 0.000 . 
78 11 1 0.000 . 
2 1 2 0.000 41.8 
10 1 2 0.000 51.5 
12 1 2 0.000 47 
18 1 2 0.000 40.2 
19 1 2 0.000 36.2 
7 2 2 0.000 43.2 
9 2 2 . . 
11 2 2 0.000 44.4 
13 2 2 0.000 44.4 
14 2 2 0.000 40.6 
48 3 2 0.000 47 
56 3 2 0.000 40.6 
57 3 2 0.000 44.2 
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58 3 2 0.009 36 
59 3 2 0.005 36.6 
44 4 2 0.008 40 
45 4 2 0.010 39.8 
51 4 2 0.012 40 
52 4 2 0.000 58.5 
54 4 2 0.000 42 
23 5 2 0.009 47.6 
32 5 2 0.000 45 
35 5 2 0.000 47.8 
37 5 2 0.017 47 
40 5 2 0.000 41.4 
3 6 2 0.000 53 
20 6 2 0.000 47.4 
41 6 2 0.000 41.2 
47 6 2 0.000 47 
55 6 2 0.004 50.5 
53 6 2 0.000 47.2 
21 7 2 0.000 51 
24 7 2 0.000 55.5 
26 7 2 0.003 42.8 
31 7 2 0.043 35 
36 7 2 0.003 52.5 
25 8 2 0.000 34.6 
29 8 2 0.000 45 
30 8 2 0.000 48.2 
33 8 2 0.000 51 
89 8 2 0.000 54 
81 9 2 0.000 46.8 
82 9 2 0.005 46.2 
64 9 2 0.000 45.8 
88 9 2 0.000 52.5 
91 9 2 0.000 37.2 
74 10 2 0.000 49 
66 10 2 0.000 42.6 
71 10 2 . . 
77 10 2 0.006 39.2 
79 10 2 0.000 40.4 
65 11 2 . . 
69 11 2 0.009 40.6 
70 11 2 0.000 41.4 
76 11 2 0.000 36.2 
78 11 2 . . 
2 1 3 0.000 . 
10 1 3 0.000 . 
12 1 3 0.000 . 
18 1 3 0.000 . 
19 1 3 0.000 . 
7 2 3 0.000 . 
9 2 3 . . 
11 2 3 0.000 . 
13 2 3 0.005 . 
14 2 3 0.000 . 
48 3 3 0.000 . 
56 3 3 0.002 . 
57 3 3 0.000 . 
58 3 3 0.018 . 
59 3 3 0.007 . 
44 4 3 0.000 . 
45 4 3 0.010 . 
51 4 3 0.010 . 
52 4 3 0.000 . 
54 4 3 0.000 . 
23 5 3 0.000 . 
32 5 3 0.006 . 
35 5 3 0.000 . 
37 5 3 0.009 . 
40 5 3 0.000 . 
3 6 3 0.000 . 
20 6 3 0.000 . 
41 6 3 0.079 . 
47 6 3 0.000 . 
55 6 3 0.000 . 
53 6 3 0.000 . 
21 7 3 0.000 . 
24 7 3 0.000 . 
26 7 3 0.000 . 
31 7 3 . . 
36 7 3 0.000 . 
25 8 3 0.000 . 
29 8 3 0.000 . 
30 8 3 0.000 . 
33 8 3 0.000 . 
89 8 3 0.000 . 
81 9 3 0.000 . 
82 9 3 0.003 . 
64 9 3 0.008 . 
88 9 3 0.029 . 
91 9 3 0.000 . 
74 10 3 0.000 . 
66 10 3 0.000 . 
71 10 3 . . 
77 10 3 0.000 . 
79 10 3 0.000 . 
65 11 3 . . 
69 11 3 0.007 . 
70 11 3 0.000 . 
76 11 3 0.000 . 
78 11 3 . . 
2 1 6 0.000 . 
10 1 6 0.000 . 
12 1 6 0.000 . 
18 1 6 0.000 . 
19 1 6 . . 
7 2 6 0.000 . 
9 2 6 . . 
11 2 6 0.000 . 
13 2 6 0.003 . 
14 2 6 0.000 . 
48 3 6 0.001 . 
56 3 6 0.000 . 
57 3 6 0.000 . 
58 3 6 0.006 . 
59 3 6 0.005 . 
44 4 6 0.007 . 
45 4 6 0.007 . 
51 4 6 0.004 . 
52 4 6 0.000 . 
54 4 6 0.001 . 
23 5 6 . . 
32 5 6 0.000 . 
35 5 6 0.007 . 
37 5 6 0.000 . 
40 5 6 0.000 . 
3 6 6 0.007 . 
20 6 6 0.020 . 
Stellenbosch University  http://scholar.sun.ac.za
175 
 
41 6 6 0.016 . 
47 6 6 0.000 . 
55 6 6 0.000 . 
53 6 6 0.000 . 
21 7 6 0.000 . 
24 7 6 0.000 . 
26 7 6 . . 
31 7 6 . . 
36 7 6 0.000 . 
25 8 6 . . 
29 8 6 0.000 . 
30 8 6 0.000 . 
33 8 6 0.000 . 
89 8 6 0.011 . 
81 9 6 0.002 . 
82 9 6 0.001 . 
64 9 6 0.042 . 
88 9 6 0.026 . 
91 9 6 0.000 . 
74 10 6 0.000 . 
66 10 6 0.000 . 
71 10 6 . . 
77 10 6 0.000 . 
79 10 6 0.024 . 
65 11 6 . . 
69 11 6 0.000 . 
70 11 6 0.000 . 
76 11 6 0.000 . 
78 11 6 . . 
2 1 9 0.000 48 
10 1 9 0.000 59 
12 1 9 0.000 47.8 
18 1 9 0.000 46.6 
19 1 9 . . 
7 2 9 0.000 39 
9 2 9 . . 
11 2 9 0.000 63 
13 2 9 . . 
14 2 9 0.000 53 
48 3 9 0.000 53 
56 3 9 0.005 44.4 
57 3 9 0.005 44.4 
58 3 9 0.001 48 
59 3 9 . . 
44 4 9 0.012 39.2 
45 4 9 0.000 51.5 
51 4 9 0.007 39.4 
52 4 9 0.000 61 
54 4 9 0.001 38.4 
23 5 9 . . 
32 5 9 0.000 49.8 
35 5 9 0.000 53 
37 5 9 0.000 48.4 
40 5 9 0.000 61.5 
3 6 9 0.011 44.8 
20 6 9 0.008 38.6 
41 6 9 0.000 55 
47 6 9 0.000 64 
55 6 9 0.000 48.4 
53 6 9 . . 
21 7 9 . . 
24 7 9 0.001 63 
26 7 9 . . 
31 7 9 . . 
36 7 9 0.006 60 
25 8 9 . . 
29 8 9 0.000 59 
30 8 9 0.001 54 
33 8 9 0.000 60.5 
89 8 9 0.011 59.5 
81 9 9 0.000 43.4 
82 9 9 0.000 57.5 
64 9 9 0.018 42.6 
88 9 9 0.018 53 
91 9 9 0.000 52.5 
74 10 9 0.000 57.5 
66 10 9 0.000 62.5 
71 10 9 . . 
77 10 9 0.005 39 
79 10 9 0.022 43.6 
65 11 9 . . 
69 11 9 0.004 52 
70 11 9 0.000 54 
76 11 9 0.000 33 
78 11 9 . . 
















































































































































Figure C.4: Mucosal immune responses elicited in ostriches during the dosing vaccine trial at Kromme Rhee farm in Stellenbosch, Western Cape. Various doses 
of the mucosal vaccines were evaluated. A. 10
9
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine, B. 10
10
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine, 
C. 10
11
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine, D. Received a 10
12
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine. 
 
















































































































































Figure C.5: Mucosal immune responses elicited in ostriches during the dosing vaccine trial at Kromme Rhee farm in Stellenbosch, Western Cape. Various doses 
of the mucosal vaccines were evaluated. A. 10
13
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine, B. Control group, C. 10
9
 c.f.u./ml dose of the VR1020 
mucosal DNA vaccine, D. Received a 10
10
 c.f.u./ml dose of the VR1020 mucosal DNA vaccine. 
 


























































































































Figure C.6: Mucosal immune responses elicited in ostriches during the dosing vaccine trial at Kromme Rhee farm in Stellenbosch, Western Cape. Various doses 
of the mucosal vaccines were evaluated. A. 10
11
 c.f.u./ml dose of the VR1020 mucosal DNA vaccine, B. 10
12
 c.f.u./ml dose of the VR1020 mucosal DNA vaccine, 
C. 10
13
 c.f.u./ml dose of the VR1020 mucosal DNA vaccine. 
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Mucosal immune response of ostriches against Mycoplasma struthionis  
The mucosal immune response of the ostriches against the OppA protein was evaluated using 
ELISA as described in section 5.2.3., using the secondary antibody rabbit anti-ostric IgA protein 2. 
An ANOVA was performed using the Statistical Analysis program Agrobase Generation II® 
(Agronomix Software Inc.). 
                   A N A L Y S I S   O F   V A R I A N C E                       
Swab – OppA – IgA Protein 2 
Kromme Rhee 
Variable: RESP 
      
Source df SS MS F-value Pr>F 
Total 329 0.039 
   
Treatment 10 0.004 0.00 3.27 0.0005 
Time 5 0.001 0.00 0.95 0.449 
Treatment x Time  50 0.004 0.00 0.65 0.9675 
Residual 264 0.031 0.00 
  
Grand mean = 0.005 R-squared = 0.2090 C.V. = 236.80% 
 
      
LSD for Treatment = 0.0055 S.E.D = 0.0028  r = 30 
 
t (2-sided a=0.050, 264 df) = 1.9690 
 
MSE = 0.00012 
   
 
     
Treatment 
     
Averages 
     
Level --- Y --- Cv Rank Group 
 
7 0.01 199.9 1 VR1020 10^9 
 
10 0.01 151.9 2 VR1020 10^12 
 
1 0.01 150.8 3 VR1012 10^9 
 
9 0.01 183.5 4 VR1020 10^11 
 
4 0.01 182.5 5 VR1012 10^12 
 
3 0.00 168.7 6 VR1012 10^11 
 
11 0.00 253.1 7 VR1020 10^13 
 
6 0.00 218.7 8 Control 
 2 0.00 203.4 9 VR1012 10^10 
 5 0.00 -9 10 VR1012 10^13 
 8 0.00 -9 11 VR1020 10^10 
 
      LSD for Time = 0.0041 
 
S.E.D = 0.0021 r = 55 
 
t (2-sided a=0.050, 264 df) = 1.9690 
 
MSE = 0.00012 
   
 
     
Time 
     
Averages 
     
Level --- Y --- Cv Rank Week 
 
1 0.01 247.4 1 0 
 
5 0.01 189.4 2 6 
 
6 0.00 219.5 3 9 
 
4 0.00 233.7 4 3 
 
2 0.00 210.1 5 1 
 
3 0.00 282.3 6 2 
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LSD for Treatment*Time = 0.0135 
 
S.E.D = 0.0069 r = 5 
 
t (2-sided a=0.050, 264 df) = 1.9690 
 
MSE = 0.00012 
   
   
 Two-way table for Treatment*Time, n=5                                             
  
 
1 2 3 4 5 6 
1 0.010 0.004 0.008 0.010 0.006 0.004 
2 0.004 0.000 0.000 0.004 0.004 0.000 
3 0.004 0.004 0.004 0.008 0.004 0.000 
4 0.002 0.002 0.002 0.006 0.012 0.008 
5 0.000 0.000 0.000 0.000 0.000 0.000 
6 0.004 0.002 0.000 0.000 0.006 0.004 
7 0.028 0.010 0.010 0.008 0.014 0.002 
8 0.000 0.000 0.000 0.000 0.000 0.000 
9 0.010 0.010 0.002 0.002 0.002 0.008 
10 0.012 0.004 0.002 0.004 0.010 0.016 
11 0.002 0.002 0.008 0.000 0.004 0.006 
 
The following table contains the input data for the ANOVA and is arranged in two columns with the 
ostrich identification number, treatment received (Trt), Time in weeks, the response as measured 
by ELISA and weights of the ostriches, read from the top to the bottom and left to right. The 
treatments consist of VR1012 mucosal DNA vaccine administered at various doses; 1x109 c.f.u./ml 
(1), 1x1010 c.f.u./ml (2), 1x1011 c.f.u./ml (3), 1x1012 c.f.u./ml (4) and 1x1013 c.f.u./ml (5); Salmonella 
enterica serovar typhimurium SL3261 control (6), VR1020 naked DNA vaccine administered at 
various doses; 1x109 c.f.u./ml (7), 1x1010 c.f.u./ml (8), 1x1011 c.f.u./ml (9), 1x1012 c.f.u./ml (10) and 
1x1013 c.f.u./ml (11). Following the data are the graphs drawn for each ostrich depicting the 
absorbance measured over time. 
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Ostrich Trt Time Resp Weight 
2 1 0 0.000 44.6 
10 1 0 0.031 47.6 
12 1 0 0.017 50.4 
18 1 0 0.000 45.2 
19 1 0 0.000 47.8 
7 2 0 0.000 44.2 
9 2 0 0.000 46.8 
11 2 0 0.000 48.4 
13 2 0 0.005 50 
14 2 0 0.007 47 
48 3 0 0.001 48.6 
56 3 0 0.000 48 
57 3 0 0.000 47.6 
58 3 0 0.011 47.6 
59 3 0 0.012 46.2 
44 4 0 0.003 48.2 
45 4 0 0.013 46.6 
51 4 0 0.000 45.6 
52 4 0 0.000 46.8 
54 4 0 0.000 51 
23 5 0 0.000 51.6 
32 5 0 0.000 46.6 
35 5 0 0.000 50.4 
37 5 0 0.000 49.8 
40 5 0 0.000 47.2 
3 6 0 0.019 52.4 
20 6 0 0.000 52.4 
41 6 0 0.000 51.8 
47 6 0 0.000 54.8 
55 6 0 0.000 55.8 
53 6 0 0.008 55.4 
21 7 0 0.000 48.8 
24 7 0 0.000 50 
26 7 0 0.003 52.8 
31 7 0 0.029 47 
36 7 0 0.107 51.2 
25 8 0 0.000 48.2 
29 8 0 0.000 46.8 
30 8 0 0.000 50 
33 8 0 0.000 53.8 
89 8 0 0.000 53.2 
81 9 0 0.000 44 
82 9 0 0.031 50.8 
64 9 0 0.002 54 
88 9 0 0.024 50.6 
91 9 0 0.000 50.8 
74 10 0 0.000 55.6 
66 10 0 0.000 48.2 
71 10 0 0.000 44.8 
77 10 0 0.028 49 
79 10 0 0.030 44.6 
65 11 0 0.000 50.4 
69 11 0 0.000 50.6 
70 11 0 0.000 47.6 
76 11 0 0.000 44 
78 11 0 0.011 46.2 
2 1 1 0.000 . 
10 1 1 0.009 . 
12 1 1 0.014 . 
18 1 1 0.000 . 
19 1 1 0.000 . 
7 2 1 0.000 . 
9 2 1 . . 
11 2 1 0.000 . 
13 2 1 0.002 . 
14 2 1 0.000 . 
48 3 1 0.000 . 
56 3 1 0.000 . 
57 3 1 0.009 . 
58 3 1 0.000 . 
59 3 1 0.005 . 
44 4 1 0.001 . 
45 4 1 0.011 . 
51 4 1 0.000 . 
52 4 1 0.000 . 
54 4 1 0.000 . 
23 5 1 0.000 . 
32 5 1 0.000 . 
35 5 1 0.000 . 
37 5 1 0.000 . 
40 5 1 0.000 . 
3 6 1 0.006 . 
20 6 1 0.000 . 
41 6 1 0.000 . 
47 6 1 0.000 . 
55 6 1 0.000 . 
53 6 1 0.008 . 
21 7 1 0.021 . 
24 7 1 0.000 . 
26 7 1 0.004 . 
31 7 1 0.014 . 
36 7 1 0.024 . 
25 8 1 0.000 . 
29 8 1 0.000 . 
30 8 1 0.000 . 
33 8 1 0.000 . 
89 8 1 0.000 . 
81 9 1 0.000 . 
82 9 1 0.042 . 
64 9 1 0.000 . 
88 9 1 0.007 . 
91 9 1 0.000 . 
74 10 1 0.000 . 
66 10 1 0.000 . 
71 10 1 0.000 . 
77 10 1 0.009 . 
79 10 1 0.012 . 
65 11 1 . . 
69 11 1 0.000 . 
70 11 1 0.003 . 
76 11 1 0.000 . 
78 11 1 0.009 . 
2 1 2 0.005 41.8 
10 1 2 0.011 51.5 
12 1 2 0.019 47 
18 1 2 0.000 40.2 
19 1 2 0.000 36.2 
7 2 2 0.000 43.2 
9 2 2 . . 
11 2 2 0.000 44.4 
13 2 2 0.004 44.4 
14 2 2 0.000 40.6 
48 3 2 0.000 47 
56 3 2 0.000 40.6 
57 3 2 0.000 44.2 
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58 3 2 0.009 36 
59 3 2 0.010 36.6 
44 4 2 0.000 40 
45 4 2 0.009 39.8 
51 4 2 0.000 40 
52 4 2 0.000 58.5 
54 4 2 0.000 42 
23 5 2 0.000 47.6 
32 5 2 0.000 45 
35 5 2 0.000 47.8 
37 5 2 0.000 47 
40 5 2 0.000 41.4 
3 6 2 0.000 53 
20 6 2 0.000 47.4 
41 6 2 0.000 41.2 
47 6 2 0.000 47 
55 6 2 0.000 50.5 
53 6 2 0.023 47.2 
21 7 2 0.000 51 
24 7 2 0.000 55.5 
26 7 2 0.004 42.8 
31 7 2 0.047 35 
36 7 2 0.000 52.5 
25 8 2 0.000 34.6 
29 8 2 0.000 45 
30 8 2 0.000 48.2 
33 8 2 0.000 51 
89 8 2 0.000 54 
81 9 2 0.000 46.8 
82 9 2 0.010 46.2 
64 9 2 0.000 45.8 
88 9 2 0.000 52.5 
91 9 2 0.000 37.2 
74 10 2 0.000 49 
66 10 2 0.000 42.6 
71 10 2 . . 
77 10 2 0.004 39.2 
79 10 2 0.007 40.4 
65 11 2 . . 
69 11 2 0.041 40.6 
70 11 2 0.000 41.4 
76 11 2 0.000 36.2 
78 11 2 . . 
2 1 3 0.009 . 
10 1 3 0.039 . 
12 1 3 0.000 . 
18 1 3 0.000 . 
19 1 3 0.000 . 
7 2 3 0.000 . 
9 2 3 . . 
11 2 3 0.000 . 
13 2 3 0.009 . 
14 2 3 0.009 . 
48 3 3 0.000 . 
56 3 3 0.000 . 
57 3 3 0.016 . 
58 3 3 0.000 . 
59 3 3 0.015 . 
44 4 3 0.014 . 
45 4 3 0.015 . 
51 4 3 0.002 . 
52 4 3 0.000 . 
54 4 3 0.000 . 
23 5 3 0.000 . 
32 5 3 0.000 . 
35 5 3 0.000 . 
37 5 3 0.000 . 
40 5 3 0.000 . 
3 6 3 0.000 . 
20 6 3 0.000 . 
41 6 3 0.000 . 
47 6 3 0.000 . 
55 6 3 0.000 . 
53 6 3 0.000 . 
21 7 3 0.001 . 
24 7 3 0.043 . 
26 7 3 0.003 . 
31 7 3 . . 
36 7 3 0.000 . 
25 8 3 0.000 . 
29 8 3 0.000 . 
30 8 3 0.000 . 
33 8 3 0.000 . 
89 8 3 0.000 . 
81 9 3 0.000 . 
82 9 3 0.006 . 
64 9 3 0.000 . 
88 9 3 0.000 . 
91 9 3 0.001 . 
74 10 3 0.000 . 
66 10 3 0.000 . 
71 10 3 . . 
77 10 3 0.007 . 
79 10 3 0.013 . 
65 11 3 . . 
69 11 3 0.000 . 
70 11 3 0.000 . 
76 11 3 0.000 . 
78 11 3 . . 
2 1 6 0.018 . 
10 1 6 0.007 . 
12 1 6 0.000 . 
18 1 6 0.000 . 
19 1 6 . . 
7 2 6 0.000 . 
9 2 6 . . 
11 2 6 0.000 . 
13 2 6 0.005 . 
14 2 6 0.012 . 
48 3 6 0.000 . 
56 3 6 0.000 . 
57 3 6 0.000 . 
58 3 6 0.004 . 
59 3 6 0.015 . 
44 4 6 0.025 . 
45 4 6 0.030 . 
51 4 6 0.000 . 
52 4 6 0.000 . 
54 4 6 0.000 . 
23 5 6 . . 
32 5 6 0.000 . 
35 5 6 0.000 . 
37 5 6 0.000 . 
40 5 6 0.000 . 
3 6 6 0.000 . 
20 6 6 0.017 . 
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41 6 6 0.000 . 
47 6 6 0.000 . 
55 6 6 0.014 . 
53 6 6 0.011 . 
21 7 6 0.021 . 
24 7 6 0.054 . 
26 7 6 . . 
31 7 6 . . 
36 7 6 0.000 . 
25 8 6 . . 
29 8 6 0.000 . 
30 8 6 0.000 . 
33 8 6 0.000 . 
89 8 6 0.000 . 
81 9 6 0.003 . 
82 9 6 0.000 . 
64 9 6 0.009 . 
88 9 6 0.004 . 
91 9 6 0.000 . 
74 10 6 0.000 . 
66 10 6 0.000 . 
71 10 6 . . 
77 10 6 0.021 . 
79 10 6 0.028 . 
65 11 6 . . 
69 11 6 0.000 . 
70 11 6 0.006 . 
76 11 6 0.007 . 
78 11 6 . . 
2 1 9 0.000 48 
10 1 9 0.022 59 
12 1 9 0.000 47.8 
18 1 9 0.000 46.6 
19 1 9 . . 
7 2 9 0.000 39 
9 2 9 . . 
11 2 9 0.000 63 
13 2 9 . . 
14 2 9 0.004 53 
48 3 9 0.000 53 
56 3 9 0.000 44.4 
57 3 9 0.000 44.4 
58 3 9 0.002 48 
59 3 9 . . 
44 4 9 0.030 39.2 
45 4 9 0.000 51.5 
51 4 9 0.007 39.4 
52 4 9 0.000 61 
54 4 9 0.000 38.4 
23 5 9 . . 
32 5 9 0.000 49.8 
35 5 9 0.000 53 
37 5 9 0.000 48.4 
40 5 9 0.000 61.5 
3 6 9 0.005 44.8 
20 6 9 0.000 38.6 
41 6 9 0.000 55 
47 6 9 0.000 64 
55 6 9 0.011 48.4 
53 6 9 . . 
21 7 9 . . 
24 7 9 0.004 63 
26 7 9 . . 
31 7 9 . . 
36 7 9 0.007 60 
25 8 9 . . 
29 8 9 0.000 59 
30 8 9 0.000 54 
33 8 9 0.000 60.5 
89 8 9 0.000 59.5 
81 9 9 0.000 43.4 
82 9 9 0.020 57.5 
64 9 9 0.024 42.6 
88 9 9 0.000 53 
91 9 9 0.000 52.5 
74 10 9 0.029 57.5 
66 10 9 0.000 62.5 
71 10 9 . . 
77 10 9 0.035 39 
79 10 9 0.011 43.6 
65 11 9 . . 
69 11 9 0.000 52 
70 11 9 0.028 54 
76 11 9 0.001 33 
78 11 9 . . 















































































































































Figure C.7: Mucosal immune responses elicited in ostriches during the dosing vaccine trial at Kromme Rhee farm in Stellenbosch, Western Cape. Various doses 
of the mucosal vaccines were evaluated. A. 10
9
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine, B. 10
10
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine, 
C. 10
11
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine, D. Received a 10
12
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine. 
 
















































































































































Figure C.8: Mucosal immune responses elicited in ostriches during the dosing vaccine trial at Kromme Rhee farm in Stellenbosch, Western Cape. Various doses 
of the mucosal vaccines were evaluated. A. 10
13
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine, B. Control group, C. 10
9
 c.f.u./ml dose of the VR1020 
mucosal DNA vaccine, D. Received a 10
10
 c.f.u./ml dose of the VR1020 mucosal DNA vaccine. 
 

























































































































Figure C.9: Mucosal immune responses elicited in ostriches during the dosing vaccine trial at Kromme Rhee farm in Stellenbosch, Western Cape. Various doses 
of the mucosal vaccines were evaluated. A. 10
11
 c.f.u./ml dose of the VR1020 mucosal DNA vaccine, B. 10
12
 c.f.u./ml dose of the VR1020 mucosal DNA vaccine, 
C. 10
13
 c.f.u./ml dose of the VR1020 mucosal DNA vaccine. 
 
Stellenbosch University  http://scholar.sun.ac.za
187 
 
Humoral immune response of ostriches against Salmonella enterica serovar typhimurium 
SL3261 LPS  
The humoral immune response of the ostriches against the LPS of Salmonella enterica serovar 
typhimurium SL3261 was evaluated using ELISA as described in section 5.2.4. The data was 
analysed using the Statistical Analysis program Agrobase Generation II® (Agronomix Software 
Inc.). FAC_A represents the treatment and FAC_B represent the time in weeks.  
                   A N A L Y S I S   O F   V A R I A N C E                       
Serum - LPS 
Kromme Rhee 
Variable: RESP 
      
Source df SS MS F-value Pr>F 
Total 329 146.639 
   Treatment 10 30.985 3.099 9.72 0.0000 
Time 5 10.501 2.100 6.59 0.0000 
Treatment x Time  50 20.993 0.420 1.32 0.0887 
Residual 264 84.159 0.319 
  Grand mean = 1.035 R-squared = 0.4261 C.V. = 54.54% 
 
      
LSD for Treatment = 0.2870 S.E.D = 0.1458  r = 30 
 
t (2-sided a=0.050, 264 df) = 1.9690 
 
MSE = 0.31878 
   
 
     
Treatment 
     
Averages 
     
Level --- Y --- Cv Rank Group 
 
9 1.54 33.8 1 VR1020 10^11 
 
6 1.38 43.6 2 Control 
 
8 1.38 49 3 VR1020 10^10 
 
7 1.21 60.1 4 VR1020 10^9 
 
10 1.19 57.6 5 VR1020 10^12 
 
5 0.94 54.8 6 VR1012 10^13 
 
3 0.93 66.8 7 VR1012 10^11 
 
11 0.82 79.5 8 VR1020 10^13 
 4 0.72 71.9 9 VR1012 10^12 
 1 0.7 67.2 10 VR1012 10^9 
 2 0.58 100.6 11 VR1012 10^10 
 
      LSD for Time = 0.2120 
 
S.E.D = 0.1077 r = 55 
 
t (2-sided a=0.050, 264 df) = 1.9690 
 
MSE = 0.31878 
   
 
     
Time 
     
Averages 
     
Level --- Y --- Cv Rank Week 
 
2 1.24 54.5 1 1 
 
1 1.21 49.2 2 0 
 
4 1.11 64.6 3 3 
 
3 1.02 63.7 4 2 
 
5 0.89 73.7 5 6 
 
6 0.74 79.1 6 9 
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LSD for Treatment*Time = 0.7031 
 
S.E.D = 0.3571 r = 5 
 
t (2-sided a=0.050, 264 df) = 1.9690 
 
MSE = 0.31878 
   
   
 Two-way table for Treatment*Time, n=5                                             
  
 
1 2 3 4 5 6 
1 0.688 0.500 0.466 0.898 0.814 0.846 
2 0.458 0.500 0.332 0.454 0.794 0.928 
3 1.112 1.006 0.882 0.762 1.040 0.748 
4 0.820 0.788 0.612 0.962 0.650 0.516 
5 0.942 1.352 1.032 0.828 0.818 0.674 
6 1.394 1.402 1.456 1.858 1.292 0.902 
7 1.452 1.864 1.534 1.112 0.832 0.454 
8 1.820 1.916 1.618 1.578 0.596 0.736 
9 1.558 1.710 1.256 1.920 1.570 1.220 
10 1.568 1.612 1.272 1.282 0.876 0.542 
11 1.488 1.008 0.800 0.604 0.464 0.532 
 
The following table contains the input data for the ANOVA and is arranged in two columns with the 
ostrich identification number, treatment received (Trt), Time in weeks, the response as measured 
by ELISA and weights of the ostriches, read from the top to the bottom and left to right. The 
treatments consist of VR1012 mucosal DNA vaccine administered at various doses; 1x109 c.f.u./ml 
(1), 1x1010 c.f.u./ml (2), 1x1011 c.f.u./ml (3), 1x1012 c.f.u./ml (4) and 1x1013 c.f.u./ml (5); Salmonella 
enterica serovar typhimurium SL3261 control (6), VR1020 naked DNA vaccine administered at 
various doses; 1x109 c.f.u./ml (7), 1x1010 c.f.u./ml (8), 1x1011 c.f.u./ml (9), 1x1012 c.f.u./ml (10) and 
1x1013 c.f.u./ml (11). Following the data are the graphs drawn for each ostrich depicting the 
absorbance measured over time. 
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Ostrich Trt Time Resp Weight 
2 1 0 0.837 44.6 
10 1 0 0.528 47.6 
12 1 0 0.713 50.4 
18 1 0 0.664 45.2 
19 1 0 0.703 47.8 
7 2 0 0.580 44.2 
9 2 0 0.000 46.8 
11 2 0 0.624 48.4 
13 2 0 0.451 50 
14 2 0 0.638 47 
48 3 0 0.313 48.6 
56 3 0 2.641 48 
57 3 0 1.290 47.6 
58 3 0 0.898 47.6 
59 3 0 0.418 46.2 
44 4 0 0.606 48.2 
45 4 0 1.425 46.6 
51 4 0 0.620 45.6 
52 4 0 1.032 46.8 
54 4 0 0.413 51 
23 5 0 1.251 51.6 
32 5 0 1.382 46.6 
35 5 0 0.804 50.4 
37 5 0 0.497 49.8 
40 5 0 0.775 47.2 
3 6 0 1.204 52.4 
20 6 0 1.544 52.4 
41 6 0 1.009 51.8 
47 6 0 1.060 54.8 
55 6 0 2.160 55.8 
53 6 0 1.504 55.4 
21 7 0 1.698 48.8 
24 7 0 1.284 50 
26 7 0 1.735 52.8 
31 7 0 0.976 47 
36 7 0 1.558 51.2 
25 8 0 2.157 48.2 
29 8 0 1.545 46.8 
30 8 0 2.074 50 
33 8 0 2.206 53.8 
89 8 0 1.111 53.2 
81 9 0 1.678 44 
82 9 0 2.318 50.8 
64 9 0 1.254 54 
88 9 0 1.447 50.6 
91 9 0 1.094 50.8 
74 10 0 1.218 55.6 
66 10 0 1.445 48.2 
71 10 0 2.549 44.8 
77 10 0 1.472 49 
79 10 0 1.146 44.6 
65 11 0 1.389 50.4 
69 11 0 1.706 50.6 
70 11 0 1.109 47.6 
76 11 0 1.421 44 
78 11 0 1.807 46.2 
2 1 1 0.380 . 
10 1 1 0.401 . 
12 1 1 0.791 . 
18 1 1 0.385 . 
19 1 1 0.538 . 
7 2 1 0.837 . 
9 2 1 . . 
11 2 1 0.477 . 
13 2 1 0.382 . 
14 2 1 0.803 . 
48 3 1 0.556 . 
56 3 1 1.982 . 
57 3 1 1.305 . 
58 3 1 0.784 . 
59 3 1 0.399 . 
44 4 1 0.353 . 
45 4 1 2.082 . 
51 4 1 0.464 . 
52 4 1 0.634 . 
54 4 1 0.423 . 
23 5 1 1.003 . 
32 5 1 2.559 . 
35 5 1 1.229 . 
37 5 1 0.859 . 
40 5 1 1.105 . 
3 6 1 1.183 . 
20 6 1 1.354 . 
41 6 1 0.795 . 
47 6 1 1.636 . 
55 6 1 2.044 . 
53 6 1 2.004 . 
21 7 1 2.111 . 
24 7 1 1.884 . 
26 7 1 1.956 . 
31 7 1 1.731 . 
36 7 1 1.637 . 
25 8 1 1.523 . 
29 8 1 2.184 . 
30 8 1 1.554 . 
33 8 1 2.612 . 
89 8 1 1.718 . 
81 9 1 1.182 . 
82 9 1 2.295 . 
64 9 1 1.866 . 
88 9 1 1.612 . 
91 9 1 1.594 . 
74 10 1 1.008 . 
66 10 1 1.970 . 
71 10 1 1.873 . 
77 10 1 1.862 . 
79 10 1 1.349 . 
65 11 1 . . 
69 11 1 1.863 . 
70 11 1 0.745 . 
76 11 1 1.133 . 
78 11 1 1.304 . 
2 1 2 0.661 41.8 
10 1 2 0.158 51.5 
12 1 2 0.823 47 
18 1 2 0.406 40.2 
19 1 2 0.282 36.2 
7 2 2 0.000 43.2 
9 2 2 . . 
11 2 2 0.422 44.4 
13 2 2 0.279 44.4 
14 2 2 0.961 40.6 
48 3 2 0.443 47 
56 3 2 1.688 40.6 
57 3 2 1.027 44.2 
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58 3 2 0.876 36 
59 3 2 0.366 36.6 
44 4 2 0.293 40 
45 4 2 1.416 39.8 
51 4 2 0.503 40 
52 4 2 0.532 58.5 
54 4 2 0.320 42 
23 5 2 1.000 47.6 
32 5 2 1.839 45 
35 5 2 0.873 47.8 
37 5 2 0.650 47 
40 5 2 0.801 41.4 
3 6 2 1.234 53 
20 6 2 1.446 47.4 
41 6 2 0.968 41.2 
47 6 2 1.755 47 
55 6 2 1.871 50.5 
53 6 2 1.643 47.2 
21 7 2 2.094 51 
24 7 2 2.313 55.5 
26 7 2 1.659 42.8 
31 7 2 0.558 35 
36 7 2 1.048 52.5 
25 8 2 1.349 34.6 
29 8 2 1.925 45 
30 8 2 1.603 48.2 
33 8 2 2.304 51 
89 8 2 0.912 54 
81 9 2 1.172 46.8 
82 9 2 2.122 46.2 
64 9 2 1.074 45.8 
88 9 2 0.994 52.5 
91 9 2 0.928 37.2 
74 10 2 1.431 49 
66 10 2 1.590 42.6 
71 10 2 . . 
77 10 2 1.804 39.2 
79 10 2 1.537 40.4 
65 11 2 . . 
69 11 2 1.893 40.6 
70 11 2 0.999 41.4 
76 11 2 1.109 36.2 
78 11 2 . . 
2 1 3 0.905 . 
10 1 3 0.678 . 
12 1 3 0.992 . 
18 1 3 1.643 . 
19 1 3 0.265 . 
7 2 3 0.663 . 
9 2 3 . . 
11 2 3 0.369 . 
13 2 3 0.475 . 
14 2 3 0.759 . 
48 3 3 0.330 . 
56 3 3 0.673 . 
57 3 3 1.482 . 
58 3 3 0.944 . 
59 3 3 0.394 . 
44 4 3 0.363 . 
45 4 3 1.955 . 
51 4 3 1.371 . 
52 4 3 0.848 . 
54 4 3 0.265 . 
23 5 3 0.843 . 
32 5 3 1.265 . 
35 5 3 0.595 . 
37 5 3 0.568 . 
40 5 3 0.857 . 
3 6 3 2.427 . 
20 6 3 1.862 . 
41 6 3 0.494 . 
47 6 3 1.802 . 
55 6 3 2.713 . 
53 6 3 1.451 . 
21 7 3 1.593 . 
24 7 3 1.493 . 
26 7 3 1.632 . 
31 7 3 . . 
36 7 3 0.848 . 
25 8 3 1.723 . 
29 8 3 1.567 . 
30 8 3 1.604 . 
33 8 3 1.859 . 
89 8 3 1.141 . 
81 9 3 0.957 . 
82 9 3 1.619 . 
64 9 3 2.491 . 
88 9 3 2.014 . 
91 9 3 2.515 . 
74 10 3 1.568 . 
66 10 3 0.912 . 
71 10 3 . . 
77 10 3 2.363 . 
79 10 3 1.569 . 
65 11 3 . . 
69 11 3 1.324 . 
70 11 3 0.789 . 
76 11 3 0.910 . 
78 11 3 . . 
2 1 6 0.562 . 
10 1 6 0.759 . 
12 1 6 0.825 . 
18 1 6 1.916 . 
19 1 6 . . 
7 2 6 0.326 . 
9 2 6 . . 
11 2 6 0.601 . 
13 2 6 0.830 . 
14 2 6 2.212 . 
48 3 6 0.347 . 
56 3 6 1.103 . 
57 3 6 1.996 . 
58 3 6 1.277 . 
59 3 6 0.473 . 
44 4 6 0.539 . 
45 4 6 1.375 . 
51 4 6 0.348 . 
52 4 6 0.767 . 
54 4 6 0.206 . 
23 5 6 . . 
32 5 6 1.279 . 
35 5 6 1.284 . 
37 5 6 0.724 . 
40 5 6 0.808 . 
3 6 6 1.050 . 
20 6 6 1.124 . 
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41 6 6 0.338 . 
47 6 6 1.467 . 
55 6 6 2.478 . 
53 6 6 0.433 . 
21 7 6 1.237 . 
24 7 6 1.222 . 
26 7 6 . . 
31 7 6 . . 
36 7 6 1.696 . 
25 8 6 . . 
29 8 6 0.990 . 
30 8 6 0.403 . 
33 8 6 1.008 . 
89 8 6 0.577 . 
81 9 6 1.736 . 
82 9 6 0.888 . 
64 9 6 1.173 . 
88 9 6 2.052 . 
91 9 6 2.002 . 
74 10 6 0.557 . 
66 10 6 0.734 . 
71 10 6 . . 
77 10 6 1.519 . 
79 10 6 1.569 . 
65 11 6 . . 
69 11 6 1.206 . 
70 11 6 0.615 . 
76 11 6 0.494 . 
78 11 6 . . 
2 1 9 0.726 48 
10 1 9 0.403 59 
12 1 9 1.182 47.8 
18 1 9 1.924 46.6 
19 1 9 . . 
7 2 9 0.927 39 
9 2 9 . . 
11 2 9 1.407 63 
13 2 9 . . 
14 2 9 2.303 53 
48 3 9 0.388 53 
56 3 9 0.627 44.4 
57 3 9 1.540 44.4 
58 3 9 1.176 48 
59 3 9 . . 
44 4 9 0.288 39.2 
45 4 9 1.099 51.5 
51 4 9 0.206 39.4 
52 4 9 0.805 61 
54 4 9 0.174 38.4 
23 5 9 . . 
32 5 9 1.623 49.8 
35 5 9 0.937 53 
37 5 9 0.522 48.4 
40 5 9 0.291 61.5 
3 6 9 1.017 44.8 
20 6 9 1.130 38.6 
41 6 9 0.404 55 
47 6 9 1.264 64 
55 6 9 0.698 48.4 
53 6 9 - . 
21 7 9 - . 
24 7 9 0.894 63 
26 7 9 . . 
31 7 9 . . 
36 7 9 1.375 60 
25 8 9 . . 
29 8 9 0.519 59 
30 8 9 0.790 54 
33 8 9 1.526 60.5 
89 8 9 0.837 59.5 
81 9 9 1.162 43.4 
82 9 9 1.600 57.5 
64 9 9 1.536 42.6 
88 9 9 0.544 53 
91 9 9 1.256 52.5 
74 10 9 0.832 57.5 
66 10 9 0.610 62.5 
71 10 9 . . 
77 10 9 0.472 39 
79 10 9 0.800 43.6 
65 11 9 . . 
69 11 9 1.379 52 
70 11 9 0.631 54 
76 11 9 0.651 33 





































































































































































Figure C.10: Humoral immune responses elicited in ostriches during the dosing vaccine trial at Kromme Rhee farm in Stellenbosch, Western Cape. Various 
doses of the mucosal vaccines were evaluated. A. 10
9
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine, B. 10
10
 c.f.u./ml dose of the VR1012 mucosal DNA 
vaccine, C. 10
11
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine, D. Received a 10
12
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine. 
 












































































































































Figure C.11: Humoral immune responses elicited in ostriches during the dosing vaccine trial at Kromme Rhee farm in Stellenbosch, Western Cape. Various 
doses of the mucosal vaccines were evaluated. A. 10
13
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine, B. Control group, C. 10
9
 c.f.u./ml dose of the VR1020 
mucosal DNA vaccine, D. Received a 10
10
 c.f.u./ml dose of the mucosal VR1020 DNAvaccine. 
 























































































































Figure C.12: Humoral immune responses elicited in ostriches during the dosing vaccine trial at Kromme Rhee farm in Stellenbosch, Western Cape. Various 
doses of the mucosal vaccines were evaluated. A. 10
11
 c.f.u./ml dose of the VR1020 mucosal DNA vaccine, B. 10
12
 c.f.u./ml dose of the VR1020 mucosal DNA 
vaccine, C. 10
13
 c.f.u./ml dose of the VR1020 mucosal DNA vaccine. 
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Mucosal immune response of ostriches against Salmonella enterica serovar typhimurium 
SL3261 LPS  
The mucosal immune response of the ostriches against the LPS of Salmonella enterica serovar 
typhimurium SL3261 was evaluated using ELISA as described in section 5.2.4. using the 
secondary antibody rabbit anti-ostrich IgA protein 1. An ANOVA was performed using the 
Statistical Analysis program Agrobase Generation II® (Agronomix Software Inc.). 
                   A N A L Y S I S   O F   V A R I A N C E                       
Swab – LPS – Protein 1 
Kromme Rhee 
Variable: RESP 
      
Source df SS MS F-value Pr>F 
Total 329 0.034 
   
Treatment 10 0.004 0.000 4.45 0.0000 
Time 5 0.000 0.000 0.63 0.6805 
Treatment x Time  50 0.003 0.000 0.63 0.9744 
Residual 264 0.026 0.000 
  
Grand mean = 0.004 R-squared = 0.2307 C.V. = 229.20% 
 
      
LSD for Treatment = 0.0051 S.E.D = 0.0026  r = 30 
 
t (2-sided a=0.050, 264 df) = 1.9690 
 
MSE = 0.00010 
   
 
     
Treatment 
     
Averages 
     
Level --- Y --- Cv Rank Group 
 
7 0.01 143.1 1 VR1020 10^9 
 
1 0.01 143.3 2 VR1012 10^9 
 
4 0 134.7 3 VR1012 10^12 
 
2 0 242.1 4 VR1012 10^10 
 
3 0 220.6 5 VR1012 10^11 
 
11 0 198.3 6 VR1020 10^13 
 
6 0 234.1 7 Control 
 
9 0 417 8 VR1020 10^11 
 5 0 203.4 9 VR1012 10^13 
 10 0 547.7 10 VR1020 10^12 
 8 0 380.6 11 VR1020 10^10 
 
      LSD for Time = 0.0038 
 
S.E.D = 0.0019 r = 55 
 
t (2-sided a=0.050, 264 df) = 1.9690 
 
MSE = 0.00010 
   
 
     
Time 
     
Averages 
     
Level --- Y --- Cv Rank Week 
 
6 0.01 233.5 1 9 
 
1 0.01 174.5 2 0 
 
3 0.00 268.4 3 2 
 
5 0.00 249.4 4 6 
 
2 0.00 207.4 5 1 
 
4 0.00 244.6 6 3 
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LSD for Treatment*Time = 0.0125 
 
S.E.D = 0.0063 r = 5 
 
t (2-sided a=0.050, 264 df) = 1.9690 
 
MSE = 0.00010 
   
   
 Two-way table for Treatment*Time, n=5                                             
  
 
1 2 3 4 5 6 
1 0.012 0.014 0.008 0.006 0.006 0.010 
2 0.004 0.002 0.002 0.002 0.012 0.002 
3 0.002 0.004 0.010 0.004 0.002 0.000 
4 0.004 0.004 0.004 0.006 0.004 0.006 
5 0.004 0.002 0.000 0.002 0.002 0.002 
6 0.008 0.000 0.000 0.002 0.004 0.004 
7 0.018 0.006 0.026 0.008 0.010 0.014 
8 0.000 0.000 0.000 0.000 0.002 0.002 
9 0.002 0.002 0.000 0.000 0.000 0.012 
10 0.000 0.000 0.000 0.000 0.000 0.006 
11 0.004 0.006 0.004 0.002 0.000 0.004 
 
The following table contains the input data for the ANOVA and is arranged in two columns with the 
ostrich identification number, treatment received (Trt), Time in weeks, the response as measured 
by ELISA and weights of the ostriches, read from the top to the bottom and left to right. The 
treatments consist of VR1012 mucosal DNA vaccine administered at various doses; 1x109 c.f.u./ml 
(1), 1x1010 c.f.u./ml (2), 1x1011 c.f.u./ml (3), 1x1012 c.f.u./ml (4) and 1x1013 c.f.u./ml (5); Salmonella 
enterica serovar typhimurium SL3261 control (6), VR1020 naked DNA vaccine administered at 
various doses; 1x109 c.f.u./ml (7), 1x1010 c.f.u./ml (8), 1x1011 c.f.u./ml (9), 1x1012 c.f.u./ml (10) and 
1x1013 c.f.u./ml (11). Following the data are the graphs drawn for each ostrich depicting the 
absorbance measured over time.  
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Ostrich Trt Time Resp Weight 
2 1 0 0.000 44.6 
10 1 0 0.008 47.6 
12 1 0 0.016 50.4 
18 1 0 0.000 45.2 
19 1 0 0.032 47.8 
7 2 0 0.012 44.2 
9 2 0 0.003 46.8 
11 2 0 0.014 48.4 
13 2 0 0.000 50 
14 2 0 0.000 47 
48 3 0 0.001 48.6 
56 3 0 0.000 48 
57 3 0 0.000 47.6 
58 3 0 0.000 47.6 
59 3 0 0.012 46.2 
44 4 0 0.000 48.2 
45 4 0 0.011 46.6 
51 4 0 0.013 45.6 
52 4 0 0.000 46.8 
54 4 0 0.000 51 
23 5 0 0.009 51.6 
32 5 0 0.000 46.6 
35 5 0 0.000 50.4 
37 5 0 0.003 49.8 
40 5 0 0.009 47.2 
3 6 0 0.000 52.4 
20 6 0 0.000 52.4 
41 6 0 0.000 51.8 
47 6 0 0.016 54.8 
55 6 0 0.020 55.8 
53 6 0 0.003 55.4 
21 7 0 0.000 48.8 
24 7 0 0.000 50 
26 7 0 0.024 52.8 
31 7 0 0.041 47 
36 7 0 0.031 51.2 
25 8 0 0.000 48.2 
29 8 0 0.000 46.8 
30 8 0 0.000 50 
33 8 0 0.000 53.8 
89 8 0 0.000 53.2 
81 9 0 0.002 44 
82 9 0 0.000 50.8 
64 9 0 0.000 54 
88 9 0 0.000 50.6 
91 9 0 0.005 50.8 
74 10 0 0.000 55.6 
66 10 0 0.000 48.2 
71 10 0 0.000 44.8 
77 10 0 0.000 49 
79 10 0 0.000 44.6 
65 11 0 0.014 50.4 
69 11 0 0.000 50.6 
70 11 0 0.000 47.6 
76 11 0 0.004 44 
78 11 0 0.008 46.2 
2 1 1 0.000 . 
10 1 1 0.007 . 
12 1 1 0.019 . 
18 1 1 0.000 . 
19 1 1 0.040 . 
7 2 1 0.002 . 
9 2 1 . . 
11 2 1 0.003 . 
13 2 1 0.006 . 
14 2 1 0.000 . 
48 3 1 0.004 . 
56 3 1 0.012 . 
57 3 1 0.000 . 
58 3 1 0.000 . 
59 3 1 0.014 . 
44 4 1 0.000 . 
45 4 1 0.005 . 
51 4 1 0.008 . 
52 4 1 0.000 . 
54 4 1 0.000 . 
23 5 1 0.006 . 
32 5 1 0.000 . 
35 5 1 0.000 . 
37 5 1 0.004 . 
40 5 1 0.001 . 
3 6 1 0.000 . 
20 6 1 0.000 . 
41 6 1 0.000 . 
47 6 1 0.000 . 
55 6 1 0.000 . 
53 6 1 0.003 . 
21 7 1 0.016 . 
24 7 1 0.000 . 
26 7 1 0.000 . 
31 7 1 0.000 . 
36 7 1 0.008 . 
25 8 1 0.000 . 
29 8 1 0.000 . 
30 8 1 0.000 . 
33 8 1 0.000 . 
89 8 1 0.004 . 
81 9 1 0.008 . 
82 9 1 0.000 . 
64 9 1 0.000 . 
88 9 1 0.000 . 
91 9 1 0.000 . 
74 10 1 0.000 . 
66 10 1 0.000 . 
71 10 1 0.000 . 
77 10 1 0.000 . 
79 10 1 0.000 . 
65 11 1 . . 
69 11 1 0.000 . 
70 11 1 0.002 . 
76 11 1 0.006 . 
78 11 1 0.019 . 
2 1 2 0.000 41.8 
10 1 2 0.002 51.5 
12 1 2 0.039 47 
18 1 2 0.000 40.2 
19 1 2 0.000 36.2 
7 2 2 0.000 43.2 
9 2 2 . . 
11 2 2 0.009 44.4 
13 2 2 0.000 44.4 
14 2 2 0.000 40.6 
48 3 2 0.038 47 
56 3 2 0.000 40.6 
57 3 2 0.000 44.2 
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58 3 2 0.000 36 
59 3 2 0.013 36.6 
44 4 2 0.000 40 
45 4 2 0.008 39.8 
51 4 2 0.012 40 
52 4 2 0.000 58.5 
54 4 2 0.000 42 
23 5 2 0.000 47.6 
32 5 2 0.000 45 
35 5 2 0.000 47.8 
37 5 2 0.000 47 
40 5 2 0.003 41.4 
3 6 2 0.000 53 
20 6 2 0.000 47.4 
41 6 2 0.000 41.2 
47 6 2 0.000 47 
55 6 2 0.000 50.5 
53 6 2 0.036 47.2 
21 7 2 0.071 51 
24 7 2 0.000 55.5 
26 7 2 0.028 42.8 
31 7 2 0.000 35 
36 7 2 0.028 52.5 
25 8 2 0.000 34.6 
29 8 2 0.000 45 
30 8 2 0.000 48.2 
33 8 2 0.000 51 
89 8 2 0.000 54 
81 9 2 0.000 46.8 
82 9 2 0.000 46.2 
64 9 2 0.000 45.8 
88 9 2 0.000 52.5 
91 9 2 0.000 37.2 
74 10 2 0.000 49 
66 10 2 0.000 42.6 
71 10 2 . . 
77 10 2 0.000 39.2 
79 10 2 0.000 40.4 
65 11 2 . . 
69 11 2 0.000 40.6 
70 11 2 0.000 41.4 
76 11 2 0.015 36.2 
78 11 2 . . 
2 1 3 0.000 . 
10 1 3 0.017 . 
12 1 3 0.000 . 
18 1 3 0.000 . 
19 1 3 0.009 . 
7 2 3 0.000 . 
9 2 3 . . 
11 2 3 0.011 . 
13 2 3 0.002 . 
14 2 3 0.000 . 
48 3 3 0.005 . 
56 3 3 0.000 . 
57 3 3 0.000 . 
58 3 3 0.000 . 
59 3 3 0.014 . 
44 4 3 0.000 . 
45 4 3 0.009 . 
51 4 3 0.017 . 
52 4 3 0.000 . 
54 4 3 0.000 . 
23 5 3 0.000 . 
32 5 3 0.000 . 
35 5 3 0.000 . 
37 5 3 0.006 . 
40 5 3 0.001 . 
3 6 3 0.000 . 
20 6 3 0.000 . 
41 6 3 0.000 . 
47 6 3 0.000 . 
55 6 3 0.011 . 
53 6 3 0.023 . 
21 7 3 0.000 . 
24 7 3 0.000 . 
26 7 3 0.000 . 
31 7 3 . . 
36 7 3 0.038 . 
25 8 3 0.000 . 
29 8 3 0.000 . 
30 8 3 0.000 . 
33 8 3 0.000 . 
89 8 3 0.000 . 
81 9 3 0.004 . 
82 9 3 0.000 . 
64 9 3 0.000 . 
88 9 3 0.000 . 
91 9 3 0.000 . 
74 10 3 0.000 . 
66 10 3 0.000 . 
71 10 3 . . 
77 10 3 0.000 . 
79 10 3 0.000 . 
65 11 3 . . 
69 11 3 0.000 . 
70 11 3 0.002 . 
76 11 3 0.010 . 
78 11 3 . . 
2 1 6 0.000 . 
10 1 6 0.000 . 
12 1 6 0.031 . 
18 1 6 0.000 . 
19 1 6 . . 
7 2 6 0.052 . 
9 2 6 . . 
11 2 6 0.010 . 
13 2 6 0.000 . 
14 2 6 0.000 . 
48 3 6 0.000 . 
56 3 6 0.000 . 
57 3 6 0.000 . 
58 3 6 0.000 . 
59 3 6 0.007 . 
44 4 6 0.000 . 
45 4 6 0.008 . 
51 4 6 0.012 . 
52 4 6 0.000 . 
54 4 6 0.000 . 
23 5 6 . . 
32 5 6 0.008 . 
35 5 6 0.000 . 
37 5 6 0.002 . 
40 5 6 0.000 . 
3 6 6 0.000 . 
20 6 6 0.000 . 
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41 6 6 0.000 . 
47 6 6 0.000 . 
55 6 6 0.018 . 
53 6 6 0.027 . 
21 7 6 0.032 . 
24 7 6 0.000 . 
26 7 6 . . 
31 7 6 . . 
36 7 6 0.015 . 
25 8 6 . . 
29 8 6 0.000 . 
30 8 6 0.000 . 
33 8 6 0.000 . 
89 8 6 0.011 . 
81 9 6 0.002 . 
82 9 6 0.000 . 
64 9 6 0.000 . 
88 9 6 0.000 . 
91 9 6 0.000 . 
74 10 6 0.001 . 
66 10 6 0.000 . 
71 10 6 . . 
77 10 6 0.000 . 
79 10 6 0.000 . 
65 11 6 . . 
69 11 6 0.000 . 
70 11 6 0.003 . 
76 11 6 0.001 . 
78 11 6 . . 
2 1 9 0.000 48 
10 1 9 0.000 59 
12 1 9 0.030 47.8 
18 1 9 0.017 46.6 
19 1 9 . . 
7 2 9 0.013 39 
9 2 9 . . 
11 2 9 0.000 63 
13 2 9 . . 
14 2 9 0.001 53 
48 3 9 0.000 53 
56 3 9 0.000 44.4 
57 3 9 0.000 44.4 
58 3 9 0.000 48 
59 3 9 . . 
44 4 9 0.000 39.2 
45 4 9 0.008 51.5 
51 4 9 0.015 39.4 
52 4 9 0.000 61 
54 4 9 0.001 38.4 
23 5 9 . . 
32 5 9 0.000 49.8 
35 5 9 0.000 53 
37 5 9 0.004 48.4 
40 5 9 0.005 61.5 
3 6 9 0.000 44.8 
20 6 9 0.000 38.6 
41 6 9 0.000 55 
47 6 9 0.018 64 
55 6 9 0.000 48.4 
53 6 9 . . 
21 7 9 . . 
24 7 9 0.009 63 
26 7 9 . . 
31 7 9 . . 
36 7 9 0.063 60 
25 8 9 . . 
29 8 9 0.000 59 
30 8 9 0.000 54 
33 8 9 0.000 60.5 
89 8 9 0.011 59.5 
81 9 9 0.000 43.4 
82 9 9 0.000 57.5 
64 9 9 0.000 42.6 
88 9 9 0.057 53 
91 9 9 0.000 52.5 
74 10 9 0.030 57.5 
66 10 9 0.000 62.5 
71 10 9 . . 
77 10 9 0.000 39 
79 10 9 0.000 43.6 
65 11 9 . . 
69 11 9 0.000 52 
70 11 9 0.003 54 
76 11 9 0.018 33 









































































































































































Figure C.13: Mucosal immune responses elicited in ostriches during the dosing vaccine trial at Kromme Rhee farm in Stellenbosch, Western Cape. Various 
doses of the mucosal vaccines were evaluated. A. 10
9
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine, B. 10
10
 c.f.u./ml dose of the VR1012 mucosal DNA 
vaccine, C. 10
11
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine, D. Received a 10
12
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine. 
 
















































































































































Figure C.14: Mucosal immune responses elicited in ostriches during the dosing vaccine trial at Kromme Rhee farm in Stellenbosch, Western Cape. Various 
doses of the mucosal vaccines were evaluated. A. 10
13
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine, B. Control group, C. 10
9
 c.f.u./ml dose of the VR1020 
mucosal DNA vaccine, D. Received a 10
10
 c.f.u./ml dose of the VR1020 mucosal DNA vaccine. 
 



















































































































Figure C.15: Mucosal immune responses elicited in ostriches during the dosing vaccine trial at Kromme Rhee farm in Stellenbosch, Western Cape. Various 
doses of the mucosal vaccines were evaluated. A. 10
11
 c.f.u./ml dose of the VR1020 mucosal DNA vaccine, B. 10
12
 c.f.u./ml dose of the VR1020 mucosal DNA 
vaccine, C. 10
13
 c.f.u./ml dose of the VR1020 mucosal DNA vaccine.  
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Mucosal immune response of ostriches against Salmonella enterica serovar typhimurium 
SL3261 LPS  
The mucosal immune response of the ostriches against the LPS of Salmonella enterica serovar 
typhimurium SL3261 was evaluated using ELISA as described in section 5.2.4., using the 
secondary antibody rabbit anti-ostrich IgA protein 2. An ANOVA was performed using the 
Statistical Analysis program Agrobase Generation II® (Agronomix Software Inc.). 
                   A N A L Y S I S   O F   V A R I A N C E                       
Swab – LPS – Protein 2 
Kromme Rhee 
Variable: RESP 
      
Source df SS MS F-value Pr>F 
Total 329 0.083 
   Treatment 10 0.011 0.001 4.73 0.0000 
Time 5 0.001 0.000 1.07 0.3746 
Treatment x Time  50 0.011 0.000 0.94 0.5942 
Residual 264 0.060 0.000 
  
Grand mean = 0.006 R-squared = 0.2740 C.V. = 251.7% 
 
      
LSD for Treatment = 0.0077 S.E.D = 0.0039  r = 30 
 
t (2-sided a=0.050, 264 df) = 1.9690 
 
MSE = 0.00023 
   
 
     
Treatment 
     
Averages 
     
Level --- Y --- Cv Rank Group 
 
9 0.02 163.5 1 VR1020 10^11 
 
6 0.01 205.9 2 Control 
 
2 0.01 163.2 3 VR1012 10^10 
 
7 0.01 178.3 4 VR1020 10^9 
 
4 0.01 285.7 5 VR1012 10^12 
 
5 0.01 136.5 6 VR1012 10^13 
 
11 0.00 242.7 7 VR1020 10^13 
 
1 0.00 276.7 8 VR1012 10^9 
 8 0.00 276.7 9 VR1020 10^10 
 3 0.00 331.7 10 VR1012 10^11 
 10 0.00 -9.0 11 VR1020 10^12 
 
      LSD for Time = 0.0057 
 
S.E.D = 0.0029 r = 55 
 
t (2-sided a=0.050, 264 df) = 1.9690 
 
MSE = 0.00023 
   
 
     
Time 
     
Averages 
     
Level --- Y --- Cv Rank Week 
 
2 0.01 256.2 1 1 
 
1 0.01 218.9 2 0 
 
6 0.01 278.4 3 9 
 
5 0.01 231.0 4 6 
 
3 0.00 304.5 5 2 
 
4 0.00 248.1 6 3 
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LSD for Treatment*Time = 0.0188 
 
S.E.D = 0.0096 r = 5 
 
t (2-sided a=0.050, 264 df) = 1.9690 
 
MSE = 0.00023 
   
   
 Two-way table for Treatment*Time, n=5                                             
  
 
1 2 3 4 5 6 
1 0.012 0.014 0.008 0.006 0.006 0.010 
2 0.004 0.002 0.002 0.002 0.012 0.002 
3 0.002 0.004 0.010 0.004 0.002 0.000 
4 0.004 0.004 0.004 0.006 0.004 0.006 
5 0.004 0.002 0.000 0.002 0.002 0.002 
6 0.008 0.000 0.000 0.002 0.004 0.004 
7 0.018 0.006 0.026 0.008 0.010 0.014 
8 0.000 0.000 0.000 0.000 0.002 0.002 
9 0.002 0.002 0.000 0.000 0.000 0.012 
10 0.000 0.000 0.000 0.000 0.000 0.006 
11 0.004 0.006 0.004 0.002 0.000 0.004 
 
The following table contains the input data for the ANOVA and is arranged in two columns with the 
ostrich identification number, treatment received (Trt), Time in weeks, the response as measured 
by ELISA and weights of the ostriches, read from the top to the bottom and left to right. The 
treatments consist of VR1012 mucosal DNA vaccine administered at various doses; 1x109 c.f.u./ml 
(1), 1x1010 c.f.u./ml (2), 1x1011 c.f.u./ml (3), 1x1012 c.f.u./ml (4) and 1x1013 c.f.u./ml (5); Salmonella 
enterica serovar typhimurium SL3261 control (6), VR1020 naked DNA vaccine administered at 
various doses; 1x109 c.f.u./ml (7), 1x1010 c.f.u./ml (8), 1x1011 c.f.u./ml (9), 1x1012 c.f.u./ml (10) and 
1x1013 c.f.u./ml (11). Following the data are the graphs drawn for each ostrich depicting the 
absorbance measured over time. 
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Ostrich Trt Time Resp Weight 
2 1 0 0.000 44.6 
10 1 0 0.008 47.6 
12 1 0 0.000 50.4 
18 1 0 0.035 45.2 
19 1 0 0.000 47.8 
7 2 0 0.000 44.2 
9 2 0 0.000 46.8 
11 2 0 0.040 48.4 
13 2 0 0.014 50 
14 2 0 0.013 47 
48 3 0 0.000 48.6 
56 3 0 0.000 48 
57 3 0 0.000 47.6 
58 3 0 0.000 47.6 
59 3 0 0.014 46.2 
44 4 0 0.000 48.2 
45 4 0 0.009 46.6 
51 4 0 0.000 45.6 
52 4 0 0.000 46.8 
54 4 0 0.000 51 
23 5 0 0.000 51.6 
32 5 0 0.005 46.6 
35 5 0 0.007 50.4 
37 5 0 0.000 49.8 
40 5 0 0.010 47.2 
3 6 0 0.000 52.4 
20 6 0 0.000 52.4 
41 6 0 0.000 51.8 
47 6 0 0.029 54.8 
55 6 0 0.009 55.8 
53 6 0 0.003 55.4 
21 7 0 0.003 48.8 
24 7 0 0.000 50 
26 7 0 0.019 52.8 
31 7 0 0.006 47 
36 7 0 0.024 51.2 
25 8 0 0.004 48.2 
29 8 0 0.004 46.8 
30 8 0 0.000 50 
33 8 0 0.002 53.8 
89 8 0 0.000 53.2 
81 9 0 0.004 44 
82 9 0 0.101 50.8 
64 9 0 0.013 54 
88 9 0 0.008 50.6 
91 9 0 0.001 50.8 
74 10 0 0.000 55.6 
66 10 0 0.000 48.2 
71 10 0 0.000 44.8 
77 10 0 0.000 49 
79 10 0 0.000 44.6 
65 11 0 0.003 50.4 
69 11 0 0.000 50.6 
70 11 0 0.006 47.6 
76 11 0 0.000 44 
78 11 0 0.024 46.2 
2 1 1 0.000 . 
10 1 1 0.000 . 
12 1 1 0.000 . 
18 1 1 0.000 . 
19 1 1 0.000 . 
7 2 1 0.022 . 
9 2 1 . . 
11 2 1 0.001 . 
13 2 1 0.012 . 
14 2 1 0.016 . 
48 3 1 0.000 . 
56 3 1 0.000 . 
57 3 1 0.000 . 
58 3 1 0.000 . 
59 3 1 0.005 . 
44 4 1 0.000 . 
45 4 1 0.000 . 
51 4 1 0.000 . 
52 4 1 0.084 . 
54 4 1 0.000 . 
23 5 1 0.000 . 
32 5 1 0.007 . 
35 5 1 0.000 . 
37 5 1 0.003 . 
40 5 1 0.003 . 
3 6 1 0.000 . 
20 6 1 0.000 . 
41 6 1 0.000 . 
47 6 1 0.021 . 
55 6 1 0.004 . 
53 6 1 0.000 . 
21 7 1 0.000 . 
24 7 1 0.008 . 
26 7 1 0.000 . 
31 7 1 0.040 . 
36 7 1 0.000 . 
25 8 1 0.006 . 
29 8 1 0.000 . 
30 8 1 0.000 . 
33 8 1 0.000 . 
89 8 1 0.000 . 
81 9 1 0.014 . 
82 9 1 0.106 . 
64 9 1 0.081 . 
88 9 1 0.000 . 
91 9 1 0.000 . 
74 10 1 0.000 . 
66 10 1 0.000 . 
71 10 1 0.000 . 
77 10 1 0.000 . 
79 10 1 0.000 . 
65 11 1 . . 
69 11 1 0.000 . 
70 11 1 0.000 . 
76 11 1 0.000 . 
78 11 1 0.041 . 
2 1 2 0.000 41.8 
10 1 2 0.000 51.5 
12 1 2 0.000 47 
18 1 2 0.000 40.2 
19 1 2 0.003 36.2 
7 2 2 0.011 43.2 
9 2 2 . . 
11 2 2 0.003 44.4 
13 2 2 0.004 44.4 
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14 2 2 0.002 40.6 
48 3 2 0.000 47 
56 3 2 0.000 40.6 
57 3 2 0.000 44.2 
58 3 2 0.000 36 
59 3 2 0.001 36.6 
44 4 2 0.000 40 
45 4 2 0.001 39.8 
51 4 2 0.000 40 
52 4 2 0.000 58.5 
54 4 2 0.000 42 
23 5 2 0.000 47.6 
32 5 2 0.005 45 
35 5 2 0.000 47.8 
37 5 2 0.007 47 
40 5 2 0.007 41.4 
3 6 2 0.000 53 
20 6 2 0.000 47.4 
41 6 2 0.000 41.2 
47 6 2 0.000 47 
55 6 2 0.000 50.5 
53 6 2 0.006 47.2 
21 7 2 0.004 51 
24 7 2 0.000 55.5 
26 7 2 0.025 42.8 
31 7 2 0.026 35 
36 7 2 0.011 52.5 
25 8 2 0.000 34.6 
29 8 2 0.000 45 
30 8 2 0.000 48.2 
33 8 2 0.000 51 
89 8 2 0.001 54 
81 9 2 0.033 46.8 
82 9 2 0.067 46.2 
64 9 2 0.000 45.8 
88 9 2 0.000 52.5 
91 9 2 0.000 37.2 
74 10 2 0.000 49 
66 10 2 0.000 42.6 
71 10 2 . . 
77 10 2 0.000 39.2 
79 10 2 0.000 40.4 
65 11 2 . . 
69 11 2 0.000 40.6 
70 11 2 0.002 41.4 
76 11 2 0.000 36.2 
78 11 2 . . 
2 1 3 0.000 . 
10 1 3 0.000 . 
12 1 3 0.000 . 
18 1 3 0.005 . 
19 1 3 0.000 . 
7 2 3 0.000 . 
9 2 3 . . 
11 2 3 0.000 . 
13 2 3 0.008 . 
14 2 3 0.000 . 
48 3 3 0.000 . 
56 3 3 0.000 . 
57 3 3 0.001 . 
58 3 3 0.000 . 
59 3 3 0.007 . 
44 4 3 0.000 . 
45 4 3 0.000 . 
51 4 3 0.006 . 
52 4 3 0.000 . 
54 4 3 0.000 . 
23 5 3 0.000 . 
32 5 3 0.025 . 
35 5 3 0.000 . 
37 5 3 0.005 . 
40 5 3 0.001 . 
3 6 3 0.000 . 
20 6 3 0.000 . 
41 6 3 0.000 . 
47 6 3 0.026 . 
55 6 3 0.000 . 
53 6 3 0.015 . 
21 7 3 0.000 . 
24 7 3 0.000 . 
26 7 3 0.000 . 
31 7 3 . . 
36 7 3 0.019 . 
25 8 3 0.000 . 
29 8 3 0.000 . 
30 8 3 0.000 . 
33 8 3 0.004 . 
89 8 3 0.028 . 
81 9 3 0.000 . 
82 9 3 0.000 . 
64 9 3 0.000 . 
88 9 3 0.000 . 
91 9 3 0.000 . 
74 10 3 0.000 . 
66 10 3 0.000 . 
71 10 3 . . 
77 10 3 0.000 . 
79 10 3 0.000 . 
65 11 3 . . 
69 11 3 0.000 . 
70 11 3 0.000 . 
76 11 3 0.008 . 
78 11 3 . . 
2 1 6 0.000 . 
10 1 6 0.004 . 
12 1 6 0.000 . 
18 1 6 0.000 . 
19 1 6 . . 
7 2 6 0.014 . 
9 2 6 . . 
11 2 6 0.000 . 
13 2 6 0.028 . 
14 2 6 0.000 . 
48 3 6 0.000 . 
56 3 6 0.004 . 
57 3 6 0.000 . 
58 3 6 0.000 . 
59 3 6 0.043 . 
44 4 6 0.000 . 
45 4 6 0.045 . 
51 4 6 0.015 . 
52 4 6 0.000 . 
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54 4 6 0.000 . 
23 5 6 . . 
32 5 6 0.000 . 
35 5 6 0.008 . 
37 5 6 0.000 . 
40 5 6 0.000 . 
3 6 6 0.000 . 
20 6 6 0.000 . 
41 6 6 0.000 . 
47 6 6 0.018 . 
55 6 6 0.055 . 
53 6 6 0.043 . 
21 7 6 0.002 . 
24 7 6 0.000 . 
26 7 6 . . 
31 7 6 . . 
36 7 6 0.000 . 
25 8 6 . . 
29 8 6 0.000 . 
30 8 6 0.000 . 
33 8 6 0.041 . 
89 8 6 0.006 . 
81 9 6 0.004 . 
82 9 6 0.000 . 
64 9 6 0.054 . 
88 9 6 0.000 . 
91 9 6 0.000 . 
74 10 6 0.000 . 
66 10 6 0.000 . 
71 10 6 . . 
77 10 6 0.000 . 
79 10 6 0.000 . 
65 11 6 . . 
69 11 6 0.000 . 
70 11 6 0.008 . 
76 11 6 0.000 . 
78 11 6 . . 
2 1 9 0.011 48 
10 1 9 0.000 59 
12 1 9 0.000 47.8 
18 1 9 0.029 46.6 
19 1 9 . . 
7 2 9 0.022 39 
9 2 9 . . 
11 2 9 0.000 63 
13 2 9 . . 
14 2 9 0.004 53 
48 3 9 0.000 53 
56 3 9 0.001 44.4 
57 3 9 0.000 44.4 
58 3 9 0.000 48 
59 3 9 . . 
44 4 9 0.000 39.2 
45 4 9 0.000 51.5 
51 4 9 0.008 39.4 
52 4 9 0.000 61 
54 4 9 0.000 38.4 
23 5 9 . . 
32 5 9 0.008 49.8 
35 5 9 0.006 53 
37 5 9 0.000 48.4 
40 5 9 0.013 61.5 
3 6 9 0.000 44.8 
20 6 9 0.000 38.6 
41 6 9 0.000 55 
47 6 9 0.013 64 
55 6 9 0.021 48.4 
53 6 9 . . 
21 7 9 . . 
24 7 9 0.000 63 
26 7 9 . . 
31 7 9 . . 
36 7 9 0.000 60 
25 8 9 . . 
29 8 9 0.000 59 
30 8 9 0.000 54 
33 8 9 0.001 60.5 
89 8 9 0.006 59.5 
81 9 9 0.007 43.4 
82 9 9 0.119 57.5 
64 9 9 0.071 42.6 
88 9 9 0.023 53 
91 9 9 0.000 52.5 
74 10 9 0.000 57.5 
66 10 9 0.000 62.5 
71 10 9 . . 
77 10 9 0.000 39 
79 10 9 0.000 43.6 
65 11 9 . . 
69 11 9 0.015 52 
70 11 9 0.000 54 
76 11 9 0.003 33 
































































































































































Figure C.16: Mucosal immune responses elicited in ostriches during the dosing vaccine trial at Kromme Rhee farm in Stellenbosch, Western Cape. Various 
doses of the mucosal vaccines were evaluated. A. 10
9
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine, B. 10
10
 c.f.u./ml dose of the VR1012 mucosal DNA 
vaccine, C. 10
11
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine, D. Received a 10
12
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine. 
 
















































































































































Figure C.17: Mucosal immune responses elicited in ostriches during the dosing vaccine trial at Kromme Rhee farm in Stellenbosch, Western Cape. Various 
doses of the mucosal vaccines were evaluated. A. 10
13
 c.f.u./ml dose of the VR1012 mucosal DNA vaccine, B. Control group, C. 10
9
 c.f.u./ml dose of the VR1020 
mucosal DNA vaccine, D. Received a 10
10
 c.f.u./ml dose of the VR1020 mucosal DNA vaccine. 
 



























































































































Figure C.18: Mucosal immune responses elicited in ostriches during the dosing vaccine trial at Kromme Rhee farm in Stellenbosch, Western Cape. Various 
doses of the mucosal vaccines were evaluated. A. 10
11
 c.f.u./ml dose of the VR1020 mucosal DNA vaccine, B. 10
12
 c.f.u./ml dose of the VR1020 mucosal DNA 
vaccine, C. 10
13
 c.f.u./ml dose of the VR1020 mucosal DNA vaccine. 
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